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1.1 Atherosclerosis: Mortality, Morbidity and Costs
With improved public health and increasing life spans, cardio–vascular disease (CVD)
has become an important problem and burden to the society as it is the number one
cause of death in the world [1]. In 2008, 17 million people died from CVD, accounting
for 30% of global deaths [1]. CVD is projected to remain the single most important
cause of global death by 2030, when 25 million people are expected to die from it [1].
Without exception, CVD is the leading cause of death in the United States [2]
and Europe [3]. In the Netherlands, CVD is the second most important cause of
death, comprising 29.2% of total deaths, which is exceeded only by diverse types of
cancer that together account for 31% of the national mortality [4].
Besides causing a high mortality, CVD also represents a major economic burden
on health care systems in terms of direct (hospitalizations, rehabilitation services,
medications) and indirect (losses of productivity due to premature mortality and
short- or long–term disability) costs that account for more expenditures than any
other major diagnostic group in the United states [2]. In fact, the costs linked to
heart failure in the United States are expected to more than double within the next
two decades going from 21 to 53 billion dollars per year, as the population ages and
treatments help patients live longer. If indirect costs related to heart failure, such as
lost productivity and wages, are included in this projection, the total costs will go
from 31 to 70 billion [5].
1.2 Atherosclerosis: Onset and Development
Atherosclerosis is the underlying cause of CVD [2] and therefore the principal target
for therapeutic intervention. Atherosclerosis is a chronic inflammatory disease and
metabolic disorder characterized by hyperlipidemia and altered leukocyte homeosta-
sis.
During the asymptomatic stages of atherosclerosis, dysfunctional and activated
endothelial cells allow the formation of fat deposits in the vasculature upon diffusion
of cholesterol lipids to the subendothelial space. This leads them to secrete chemo-














starts with integrin dependent tight adhesion and rolling on the endothelium, followed
by transmigration across the endothelial lining and adhesion to other cells and the
extracellular matrix present in the vascular interstitium (Fig. 1.1).
Figure. 1.1. Leukocyte extravasation in atherosclerosis. Schematic rep-
resentation of the diapedesis process that starts with leukocyte capture on the en-
dothelial surface, followed by selectin mediated slow rolling, chemokine dependent
activation and integrin arrest. Activation of Src kinases allows the cell stronger
adhesion to the endothelium in anticipation to intra–luminal crawling, transmigra-
tion across the endothelial cells and passage across the basement membrane. Key
molecules involved in each step are indicated in boxes. ESAM, Endothelial–cell Se-
lective Adhesion Molecule; ICAM1, Inter–Cellular Adhesion Molecule–1; JAM, Junc-
tional Adhesion Molecule; LFA1, Lymphocyte Function Associated Antigen–1 (also
known as α–1β–2–Integrin); MAC1, Macrophage Antigen–1; MADCAM1, Mucosal
Vascular Addressin Cell Adhesion Molecule–1; PSGL1, P–Selectin Glycoprotein Lig-
and–1; PECAM1, Platelet/Endothelial Cell Adhesion Molecule–1; PI3K, Phospho-
inositide–3–Kinase; VCAM1, Vascular Cell Adhesion Molecule–1; VLA4, Very Late
Antigen–4 (also known as α–4β–1–Integrin). Adapted from [6].
1.3 Altered Leukocyte Homeostasis in Atherosclerosis
Monocyte extravasation and differentiation drive a slow accumulation of monocyte de-
rived macrophages that scavenge and ingest oxidized cholesterol (Fig. 1.2), becoming
the most prominent cell type at all stages of the disease, although multiple leuko-
cyte subsets are recruited to the lesion and have been demonstrated to contribute to
atherosclerosis onset and development [7].
The development and progression of atherosclerosis not only proceeds locally,
inside lesions, but is also characterized by altered peripheral leukocyte homeostasis.
In fact, a higher prevalence of leukocytosis has been shown to occur in patients with
chronic coronary artery disease (CAD) [8]. In addition, evidence is accumulating that












1.3. Altered Leukocyte Homeostasis in Atherosclerosis 3
neutrophils to infiltrate early atheroclerotic lesions to subsequently recruit and mod-
ulate the function of inflammatory monocytes [12]. As result, a positive correlation
exist between peripheral blood PMN cells count and acute coronary events in atheros-
clerotic patients [13, 14]. Similarly, clinical data has shown that human monocytosis
is an independent risk factor for coronary artery disease [8].
Dendritic cells (DC) also display altered peripheral homeostasis in atheroscle-
rosis. In fact, reduced counts of circulating myeloid and plasmacytoid dendritic cells
(mDC and pDC, respectively) have been observed in patients with atherosclerotic
CAD [15, 16]; which correlates with its clinical manifestations [17–19]. Furthermore,
a stage–dependent decrease in the number of circulating mDCs and pDC precursors
is an independent predictor of the requirement for percutaneous coronary interven-
tion and artery bypass graft in patients with stable coronary artery disease [20]. But
beyond the inverse correlation of circulatory dendritic cells counts in CAD, these cells
have the potential to modulate T and B cell dependent adaptive immune responses to
modified lipids and self–antigens present in atherosclerotic lesions [21, 22], and have
been demonstrated to regulate plasma cholesterol levels [23] and lipid metabolism [24].
Hence, induction of CD11c+ dendritic cell apoptosis results in increased atheroscle-
rotic lesion burden [25].
Recent studies indicate that the function of DC in atherosclerosis depends on
their origin, maturation stage and differentiation phenotype. In particular, imma-
ture DC that lack sufficient exposure to co–stimulatory cytokines acquire tolerogenic
properties and induce Treg activation, which in turn inhibits effector T cells and
therefore suppresses adaptive immune responses [26]. Hence, interfering with TLR
activation of conventional DC in CD11c–MyD88 deficient mice [27] and interrupting
monocyte–independent Flt3L driven DC maturation [28] leads to increased atheros-
clerosis and monocyte extravasation by loss of Treg mediated suppression of inflam-
mation. Conversely, oral administration of calcitriol [29] or injection of DC previ-
ously pulsed with atherosclerotic antigens such as oxidized Low Density Lipoproteins
(oxLDL) [30, 31] or immunoregulatory cytokines such as IL–10 in combination with
the protein moiety of LDL, apolipoprotein B100 (ApoB100) [32], causes reduced athe-
rosclerotic lesion burden and macrophage accumulation by dendritic cell mediated
induction of immune regulation, highlighting the importance of dendritic cells for
monocyte extravasation and macrophage homeostasis in atherosclerosis.
Simultaneously, studies where pro–inflammatory DC functions have been dis-
abled turned out to decrease atherosclerosis, suggesting a major role of these cells in
activation of proatherogenic effector T cells [33–35]. In addition, blockage of dendritic
cell and T lymphocyte migration to secondary lymph nodes causes their accumulation
in atherosclerotic lesions, thereby reducing macrophage accumulation and delaying
atherosclerotic lesion expansion [36]; which indicates that the egress of DC and T
cells from inflamed vascular lesions into the draining lymphatics is essential for the
generation of adaptive immune responses that promote lesion progression [36].
The role of macrophages in atherosclerosis is highly dependent on the extracel-
lular environment present in atherosclerotic lesions, that evolve through stages from
fatty streaks with few leukocytes, to advanced plaques rich in macrophages and char-
acterized by the accumulation of apoptotic and necrotic cells surrounding lipid pools
filled with necrotic debris. As such, the main function of macrophages during the ear-













temporally beneficial, inhibits their migration [37] and causes the upregulation of
adhesion molecules, pro–inflammatory cytokines and growth factors. Atherosclerotic
lesion macrophages become therefore trapped in an extra–cellular environment that
promotes their proliferation and hinders their getaway out of lesions [38].
1.4 Vascular Remodeling and Atherosclerotic Lesion
Destabilization
As the lesion progresses, the accumulation of cytotoxic molecules induces macro-
phage death in a vicious circle that promotes lesion expansion by further recruit-
ment of monocytes and accumulation of monocyte derived macrophages. Tertiary
lymphoid organs form outside the lesions [39] and Vascular Smooth Muscle Cells
(VSMC)proliferate and migrate from the media to the intima in response to macro-
phage signals (Fig. 1.3). Once in the intima, lesion smooth muscle cells (SMC) change
their contractile phenotype into a synthetic one, active in extracellular matrix protein
deposition and formation of fibrous caps that stabilize the lesion keeping its contents
isolated from the blood stream (Fig. 1.3).
Arterial enlargement and fibrous cap formation prevent early detection and
treatment of atherosclerosis, keeping it silent for decades [41, 42]. The progressive
accumulation of macrophages along with the formation of fibrous caps, is accompa-
nied by outward expansion of the artery to accommodate the growing plaque and
normalize the flow of blood, that would otherwise present disturbed fluid dynam-
ics, causing excessive shear stress on the endothelium. This natural compensation is
initially beneficial, as it prevents stenosis and ischemia, keeping the disease asymp-
tomatic up to its end stage [43].
Arterial remodeling however contributes to high mortality rates in asymptomatic
individuals; in fact fifty percent of men and 64% of women who die suddenly of
CAD in the United States had no previous symptoms of atherosclerosis [2]. Those
percentages are in the Netherlands 55% and 52% for men and women, respectively
[4]. Atherosclerosis is therefore considered a silent killer that starts early in life and
progresses over time.
1.5 Macrophage Apoptosis and Lesion Destabilization
The progression from stable to vulnerable and clinically relevant atherosclerotic le-
sions is characterized by accumulation of apoptotic macrophages and formation of
necrotic cores that cause erosion and rupture of fibrous caps [44] (Fig. 1.4). In fact,
macrophage apoptosis is significantly higher at sites of plaque rupture and thrombo-
sis in patients with sudden coronary death [45]. In addition, macrophage apoptosis
causes secondary necrosis [46] which together with non–post–apoptotic programmed
necrosis [47, 48] cause the formation of necrotic cores [49, 50], characteristic of ad-
vanced human atherosclerotic lesions [51].
The accumulation of apoptotic macrophages and formation of necrotic cores
has three important consequences for macrophage homeostasis and atherosclerotic
lesion vulnerability: First is the induction of lesion macrophage differentiation to-
wards a proinflammatory phenotype active in inducing lesion vulnerability (Fig. 1.5).
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Figure. 1.2. Atherosclerosis onset. Schematic representation of healthy ar-
teries, depicting their intima media and adventitia. The endothelial layer provides
a barrier that provides vascular tone and regulates immune cell permeability, (top
panel). Upon the onset of atherosclerosis, endothelial cells secrete proinflammatory
cytokines and display dysfunctional permeability. Fat deposits form and circulatory
monocytes extravasate to scavenge and ingest oxidized cholesterol becoming foam cells
(bottom panel). The progressive accumulation of intra and extra–cellular cholesterol













Figure. 1.3. Progression of Atherosclerosis. The growing fatty streak even-
tually forms a lipid core (top panel), that gets isolated by the progressive formation
of a fibrous cap (bottom panel) that contains collagen, proteoglycans and activated
smooth muscle cells. The sturdier the cap, the less likelihood there is of plaque rup-
ture. Lipid accumulation and cell stressors such as free radicals cause cell dead and












1.5. Macrophage Apoptosis and Lesion Destabilization 7
Figure. 1.4. Atherosclerotic Lesion Rupture. Oxidized LDL activates ma-
crophages and stimulates the expression of tissue factor (TF), a major inflammatory
cytokine, pro–coagulant and trigger of thrombosis. oxLDL also stimulates increased
production of Plasminogen Activator Inhibitor type 1 (PAI–1), which inhibits fibri-
nolysis. The end result is a state of hyper–coagulability around the plaque. Activated
macrophages weaken the fibrous cap by releasing metalloproteases that also degrade
the connective tissue withing the lesion. Uncontrolled necrosis of macrophages con-
tributes to fibrous cap erosion and lesion destabilization by leakage of intracellular
lytic enzymes. The erosion of the fibrous cap causes lesion rupture (top panel) with
subsequent formation of thrombus and arterial occlusions that interrupt the flow of
blood (bottom panel). The occlusions may be either partial, upon the formation of
fibrin and platelet rich wall thrombus (bottom panel left), or complete (bottom panel,
right). Partial occlusions are prone to embolization and, as such, can give rise to
distal occlusions. Total occlusions in contrast are thrombin rich and cause ischemia














other leukocytes that migrate in response to secondary necrosis derived inflammatory
clues [48] (Fig. 1.5). Finally, the third and most threatening consequence of lesion
necrosis is the erosion and rupture of fibrous caps by lytic enzymes arising either from
intracellular contents of necrotic cells, or released by proinflammatory macrophages
(Fig. 1.5). Fibrous cap rupture cause leakage of thrombogenic contents from the
lesion to the circulation, leading to thrombus formation, acute blood vessel occlusion,
cerebral or myocardial infarction and sudden death, as first clinical manifestation of
atherosclerosis (Fig. 1.4).
The impact of macrophage apoptosis on atherosclerosis is however dependent on
the cause of cell death and stage of the disease. In fact, macrophage cell turnover by
apoptosis coupled to prompt phagocytosis of apoptotic bodies, delays the expansion
of early atherosclerotic lesions and causes phagocytes to secrete anti–inflammatory
signals [25, 52]. But, cholesterol–induced macrophage apoptosis, as occurs in athe-
rosclerosis, triggers inflammation in phagocytes [53]. In addition, when the clear-
ance capacity of lesion phagocytes is impaired or overwhelmed, or viable phagocytes
are depleted [54]; apoptotic cells that are not removed loose the integrity of their
membrane leading to secondary necrosis and the formation of necrotic pools rich in
pro–apoptotic, pro–inflammatory and thrombogenic intracellular contents, character-
istic of lesion destabilization (Fig. 1.5).
Phagocytosis of death cells is therefore and important process that prevents
plaque progression and induces its stability by triggering intracellular signal transduc-
tion pathways that result in the release of anti–inflammatory factors while preventing
the leakage of apoptotic cell contents that would otherwise lead to autoimmunity,
necrotic core expansion, plaque destabilization and thrombus formation.
1.6 Myelocyte Differentiation as Determinant of
Lesion Stability
A further determinant of lesion instability is the skewed differentiation of monocytes
into pro–inflammatory and lytic macrophages prompt to inducing inflammation and
fibrous cap erosion and rupture. These macrophages [55], usually found in Type I
diseases, are commonly denoted as M1, to follow a nomenclature similar to that used
for T helper cells.
Infiltrating monocytes, homing into atherosclerotic lesions are deemed to pref-
erentially differentiate into proinflammatory M1 macrophages that secrete immune
mediators in response to apoptotic cells and other stressors found inside atheroscle-
rotic lesions. Cytokines secreted by M1 macrophages such as IFNγ, TNFα, IL–12
and IL–18 induce pro–inflammatory responses in T and B lymphocytes and promote
inflammation and newly recruited monocyte differentiation into M1 macrophages,
in a vicious cycle that progressively reduce the contents of tissue repairing and im-
munoregulatory M2 (again, following the T helper dichotomy) alternatively activated
macrophages (AAM). In addition, proinflammatory M1 macrophages, produce pro-
teases and chemokines that degrade the components of the fibrous cap [54,56] leading
to lesion vulnerability (Fig. 1.5).
The skewed differentiation of extravasated monocytes into pro–inflammatory
macrophages is deemed to occur in response to the local extracellular environment
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CCR2+Ly6chi circulatory monocytes might be precursors of inflammatory macro-
phages in mice; while their CX3CR1
hiCCR2−Ly6clo counterparts might give rise to
wound healing and immunoregulatory macrophages. This has led to the hypothe-
sis that the progression of atherosclerotic lesions towards vulnerability to rupture
and thrombus formation might be predetermined already in the circulation. In fact,
blood Ly6chi monocytes are increased in hyperlipidemic mice, where they have been
demonstrated to selectively accumulate [57,58] and destabilize atherosclerotic lesions
by secretion of proteases and inflammatory cytokines [59–61]. Circulatory Ly6clo
monocytes are in contrast reduced in atherosclerotic mice, which likely contribute to
lesion vulnerability, as this subset is deemed to differentiate into M2 macrophages
that induce collagen secretion, wound healing and reduced inflammation [59,61].
Analogous to the observations in mice, the level of CX3CR1 expression defines
two major human monocyte subsets, referred to as CD14hiCD16− and CD14loCD16+,
that share phenotype and homing potential with their mouse counterparts [62]. In-
terestingly, increased levels of human CD14hiCD16− monocytes, deemed to be the
human counterpart of mice Ly6chi cells, correlate with high risk and predisposition
to coronary hearth disease [63].
Taken together, these data suggest that subset specific blood monocytosis might
be determinant of the phenotype taken on by atherosclerotic lesions, both in humans
and mice. In addition, hyperlipidemia, as observed in atherosclerosis, dyregulates
medullar homeostasis by promoting bone marrow hematopoietic stem cell mobiliza-
tion and intravasation from the bone marrow niche to the peripheral circulation [64].
This is of enormous importance considering that once in the circulation these cells
can extravasate and differentiate into tissue macrophages, without monocyte interme-
diates, [65]. Furthermore, intravasated hematopoietic stem cell progenitors migrate
to the spleen, where they differentiate, becoming a major source of proinflammatory
Ly6chi monocytes that infiltrate atherosclerotic lesions [66], which suggest that be-
sides causing atherosclerotic lesion onset, hyperlipidemia might drive a preferential
differentiation of monocytes into pro–inflammatory macrophages.
1.7 Thesis Outline
Considering the above, the onset of atherosclerosis seems to have a predetermined fate
towards lesion vulnerability to rupture and clinical manifestations such as sudden in-
farct and death. However, the processes responsible for the development of atheroscle-
rosis are dynamic and can be modulated towards lesion regression and stabilization.
In fact, anastomosis of atherosclerotic vessel segments from ApoE−/− donors into
wild–type recipients causes lesion shrinkage and reduced contents of macrophage de-
rived foam cells by induction of CD68+ macrophage migration out of lesions [67,68];
suggesting that lesion regression could be achieved by increasing myelocyte cell ef-
flux out of lesions. Similarly, viral mediated transfer of ApoE into atherosclerotic
ApoE−/− mice, triggers lesion regression by inducing reduced monocyte diapedesis
and intra–lesion macrophage turnover by apoptosis [69].
The modulation of monocyte and macrophage homeostasis towards resolution
of inflammation and wound healing could therefore represent a successful strategy to














Figure. 1.5. The ratio of proinflammatory and tissue repairing macrophages
is a key determinant of atherosclerotic lesion stability. Macrophages have the potential
to activate proinflammatory (top panel) or tissue repairing and wound healing (bottom
panel) differentiation programs. Proinflammatory macrophages release cytokines that
induce inflammation and proteases that decrease fibrous cap resistance (top panel).
Tissue repairing macrophages in contrast induce wound healing and resolution of in-
flammation. Cell death, thrombogenicity and endothelial dysfunction are consequently












1.7. Thesis Outline 11
This thesis presents the results of a series of experiments performed to modulate
leukocyte homeostasis in atherosclerosis using two strategies:
1. Deletion and upregulated expression of target genes known to regulate pro-
cesses that control leukocyte homeostasis including hematopoiesis, intravasa-
tion, leukocyte differentiation, lipid homeostasis, extravasation and cell survival.
2. Time controlled systemic and local induction of macrophage apoptosis in ad-
vanced atherosclerosis to assess the impact of this process in intravascular and
extravascular leukocyte homeostasis at the end of apoptosis induction, and after
a period allowed for recovery and normalization of leukocyte levels.
The role of target genes in monocyte and macrophage homeostasis in atheroscle-
rosis was evaluated using knock–out and lentiviral mediated gene knock–in methodolo-
gies, combined with Bone Marrow Transplantation (BMT) to generate atherosclerotic
mice chimeras bearing genetic alterations in their hematopoietic cells.
Time controlled macrophage apoptosis was induced in atherosclerotic mice by
suicide genes engineered to be expressed in macrophages by use of cell specific gene
promoters.
Leukocyte homeostasis and atherosclerotic lesion phenotype was evaluated upon
each treatment.
The experiments performed are presented in four chapters arranged in two sec-
tions. The first section comprises Chapters 2 and 3. This section uses the first
strategy previously described. The experiments presented in this section were per-
formed to evaluate the possibility of increasing the amounts of tissue repairing and
anti–inflammatory macrophages, while reducing the accumulation of their lytic and
proinflammatory counterparts. This section presents novel results and demonstrate
the feasibility of targeting different monocyte and macrophage subpopulations to skew
atherosclerotic homeostasis towards lesion regression, resolution of inflammation and
fibrous cap stability.
Each chapter in the first section includes an evaluation of the expression of the
genes studied in a genomic context. Cluster, network and gene ontology analysis
of differentially expressed genes from human macrophages stimulated with TNFα,
IL–4, IL–17 LPS, IFNγ or LPS+IFNγ permitted the location of genes used, in ge-
netic networks controlling macrophage differentiation into proinflammatory and tissue
repairing phenotypes, which was related to the expression of those genes in human
atherosclerotic lesions obtained from patients undergoing carotid endarterectomy or
at autopsy. This analysis provided a framework for analysis of results obtained in
mice and their relevance for human atherosclerosis.
The second section is dedicated to the induction of macrophage apoptosis in
atherosclerosis. Chapter 4 studies atherosclerotic lesion stability and composition
upon induction and after recovery from acute CD169+ macrophage apoptosis in LDL
receptor deficient atherosclerotic mice. Chapter 5 presents a comparison of the impact
that systemic and local induction of CD115+ macrophage apoptosis exerts on athe-
rosclerosis and vascular and extravascular leukocyte homeostasis in ApoE deficient
mice. The results of this section have important implications for the development
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Janus role of Hck and Fgr
in atherosclerosis
progression and stability
”With every day, and from both sides of my intelligence, the moral
and the intellectual, I thus drew steadily nearer to the truth, by
whose partial discovery I have been doomed to such a dreadful
shipwreck: that man is not truly one, but truly two.”
R. L. Stevenson, Dr. Jekyll and Mr. Hyde.
2.1 Abstract
Background: Leukocyte migration is critical for the infiltration of monocytes and
the accumulation of macrophages in inflammation. Considering that Hck and Fgr
are instrumental for this process, their involvement in macrophage accumulation in
atherosclerosis and their influence in lesion formation and stability, was evaluated.
Methods and Results: Hematopoietic Hck/Fgr–deficient, LDLr−/− chimeras,
obtained by bone marrow transplantation, had smaller lesions with fewer macropha-
ges despite blood Ly6chi monocytosis. Hck/Fgr deficient monocytes and macrophages
displayed impaired mesenchymal migration and disrupted adhesion and transmigra-
tion across endothelial monolayers in-vitro and established atherosclerotic plaques
in–vivo, as assessed by intravital microscopy.
Reduced lesion size and macrophage infiltration, which is considered to induce
lesion stability, were paradoxically contrasted by marked signs of lesion vulnerabil-
ity such as reduced fibrosis and VSMC accumulation and expanded necrotic cores;
implicating Hck and Fgr in lesion stability. Furthermore, SMC collagen deposition
was reduced in SMC stimulated with conditioned medium from Hck/Fgr deficient
macrophages. Gene expression analysis classical and alternative activated macropha-
ges and human atherosclerotic lesions, indicated that Hck and Fgr are implicated in
macrophage tissue repairing functions.
Conclusions: Combined hematopoietic deficiency of Hck and Fgr attenuated
atherosclerotic plaque burden due to impaired endothelial adhesion and migration,
but promoted plaque instability by causing monocyte subset imbalance and reduced













18 Dual Role of Hck and Fgr in Atherosclerosis
2.2 Introduction
Inflammation and tissue repair are determinants of the clinical outcome of atheros-
clerosis, and are emerging now as two interrelated processes with many overlapping
molecular mechanisms controlling monocyte infiltration and differentiation into ma-
crophages, whose phenotype modulates the stability of lesions, by controlling the
balance between matrix degradation and inflammation versus matrix deposition and
wound healing [70].
Monocyte extravasation is an essential step for metabolic disease pathogenesis
including atherosclerosis. The ability of monocytes to roll and adhere to the endothe-
lium in response to chemokines is crucial for macrophage accumulation [6]. It relies on
actin dependent morphological polarization, formation of filopodia and lamellipodia,
binding of integrins to endothelial adhesion molecules, cytoskeletal reorganization [71]
and signal transduction pathways ultimately leading to concerted loosening of adher-
ent junctions on endothelial cells [72] and monocyte transmigration across endothelial,
basement membrane and fibrous cap barriers, before their homing in expanding le-
sions and differentiation into macrophages that display either pro-inflammatory or
tissue repairing phenotypes.
Hck and Fgr are two Src tyrosine kinases that display restricted co–expression
and co–regulation in myeloid cells [73] where they induce LFA–1 integrin binding
to endothelial ICAM to facilitate cell adhesion and migration upon PSGL–1 and
CD44 interaction with endothelial E–selectin and P–selectin [74]. In addition, Hck
and Fgr are a convergence point of signaling pathways initiated by a wide range of
cell receptors implicated in the pathogenesis of atherosclerosis, including integrins,
immune and growth factors, FcγR, adhesion and chemokine receptors.
These kinases exert their functions by activation of Rac/CDC42, Syk and Pyk
[75] which are implicated in the accumulation and trapping of macrophages in athe-
rosclerosis [76–79]. In addition, and as expected from signaling molecules downstream
of multiple receptors, Hck and Fgr mediate a broad spectrum of cell processes, rang-
ing from cell proliferation, survival and differentiation; to cytokine secretion, cy-
toskeleton dynamics, integrin dependent cell adhesion to the endothelium, and mi-
gration [75,80–82].
In light of these data, Hck/Fgr–deficiency was hypothesized to lead to reduced
accumulation of macrophages in atherosclerosis as consequence of reduced diapedesis
and migration. The data here presented imply that Hck and Fgr control critical
molecular processes that allow monocyte adhesion to the endothelium, mesenchymal
migration, blood monocyte subset balance, macrophage accumulation and atheros-
clerotic lesion stability.
2.3 Materials and Methods
Animal Experiments: Bone marrow transplantation and perivascular collar place-
ment experiments were approved by the local regulatory authorities of Leiden and
Maastricht, and performed in accordance with the Dutch Government guidelines.
For bone marrow transplantation experiments, female LDLr−/− recipient mice were
obtained from the local animal breeding facility at the University of Leiden, Gor-












2.3. Materials and Methods 19
radiation (0.19Gy/min, 200kV, 4mA) using an Andrex Smart 225 Rontgen Source
(YXLON International, Copenhagen, Denmark) one day before reconstitution with
bone marrow cells from wild–type C57Bl6/J mice obtained from Charles River Inc.,
or Hck/Fgr–deficient mice on C57Bl6/J background, kindly provided by Dr. Clifford
Lowell (University of California, Department of Laboratory Medicine in San Francisco
CA, USA) and bred at the local animal facility of CNRS/IPBS, Toulouse, France.
Drinking water with antibiotics (83 mg/l ciprofloxacin and 67 mg/l Polymixin) and
5g/l sucrose was introduced one week before irradiation and supplied during the ex-
periment. Mice were fed western type diet (0.25%cholesterol and 15% cacao butter;
Special Diet Services, Witham, Essex, UK) during 13 weeks, starting eight weeks
after bone marrow transplantation and ending at sacrifice.
The percentage of chimerism was used as a measure of bone marrow transplanta-
tion efficiency. It was determined as described previously [83], by quantification of the
percentage of LDLr+/+ present in genomic DNA obtained from peripheral blood of
LDLr+/+Hck−/−Fgr−/− donor to LDLr−/−Hck+/+Fgr+/+ recipient chimeras (Pure-
Link Genomic DNA Purification Kit, Invitrogen). Samples were run in duplicate
and CT values obtained from chimeras were used for interpolation of LDLr+/+ DNA
percentage by comparison to CT values obtained from a standard curve of a dilu-
tion series mix of 100% : 0% to 0% : 100% of LDLr−/−:LDLr+/+ mouse genomic
DNA. CT values were calculated by Real–time PCR done with a Taqman IQ R©SYBR
Green Super Mix (BIO–RAD, Hercules, CA) in a MyiQ Icycler (Biorad) using LDLr
specific primers (LDLr-forward: 5’-GCTGCAACTCATCCATATGCA-3’ and LDLr-
reverse: 5’-GGAGTTGTTGACCTCGACTCTAGAG-3’). A p50-specific primer set
(P50-forward: 5’-AACCTGGGAATACTTCATGTGACTAA-3’ and P50-reverse: 5’-
GCACCAGAAGTCCAGGATTATAGC-3’); was used to standardize for the amount
of imput DNA per sample.
Perivascular Collar Placement, Adoptive Fluorescent Cell Transfer and Intravital
Microscopy: Perivascular collars were placed in female LDLr−/− (n=5), as described
elsewhere [84]. Mice were fed western type diet containing 0.25% cholesterol and 15%
cacao butter (W. Special Diet Services, Witham, Essex, UK) four weeks before collar
placement and throughout the experiment. Mice were anesthetized twelve weeks
after collar placement, once advanced plaques had formed, and a mixture of DAPI
labeled Hck/Fgr double knockout (dKO) and DiI labeled wild type (WT) bone marrow
derived macrophages (BMDM, 1X106 cells each) was transferred by cardiac injection.
Fifteen minutes after injection the left carotid was exposed for intravital microscopy
recording during 1 minute, to quantify fluorescent labeled cell adhesion using an
Olympus BX51 microscope equipped with a saline immersion 20X objective. Wounds
were then sutured and animals allowed to recover from anesthesia and left one day
until sacrifice to allow labeled cells to transmigrate to the plaques for analysis of post
mortem cryosections by fluorescence microscopy.
Labeling of Circulatory Leukocytes and Intravital Microscopy Circulatory leuko-
cyte adhesion in–vivo to the carotid artery was analyzed in WT versus Hck/Fgr dKO
chimeras by intravital microscopy. For this, the right jugular vein was canulated with
a catheter for antibody and dye injection. After exposure of the left carotid artery,
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(Ebiosciences) were administered to label various leukocyte subsets. Rhodamine 6G
(100 l of a 0.1 solution) was injected to label all circulating leukocytes. Recordings
were made 3 min after injection of each antibody. Intravital microscopy was per-
formed using an Olympus BX51 microscope equipped with a Hamamatsu 9100–02
EMCCD camera and a 10x saline–immersion objective. For image acquisition and
analysis Olympus Cell software was used.
Monocyte Labeling in LDLr−/− Hck/Fgr dKO Chimeras Chimeric mice gener-
ated by reconstitution of lethally irradiated LDLr−/− mice with bone marrow from
Hck/Fgr dKO donors, received intravenous injections of Latex Beads (Polysciences)
18h after receiving chlodronate liposomes to label Ly6chi monocytes as described be-
fore [58]. Mice were sacrificed twenty four hours after labeling for excision of hearts
and analysis.
Cholesterol and Triglyceride Levels: Blood samples were taken by tail bleeding one
day before the introduction of western type diet, five weeks after introduction of WTD
and at sacrifice. Total plasma, triglyceride and phospholipid contents were measured
by an enzymatic–colorimetric assay (Roche Diagnostics, Almere, The Netherlands).
Plasma Cytokine Levels: The Luminex 100 Bio–Plex cytokine assay (Bio–Rad Lab-
oratories, Inc; Hercules CA, USA) was used to determine cytokine expression in serum
samples; cytokines investigated were: IL–1α, IL–1β, IL–2, IL–4, IL–5, IL–6, IL–10,
IL–12(P40 and P70), IL–17, Eotaxin, Keratinocyte Chemoattractant (KC), Monocyte
Chemoattractant protein–1 (MCP1), Monocyte inflammatory protein–1α (MIP1α)
and Tumor Necrosis Factor–α (TNFα). Statistical analysis was performed for those
cytokines that reached the limit of detection (IL–1β, IL–12, eotaxin, MCP1 and
IL–1α).
Blood Cell Analysis and Flow Cytometry: Single cell suspensions of blood, bone
marrow and peritoneal cells harvested at sacrifice were stained with fluorescent label
conjugated antibodies after lysis of erythrocytes in ice cold NH4Cl (8.4g/l) NaHCO3
(1g/l) EDTA (37mg/l) during 3 minutes. Aortas were enzymatically digested with
Liberase (Roche). Antibodies (eBioscience: B220 (25-0452-82, 1:150), CD11b (57-
0112-82, 1:40), CD3e (45-0031-82, 1:50 or 11-0031-82, 1:300), CD19 (45-0193-82,
1:100 or 12-0193-83, 1:100), CD25 (17-0251-82, 1:300), MHCII(11-5322-82, 1:800),
CD8a (48-0081-82, 1:300), FoxP3 (12-5775-82, 1:40), BD Pharmingen: Ly6G (551461,
1:100), CD11c (558079, 1:400), B220 (553089, 1:100), CD11b (552858, 1:300), CD4
(553052, 1:300), Miltenyi: Ly6c (130-093-134 or 130-093-136, 1:10) and Biolegend:
F4/80 (123126, 1:25)) were used after Fc receptor blockage with CD16/32 blocking
antibody (eBioscience 14-0161-85, 1:100). A FACSCanto II (BD Biosciences) flow
cytometer coupled to the FACSdivaTM software was used for acquisition and anal-
ysis of data. Whole blood samples were analyzed on a Sysmex blood cell analyzer
(XT-2000i, Sysmex Europe GmbH, Norderstedt, Germany).
Cell Culture: Bone marrow derived from non adherent precursors and peritoneal
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M–CSF (20ng/ml, ImmunoTools, GmbH) or L929 conditioned medium (LCM, 15%)
as previously described [85]. A clonal population of VSMC derived from C57Bl6
aortic explants was kindly provided by Dr. Eric van der Veer (Leiden University
Medical Center. Leiden, The Netherlands) and cultured for less than 5 passages
on 1% gelatin and 10µg/ml fibronecting coated wells with DMEM low glucose sup-
plemented with 10% FCS, 2mM glutamine, 1% pyruvate, 100U/ml penicillin and
100µg/ml streptomycin. Human aortic endothelial cells, (HAoEC, PromoCell) were
grown in endothelial growth medium MV (PromoCell). Jurkat (JS–10) lymphocytes
were cultured in DMEM supplemented with 10% FBS, 2mM glutamine, 1% pyruvate,
100U/ml penicillin and 100µg/ml streptomycin.
Thioglycolate Induced Peritonitis: Cells were collected for analysis by FACS stain-
ing 1, 3 or 5 days (as indicated) after induction of peritonitis by intraperitoneal
injection of a sterile solution of dehydrated Brewer’s complete thioglycolate (TG)
broth (2− 3% w/v, Difco Laboratories, West Molesy, UK).
Phagocytosis Assays: Apoptosis was induced in cell tracker CMTMR (5µM, Molec-
ular Probes) labeled Jurkat lymphocytes by incubation with staurosporine (1µM,
Sigma) for 2h. The degree of apoptosis was > 70% as judged by AnnexinV and Pro-
pidium Iodide staining (BD biosciences) and flow cytometry. BMDM were incubated
for 1h with LPS (10ng/ml) or complete medium, washed and incubated with labeled
apoptotic cells (moi=20:1). Phagocytosis was analyzed on a FACSCanto flow cytome-
ter with FACSDiva software (BD Biosciences), extracellularly bound particles were
distinguished from internalized particles by excluding cell aggregates from singlets in
FSC vs FSC and SSC plots. In separated experiments, BMDM were incubated with
FITC–coupled zymosan particles (moi: 20 : 1) opsonized by incubation with human
IgG (13mg/ml in PBS, 20 min at 37oC). Cells were washed, fixed with parafolmalde-
hyde (3.7%, Sigma), supplemented with 15mM sucrose, rinsed with PBS containing
and stained with TRITC–conjugated antibodies. Yellow (FITC and TRITC positive)
extracellular zymosan particles were distinguished from green FITC–positive inter-
nalized particles. Cells were counted by fluorescence microscopy to determine the
percentage of cells that had ingested at least one particle.
Lipid Loading of BMDM: LDL was isolated from serum obtained from healthy
volunteers using the density gradient ultracentrifugation method of Redgrave [86],
oxidized with CuSO4 (40µM, 37
oC, 24h) and dialyzed against PBS at 4oC as previ-
ously described [87].
After incubation with 50µg/ml of LDL or oxLDL in 12–well plates, BMDM
(1x106 cells per well) were detached from the culture surfaces, suspended in PBS and
frozen at -20oC for storage before further analysis. Cells were subsequently thawed
and mechanically lysed by passing them through a 22 gauge needle attached to a 10
ml syringe. Cell lysates were resuspended to 0.25µg/µl of protein. Cholesterol acetate
(20µg/ml in chloroform) was added as internal standard, to a total volume of 1200µl
and samples centrifuged at 3000rpm, for isolation of the chloroform fraction. Lipid
extracts were subjected to HP–TLC chromatography (Alltech/Applied Science) and
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Macrophage Apoptosis and Proliferation: BMDM (5x105 cells/well) cultured on
0.2% gelatin coated 24–well plates, were serum–starved for 24h, incubated 48h in
complete medium, harvested with EDTA (10mM) and stained with Propidium Iodide
(50mg/ml) in PBS containing 2mM MgCl2, 50units/ml DNAse free RNAse, 0.2%
Triton X–100 (pH6.8). The same procedure was used for BMDM induced to undergo
apoptosis by incubation with staurosporin (100nM) and/or LPS (10ng/ml) for 4h
before harvesting. The proliferation index was calculated as the ratio of cells in the
S, G2 and M phases of the cell cycle, relative to the total number of cells. The
experiments were done in triplicate and the results averaged. Data acquisition and
analysis was done by flow cytometry using a FACSCanto II (BD Biosciences) coupled
to FACSdivaTM software. No less than 10,000 cells were analyzed in each sample.
Macrophage Adhesion and Transmigration Across the Endothelium: Laminar flow
assays were performed as described [89]. Briefly, endothelial HAoEC cells (PromoCell)
were grown and pre–incubated with TNFα (10ng/ml) for at least 4h. Hck and Fgr
mutant BMDM or WT controls were suspended at 5X105 cells/ml in 1X Hank’s
buffer, 20mM Hepes, 0.5% HSA (Baxter) and 1mM calcium and magnesium after
stimulation with IFNγ ( 100U/ml Peprotech) during 16 hours. For assessment of cell
adhesion, macrophages were perfused over inflamed HAoEC monolayers during 2min
at 0.1 ml/min and cells counted in 6 High Power Field (HPF, 100X magnification)
pictures. Transmigration was recorded at a flow rate of 0.05 ml/min for 30min in
15sec intervals using a differential interference contrast (DIC) microscope.
Macrophage Morphology, Migration, Podosome Rosette Formation and Matrix
Degradation: Transwell experiments: 100µl of Matrigel (BD Biosciences, batches
from 8 to 10 mg/ml) or type I fibrillar collagen (2mg/ml Nutacon, Leimuiden, The
Netherlands) were poured in transwells (8µm pores, BD Biosciences), polymerized
at 37oC for 30 minutes and 1 hour respectively, and rehydrated with RPMI 1640 to
obtain dense matrices. 5x104 BMDM (n=3) were seeded in the upper chamber on top
of the matrices for assessment of macrophage mesenchymal and amoeboid migration
respectively, as previously described [90, 91]. Gelatin–FITC matrix degradation and
podosome structures were assessed as described [91]. Rosettes of podosomes were
considered large or small when their diameter was respectively bigger or smaller than
20µm. When indicated a cocktail of protease inhibitors (PI, for composition see [91])
was added. Wound healing assay: BMDM monolayers on 0.2% gelatin coated 24 well
plates (0.5x106 cells per well) were serum starved for 24h, scraped with a pipette tip,
incubated 48h in complete medium and either photomicrographed for quantification
of cell migration or collected for assessment of proliferation. Cell morphology and
polarization: peritoneal macrophages (PEM) were judged to be elongated or rounded
when displaying an Elongation Index (EI, defined as the ratio of cell length to breadth)
respectively greater or lower than 2 or 1.2, 36h after collection and culture. Cells
showing more than three filopodial extensions, were judged to possess filopodia [92].
Gelatin Zymography and β–Hexosaminidase Release: Zymography experiments
were performed as previously described [91]. Briefly, BMDM (1x106 cells/well) were
seeded overnight into 6–well fibronectin coated plates. Conditioned culture medium
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sis. For β–hexosaminidase release, BMDM (1x106 cells/well) were seeded overnight
into 6–well plates, the assay was performed on cell extracts obtained in 1% Triton
X100 and supernatants, as previously described [93].
Classic and Alternative Macrophage Polarization: Immune polarization of BMDM
(5x105 cells/well in ) BMDM were seeded at 5x105 cells/well in 24–well plates) was
induced by plates and allowed to adhere overnight before immune polarization incuba-
tion either with 100U/ml IFNγ (Peprotech) or 20ng/ml IL–4 (Peprotech). RNA was
isolated using a Nucleospin RNA II kit (Macherey Nagel, Duren, Germany). cDNA
was obtained with the iSCript R©cDNA synthesis kit (BIO–RAD, Hercules, CA).
Real–time PCR was done with a Taqman IQ R©SYBR Green Super Mix (BIO–RAD,
Hercules, CA) in a MyiQ Icycler (Biorad). Cyclophilin was used as house keeping
gene. Primer sequences are detailed in the Table 2.1. Samples were run in triplicate
and the comparative Ct method was used for analysis. Ct values were defined as the
cycle number at which the fluorescence signals were detected.









Table 2.1. Primers Used for M1/M2 polarization in Hck/Fgr deficient BMDM.
SMC Collagen Synthesis and Proliferation: Cell proliferation, extracellular colla-
gen and non–collagenous protein deposition were assessed in VSMC cell layers by
ELISA (Roche, BrdU colorimetric kit, Cat. No. 11647229001) and a quantitative
collagen and protein micro–assay kit (Chondrex, Inc. Redmond, WA, USA), respec-
tively; according to manufacturer’s instructions.
Tissue Harvesting, FACS Analysis of Aortas, Immunohistochemistry and Plaque
Morphometry: Mice were anesthetized and sacrificed. Animals were perfused with
PBS followed by 4% formaldehyde before dissection of heart, aorta, common carotid
arteries, spleen, thymus and liver. Aortas were enzymatically digested with Liberase
TM (Roche) and single cell suspensions were stained for FACS analysis of macro-
phages and T lymphocytes. Samples of spleen, thymus, liver, lung and bone marrow
were collected for analysis of gene expression and histology. Three samples per or-
gan were obtained, one of which was snap–frozen in liquid nitrogen and stored at
-80oC. The other two samples were stored in 4% formaldehyde (4.5 times diluted Zinc
Formal–Fix, Thermo Electron Corporation, Breda, The Netherlands) overnight, be-












24 Dual Role of Hck and Fgr in Atherosclerosis
Sakura Finetek). Hearts were only embedded in OCT compound after fixation. Ten
or five micrometer thick cryosections were obtained respectively from the aortic root
or the carotids. Aortic root sections were stained using MOVAT’s penthachrome
procedure. Corresponding sections on separated slides were stained for α–naphthyl
acetate esterase to detect monocytes and macrophages (Sigma–Aldrich); or with rat
anti–Ly6G (1:200, Clone 1A8, BD Biosciences Pharmigen ), Rabbit anti rat–biotin
(Dako), ABC Alkaline Phosphatase (Vector Laboratories) and Vectastain Red (Vector
Laboratories) for granulocytes. Picrosirius red was used for quantification of collagen.
For analysis of Ly6c+/+ monocyte infiltration, hearts of animals receiving beads were
mounted with Dapi and used only for fluorescent microscopy. Cryosections from adop-
tive cell transfer, were analyzed by fluorescence microscopy. Sections were analyzed
by two different blind observators, using the Leica Qwin Image Analysis Software, or
ImageJ. All counterstains were done with hematoxylin.
Analysis of microarray Data: For micro–array analysis, total RNA was extracted
using the Guanidine Thiocyanate (GTC),CsCl gradient method [94] and a Nucle-
oSpin RNA II kit (Macherey Nagel, Duren, Germany). Comparison of gene expres-
sion was done for early (n=13) vs. advanced stable (n=16) lesions obtained after
autopsy (Department of Pathology, University Hospital Maastricht, Maastricht, The
Netherlands) or advanced stable (n=21) vs. advanced unstable (n=23) lesions ob-
tained upon surgery (Department of Surgery, Maasland Hospital Sittard, Sittard,
The Netherlands). RNA concentration was determined using a Nanodrop ND–1000
and RNA quality assessed using the RIN (RNA integration number) values obtained
with an RNA 6000 Nano/Pico LabChip (Agilent 2100) Bioanalyzer. Samples where
the RIN number was lower than 5.6 were excluded from the study. The mean RIN was
7.2±0.49. Samples from autopsy were individually hybridized to HGU133 2.0 Plus
arrays (Affymetrix, Santa Clara, USA, California) and samples from surgery to Illu-
mina Human Sentrix–8 V2.0 BeadChip (Illumina Inc., San Diego, USA, California).
Plaques were staged by histological analysis of adjacent slides according to Virmani
et al. [95]. Intimal thickening (IT), thick fibrous atheroma (TkfcA) and intraplaque
hemorrhaged lesions (IPH) were characterized respectively as early, advanced stable
and advanced unstable lesions, respectively. All human work was approved by the
Ethics Committee of the University Hospital Maastricht. Written informed consent
for participation in the study was obtained from all individuals. Microarray expression
data of macrophage immune polarization was obtained at the Gene Expression Om-
nibus Web site (www.ncbi.nlm.nih.gov/geo) under accession number GSE18686 [96].
For analysis of advanced vs unstable and early vs advanced stable lesions, probe set
normalization and summarization was performed using robust multi–array averag-
ing RMA (RMA background subtraction, median polish summarization and quan-
tiles normalization). Data normalization, summarization and statistical differences
computed with permutation were assessed using respectively the R/Bioconductor
packages Affy [97] and Maanova [98]. Probes mapping to single gene IDs were se-
lected using the highest Hyndman’s type 7 IQR [99] after non specific removal of
low expression probes using MatLab’s (Ver7.9) Bioinformatics Tool Box (Ver3.4).
Genes with Benjamini Hochberg corrected false discovery rate and fold change (FC)
FC > 2 were considered differentially expressed. K–means with permutation cluster













MatLab [100]. Overrepresented biological categories within each cluster were iden-
tified using DAVID (Database for Annotation, Visualization and Integrated Discov-
ery) [101] and InnateDB (Innate Immunity Interactions and Pathways) [102–104]
databases. Cluster expansion was performed using Innatedb [102–104]. Transcription
factor and transcription regulator analysis were performed using MRA-FET [105,106]
in geWorkbench. The network used for MRA-FET was constructed using ARACNe
with adaptive partitioning (P value treshold: 0.01) [107]. Transcription factors and
transcription regulators in the whole GSE18686 dataset where found by overrepre-
sentation analysis for gene ontologies GO:0006351 (transcription) and GO:0006355
(regulation of transcription) using InnateDB (Hypergeometric algorithm with Ben-
jamini Hochberg correction) [102–104]. Pathway analysis was performed with KEGG
system retrieved information using the SOAP/WSDL based web serviced from withing
MatLab’s bioinformatics toolbox. Venn diagrams were obtained withing Cytoscape
(http://cytoscape.org) using a Diagram Generator application [108].
Statistical Analysis of Experimental Data: Non–parametric Mann–Whitney U test
or t–test, were done as appropriate, using MatLab Software. Two sided P values
< 0.05, were considered significant and denoted with one, two or three asterisks when
lower than 0.05, 0.01 or 0.001, respectively. Data are presented as mean±SEM. Cor-
relation analyses were performed by Spearman’s rank correlation test. Correlations
were compared with the Fischer R–to–Z transformation, and the F test was used to
assess the significance of the difference between correlations. Multiple comparisons
were analyzed by one–way ANOVA, followed by Bonferroni multi–comparison test.
2.4 Results
Deficiency in Hck and Fgr Leads to Reduced Atherosclerotic Lesions with Reduced
Contents of Myelocyte Cells Despite Ly6chi Monocytosis: Atherosclerosis prone
chimeric mice were generated by reconstitution of lethally irradiated LDLr−/− recipi-
ent animals with Hck−/−Fgr−/− double Knock–Out (dKO) or Wild Type (WT) bone
marrow cells, to establish the role of leukocyte Hck/Fgr–deficiency in atherosclerosis
onset and progression. An average of 95.9% of white blood cells was of donor origin,
indicating successful engraftment. Hck/Fgr deletion did not lead to any alteration
in total body weight along the experiment nor did it affect total plasma cholesterol
levels before (199.4 mg/dl vs. 150.8 mg/dl for WT controls), and after (1616.1 mg/dl
vs. 1488.9 mg/dl, for WT controls) WTD introduction. Plasma cytokine levels of
IL–1β, IL–12, Eotaxin, MCP1, and IL–1α, measured at sacrifice, were not influenced
by Hck/Fgr–deficiency (Appendix A. Fig. A.1).
Chimeric mice transplanted with Hck/Fgr dKO bone marrow exhibited 37%
(P ≤ 0.01) reduction in atherosclerotic lesion size (Fig. 2.1A), coupled with 34%
(P ≤ 0.001) and 61% (P ≤ 0.05) reduction in intimal macrophage and adventitial
neutrophil contents, respectively (Fig 2.1B-C). FACS analysis of atherosclerotic aor-
tas confirmed reduction in macrophage accumulation (Appendix A. Fig. A.2A) and
further indicated that deficiency in Hck/Fgr had no effect in lymphocyte accumu-
lation in atherosclerotic lesions (Appendix A. Fig. A.2B). A similar reduction was
observed in the peritoneal cavity of dKO chimeras 120 hours after induction of peri-
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the activation of macrophages were observed, as assessed by the expression of CD86,
CD40 and MHCII (Appendix A. Fig. A.3D); suggesting that Hck/Fgr–deficiency did
not perturb the activation potential of atherosclerotic lesion macrophages. Corre-
lation analysis indicated delayed development of atherosclerotic lesions, as intimal
macrophage area correlated well to plaque size (Appendix A. Fig. A.4A) both in WT
controls (Spearman’s correlation coefficient: R = 0.9636, P ≺ 0.0001) and mutant
chimeras (R = 0.9833, P ≺ 0.0001). Correlation coefficients were not significantly
different between groups (P = 0.5). Adventitial neutrophil contents did not correlate
to lesion size, neither in dKO chimeras nor in WT controls (Appendix A. Fig. A.4B).
Figure. 2.1. Reduced lesion size and myeloid cell accumulation in dKO
Hck/Fgr chimeras. Hck/Fgr–deficiency caused 37% reduction in atherosclerotic lesion
size (n=13, 10 sections per experimental unit) in aortic roots of WTD fed LDLr−/−
mice (A). Intimal macrophages (B) and adventitial neutrophils (C), were reduced by
34% and 61%, respectively. Middle and right panels in A-C display representative
slides of plaque size, macrophage and neutrophil stainings, respectively. (∗P ≤ 0.05,













Leukocyte subsets levels were quantified in blood, bone marrow and spleen, to
assess the effect of Hck/Fgr–deficiency and determine whether the reduced contents
of macrophages and neutrophils observed in atherosclerotic lesions was caused by
reduced availability in the circulation or impaired hematopoiesis or extravasation of
myelocyte precursors.
The absolute and relative levels of circulatory, bone marrow and spleen white
blood cells, T (cytotoxic, helper and Tregs) and B lymphocytes, as well as of spleen
dendritic cells (DC, resident and plasmacytoid), were not disturbed in chimeric mice
fed WTD (data not shown). Similarly, equivalent bone marrow myelocyte cell compo-
sition (Appendix A. Fig. A.5A) and monocyte subset levels (Appendix A. Fig. A.5B)
were observed. In addition, Hck/Fgr deficiency did not influence the expression of
Ly6c in blood monocyte subsets (Appendix A. Fig. A.5C-D) nor the absolute and
relative levels of circulatory myelocytes (Appendix A. Fig. A.5E-F). However, a sig-
nificant increase in Ly6chi monocytes (+23%, P ≺ 0.01), caused marked blood Ly6chi
monocytosis (Appendix A. Fig. A.5G), suggesting that less macrophages extravasated
into atherosclerotic lesions, despite higher availability of blood Ly6chi monocytes.
Lack of Hck/Fgr Leads to Reduced Monocyte Adhesion to the Endothelium and
Recruitment Into Atherosclerotic Lesions Explaining the cause of reduced accu-
mulation of dKO macrophages in atherosclerotic lesions induced in dKO chimeras,
intravital microscopy of in–vivo labeled cells demonstrated reduced leukocyte adhe-
sion to atherosclerotic lesions (Fig. 2.2A-C). In fact, reduced counts of CD11b+
myelocytes (Fig. 2.2A), as well as Ly6G+ granulocytes (Fig. 2.2B) and Ly6chi mono-
cytes (Fig. 2.2B) were observed on carotid lesions of dKO–LDLr−/− chimeric mice,
compared to WT–LDLr−/− controls. In agreement with these results, reduced levels
of newly recruited Ly6chi monocytes were observed, twenty four hours after labeling
with fluorescent beads (Fig. 2.3A-C).
Similarly, adoptively transferred fluorescent labeled dKO BMDM displayed pro-
foundly reduced adhesion (-67%, P ≤ 0.001) and almost ablated transmigration (-
88%; P ≤ 0.001) to preexisting atherosclerotic lesions induced in WTD fed LDLr−/−
mice by perivascular collars (Fig. 2.4A-D). Matching these results in–vivo, dKO
BMDM perfused through a monolayer of inflamed endothelium in-vitro displayed
reduced adhesion (Fig. 2.4 E-F). Once adhered, the percentage of cells that transmi-
grated across the endothelium in-vitro was not influenced by Hck/Fgr–deficiency (Fig.
2.4G), implying that transendothelial macrophage migration was reduced indirectly
by prior impairment of the adhesion mechanism.
In-vitro, dKO BMDM displayed reduced cell densities on the scraped area in
wound healing assays (-94%, P ≤ 0.001; Fig. 2.5A), despite that proliferation rates
(Appendix A. Fig. A.6A) and seeded cell densities were similar in both genotypes,
indicating impaired two dimensional migration. In addition, dKO peritoneal macro-
phages (PEM) presented altered morphology in-vitro characterized by lack of elonga-
tion and morphological polarization, and reduced formation of filopodium and lamel-
lipodium (Fig. 2.5B-F); suggestive of dysfunctional actin network polymerization.
Taken together these results indicate impaired monocyte adhesion on the en-
dothelium and disrupted diapedesis, as contributing factors to the reduced accumu-
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Figure. 2.2. Impaired adhesion to the endothelium and transmigration
of Hck/Fgr–deficient circulatory leukocytes. Circulatory leukocyte adhesion to the
carotid artery was analyzed in WT versus Hck/Fgr dKO chimeras by intravital mi-
croscopy. For this, the right jugular vein was canulated with a catheter for dye and
antibody injection after exposure of the left carotid artery. Intra–vital microscopy
recordings were made three minutes after injection of Rhodamine or antibodies for
CD11b, Ly6G and Ly6C were administered. A-D. Reduced adhesion of Rhodamine+
fluorescent blood leukocytes (A) labeled in in–vivo were observed in dKO–LDLr−/−
chimeras, compared to WT–LDLr−/− control mice. Similar reductions were obser-
ved in circulatory CD11b+ myelocytes (A) as well as Ly6G+ neutrophils and Ly6c+
monocytes (B). C-D. Representative pictures of intravital microscopy corresponding


























Figure. 2.3. Hck/Fgr deficiency causes reduced accumulation of newly recruited Ly6c+ monocytes in atherosclerotic
lesions. A-C. Chimeric mice were generated by reconstitution of lethally irradiated LDLr−/− mice with bone marrow from Hck/Fgr
dKO donors. These animals received intravenous injections of Latex Beads 18h after receiving chlodronate liposomes to label Ly6chi
monocytes [58]. Mice were sacrificed twenty four hours after labeling for excision of hearts and analysis by fluorescent microscopy
of aortic root sections. A. Reduced accumulation of newly recruited monocytes was observed in dKO chimeras, compared to WT
controls. B-C. Representative pictures of sections used for quantification of bead labeled monocytes (green). DAPI was used for
staining of cell nuclei.(Scale bars in B-C, left panels: 500µm. Central and right panels: 100µm. Pictures in central and right panels
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Hck/Fgr–Deficient Macrophages Display Reduced Three–Dimensional Migration
The three–dimensional migration capacity of dKO macrophages was next assessed,
taking into account that particularly at late stages of lesion development, extravasated
cells must pass through collagen and VSMC rich fibrous caps. Macrophages employ
mesenchymal and amoeboid migration mechanisms to perform three dimensional infil-
tration [90] either by protease dependent degradation of dense Extracellular Matrices
(ECM) or by squeezing and deforming their cell body across similar sized pores, re-
spectively.
In-vitro, dKO macrophages displayed unimpaired amoeboid migration across
type I fibrillar collagen (Fig. 2.6A), which contrasted with their markedly inhib-
ited mesenchymal migration through dense Matrigel (Fig. 2.6B). Furthermore, the
addition of Proteinase Inhibitors (PI) inhibited the mesenchymal migration through
matrigel in WT BMDM to levels observed in untreated mutant cells. PI were how-
ever unable to further impair the migration capacity of mutant BMDM (Fig. 2.6B)
suggesting that Hck/Fgr–deficiency caused reduced mesenchymal migration either by
downregulating the expression or disrupting the release of proteases. However, dKO
BMDM displayed no abnormality in lysosomal secretion of β–hexosaminidase (Fig.
2.6C), MMP2 and MMP9 (Fig. 2.6D), excluding that vesicular secretion defects had
underlaid the observed impairment of macrophage migration.
During mesenchymal migration, protease delivery is thought to take place at
podosomes [90]. The formation of podosomes and their organization as rosettes was
therefore assessed. As previously shown, podosome rosettes are structures formed
upon Hck activation in Macrophages [91,93], used for focal release of proteases at sites
of cell penetration, to allow cell passage without distal ECM degradation [109]. As
expected, WT cells formed large podosome rosettes; dKO cells in contrast, formed less
and smaller podosome rosettes (Fig. 2.6E-F). Moreover, dKO macrophage rosettes
had reduced ECM degradation capacity as assessed by FITC gelatin degradation
(-44%, P ≤ 0.001. Fig. 2.6G-H).
Taken together these results indicate that Hck/Fgr gene deletion causes reduced
mesenchymal migration by impairing the formation of podosome rosettes leading to
reduced pericellular degradation of the ECM, which likely contributed to the reduced
accumulation of macrophages observed in atherosclerosis, by impairing their migration
through lesion fibrous caps.
Hck/Fgr–Deficiency Promotes a Potentially Vulnerable Plaque Phenotype De-
spite their reduced size and macrophage contents, plaques from Hck/Fgr dKO chime-
ras unexpectedly exhibited a vulnerable plaque phenotype, characterized by necrotic
core expansion (+68%; P ≤ 0.01), and significant reductions in minimal fibrous cap
thickness (-53%, P ≤ 0.001) SMC (-75%, P ≤< 0.001) and collagen contents (-82%,
P ≤< 0.001) (Fig. 2.7A-F). Statistical analysis revealed that except for necrotic core
size, these variables did not correlate with lesion size (Appendix A. Fig. A.4C-F).
The possibility that dKO macrophages displayed increased apoptosis and/or
reduced phagocytosis was therefore evaluated, as they correlate with necrotic core
expansion and lesion vulnerability. In agreement with this, increased susceptibility
to apoptosis induction was observed in dKO macrophages, compared to WT con-
trols (Appendix A. Fig. A.6B). However, Hck/Fgr–deficient BMDM exposed normal













Figure. 2.4. Impaired adhesion to the endothelium and transmigration of
Hck/Fgr–deficient macrophages. Fluorescent labeled dKO macrophages adoptively
transferred to LDLr−/− mice displayed reduced adhesion to (A-B) and diapedesis
into (C-D) preexisting atherosclerotic lesions induced by perivascular collar place-
ment (n=6). Representative pictures of intravital microscopy (B) and fluorescence
microscopy (D) correspond to experiments depicted in A and C, respectively. DAPI
labeled Hck/Fgr dKO (arrowheads, blue) and DiI labeled WT (arrows, red) BMDM,
are shown to adhere to the endothelium in–vivo (B) and home to the subendothelial
space (D, Postmortem section) 15 min (B) and 1 day (D) after cell co–transfer (106
BMDM/genotype/mouse) into atherosclerotic LDLr−/− mice (Scale bar: 100µm).
Adhesion (E-F) but not transmigration (G) across monolayers of inflamed endothe-
lium (in-vitro) is reduced in dKO BMDM (n=3, 6 High Power Microscopic Field
(HPMF) quantifications per sample). (F. Representative differential Interference
Contrast Microscopy HPMF pictures of BMDM adherent to inflamed endothelium
in-vitro). (*P=0.05, ***P=0.001).
cholesterol, in-vitro (Appendix A. Fig. A.6C-F).
In addition, incubation of VSMC layers with conditioned medium (CM) from
unstimulated Hck/Fgr dKO BMDM did not influence their proliferation (Fig. 2.8A),
but reduced their deposition of extracellular collagen and non–collagenous proteins
akin to conditioned medium from LPS–stimulated WT macrophages and starvation
medium (SM) (Fig. 2.8B-C) indicating that Hck/Fgr–deficiency causes skewed macro-
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Figure. 2.5. Hck/Fgr dKO macrophages display impaired two dimensional
directional migration and aberrant morphology. A. dKO macrophages display 94%
reduced two dimensional migration and wound healing capacity in-vitro (n=3, 5 area
quantifications per replicate). B-C. Morphology of peritoneal macrophages (PEM)
cultured for 36h (n=5, 100 cells per replicate). B. Mean elongation index (EI), defined
as the ratio of cell length to cell breadth). C. Percentage of rounded (EI ≤ 1.2 black
bar segments), elongated (EI ≥ 2,grey bar segments) and partially elongated cells
(1.2 ≺ EI ≺ 2, white bar segments) as judged by the elongation index (EI). D-E.
Percentage of PEM cultured for 16 hours, forming filopodia (D) and Lamellipodia
(E) (n=5, 100 cells per replicate). F. Representative pictures depicting rounded cell
morphology in dKO cells compared to WT PEM (Scale bar: 10µm. ∗ ∗ ∗P ≤ 0.001).
to degrade the extracellular matrix.
The participation of Hck and/or Fgr in tissue repairing gene networks was as-
sessed by transcriptome analysis of differentially expressed genes from human macro-
phages stimulated with TNFα, IL–4, IL–17, LPS, IFNγ or LPS+IFNγ (GSE18686,
[96]). K–means cluster analysis of gene expression data revealed five gene clusters
of which clusters III and IV (C-III and C-IV) contained respectively FGR and HCK
(Fig. 2.9A).
Principal component analysis (PCA) indicated that C-I, C-II and C-III on one
hand, and C-IV along with C-V, on the other, contained genes with upregulated
expression in response to IL–4 and LPS–IFNγ, respectively (Fig. 2.9B, see also Ap-
pendix A. Fig. A.7 and A.8); suggesting that HCK and FGR participate in different
molecular networks that determine the polarization phenotype of macrophages, in
agreement with their differences in structure and classification withing the Src family
of tyrosine kinases [110].
Consistently, HCK and FGR were higher than two fold regulated in response













Figure. 2.6. Assessment of three–dimensional migration. Hck/Fgr–deficient
BMDM displayed normal amoeboid (n=3) (A) but reduced mesenchymal migration
(n=3) across Matrigel transwells where proteinase inhibitors (PI) inhibited WT but
not dKO BMDM migration (n=2). C. β–hexosaminidase was released at similar levels
in WT and dKO BMDM (n=3). D. Metalloproteinases MMP–2 and MMP–9 content
and secretion, assessed gelatin zymography, is unaffected in dKO BMDM. E. dKO
BMDM form less and smaller podosome rosettes than WT controls (n=5). F. Rep-
resentative pictures illustrating reduced podosome rosette size in dKO BMDM, 100X
magnification. G. FITC–gelatin degradation is reduced in dKO BMDM (n=9). H.
Representative pictures of BMDM showing fewer, smaller and paler gelatin proteolysis
areas (in dark) colocalizing with podosome rosettes in dKO BMDM compared to WT
controls. (Blue for cell nuclei, red for F–actin in F and H. Green for Vinculin in F,
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Figure. 2.7. Atherosclerotic lesion composition in Hck/Fgr dKO atheroscle-
rotic chimeras. Atherosclerotic lesions from Hck/Fgr dKO chimeras display features
of plaque vulnerability characterized by bigger necrotic cores (+68%)(A) thinner fi-
brous caps (-53%) (B) and reduced SMC (-75%) (C) and collagen (-82%) contents
(D) (n=13, 6 sections per experimental unit). E-F. Representative pictures denoting
lumen size (L) necrotic core (NC) expansion, minimal fibrous cap (FC) thinning and
reduced VSMC (arrows delimited red–purple areas in Movat’s staining E) and collagen
areas (Picrosirius Red staining, F) in dKO chimeras. (∗ ∗P ≤ 0.01, ∗ ∗ ∗P ≤ 0.001).
that positive regulators of gene expression associated with alternative activation of
macrophages (HIF2A–EPAS1, IRF4, KLF2, KLF4, MAF, MYC, PPARγ, STAT3
and STAT6) regulated the expression of genes belonging to C-I, C-II and C-III (Fig.
2.9D and 2.10). In particular the expression of FGR was predicted to be positively
regulated by STAT3, PPARG and KLF2 (Pval ≺ 0.0001).
Similarly, transcription factors linked to classical activation of macrophages
(HIF1α, IKBKG, JUND, NFKB, SOCS3, STAT1, STAT2,STAT5) acted as positive
regulators of gene expression for clusters C-IV and C-V (Fig. 2.9E and 2.11). IKBKG













Figure. 2.8. Conditioned medium from Hck/Fgr dKO BMDM attenuates
VSMC collagen deposition. Despite similar proliferation rates (A), VSMC cultured
during 48 hours with starvation medium (SM) and conditioned medium (CM) from
dKO BMDM or WT LPS activated BMDM, displayed reduced extracellular deposition
of collagen (B) and non collagenous proteins (C), compared to VSMC cultured in CM











































Figure. 2.9. Transcriptome analysis of gene expression in human macrophages. A. K–means clustering of human genes
modulated upon stimulation with IFNγ, IL–17, IL–4, LPS, IFNγ + LPS (denoted as IFN+) or TNFα generates five clusters (C-I
to C-V). FGR and HCK belong to C-III and C-IV respectively (A). B. PCA of K–means clustered genes. 99.3% of the variance of
the system lies within the first three PC (PC1:1.3, PC2:84.8 and PC3:13.2%). Two dimensional PC2 vs PC3 biplot projection of
gene scores and component coefficients for each treatment. Note the divergent positioning of C-III (red) and C-IV (blue) along the
PC2 axis. The direction and length of the vectors indicate how each treatment contributes to the components. C. HCK and FGR
display opposite expression patterns in response to IFNγ and IL–4. D-E. Transcription factor analysis permitted the identification
of positive and negative regulators of gene expression corresponding to CI to CIV. Euler diagrams indicate that positive regulators













REGULATOR EXPRESSION REGULATED GENES(%)
PROFILE C-I C-II C-III
HIF2A/EPAS1 C-III 27 36 39
IRF4 C-I 9
KLF2 C-I 18 26 31
KLF4 C-II 17 40 48
MAF C-II 34 19 15
MYC C-II 21 16 21
PPARG C-III 40 48 59
SOCS1 C-III
STAT3 C-III 27 60 73
STAT6 C-I 20 17 16
Figure. 2.10. Transcription factors linked to tissue repair and resolution of
inflammation, that control the expression of genes upregulated upon IL–4 stimulation.
Top panel: Percentage of regulated genes per cluster(∗P ≺ 1E − 5). Bottom panel:
bar graph view of genes regulated in cluster C-III. Vertical bars correspond to ranked
positions of genes regulated, ordered by P value. The position is given by the red–blue
gradient at the bottom of the graph, that represents the ranking between the highest
(farthest left (red) and right (blue)) and the lowest (middle, white) test statistic, for
differential expression. Red and blue vertical bars represent respectively genes that are
positively or negatively correlated to the expression of each transcription factor.
Network expansion was then performed to include all genes that did not present
differential expression upon stimulation with TNFα, IL–4, IL–17, LPS, IFNγ or
LPS+IFNγ, but which interact with genes in clusters C-I, C-II, C-III, C-IV and
C-V (obtained by K–means analysis of differentially expressed genes). Networks N-I,
N-II, N-III, N-IV and N-V were respectively obtained. Curated interactions where
obtained from InnateDB database [104].
As expected, and in agreement with the reduced adhesion to the endothe-
lium and deficient migration observed in double deficient macrophages (Fig. 2.2 to
2.6), both, HCK and FGR had common interactors involved in actin polymerization
and filament organization (GO:0008154, GO:0007015, Benjamini Hochberg corrected
over–representation Pval ≺ 1E − 05), cell migration (GO:0030335, GO:0050900, cor-
rected Pval ≺ 1E − 05), cell adhesion (GO:0045785, corrected Pval ≺ 1E − 02) and
podosome organization (GO:0071801, corrected Pval ≺ 1E − 02). In addition, HCK,
FGR and their first neighbor interactors were found to over–represent the chemokine
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REGULATOR EXPRESSION REGULATED GENES(%)
PROFILE C-IV C-V
FOSB C-IV
HIF1A C-IV 33 32
IKBKG 12
JUND 5 13
NFKB1 C-IV 23 24
NFKB2 C-IV 40 66
SOCS3 C-IV
STAT1 C-V 17 15
STAT2 C-IV 32 46
STAT5A 9
Figure. 2.11. Transcription factors linked to proinflammatory macrophage
differentiation that control the expression of genes upregulated upon IFNγ stimula-
tion. Top panel: Percentage of regulated genes per cluster (∗P ≺ 1E − 5). Bottom
panel: bar graph view of genes regulated in cluster C-IV. Vertical bars correspond to
ranked positions of the genes regulated, ordered by P value. The position is given by
the red–blue gradient at the bottom of the graph, that represents the ranking between
the highest (farthest left (red) and right (blue)) and the lowest (middle, white) test
statistic, for differential expression. Red and blue vertical bars represent respectively
genes that are positively or negatively correlated to the expression of each transcription
factor.
in immune cell function and cell migration (Appendix A. Fig A.9).
Interestingly, while FGR was only present in N-III (Fig. 2.12A), as expected,
HCK was included in N-I, N-II, N-III and N-IV (Fig. 2.12B, see below for a discus-
sion). Similarly, many gene products were shared by more than one network (Fig.
2.12A-C), which suggest that they form part of a core set of proteins active in both
classic and alternative macrophage differentiation.
Hck and Fgr are expected to participate in different biological processes, due to
their differences in structure, and different classification among Src kinase subfami-
lies [110]. Network expansion facilitated the identifications of molecular interactions
and functions not shared by HCK and FGR. In fact, inside its network, FGR, but not
HCK, displayed multiple interactions with proteins that induce anti–inflammatory
and tissue repairing programs, including the PPARG co–activator NCOA6 [111] and
PXR (NR1I2), an anti–inflammatory protein that blocks NFKB activation [112–













Figure. 2.12. Euler diagram of gene networks expanded from Clusters I-V.
A-C. Network expansion was performed using clusters of genes with similar expression
profile in response to IFNγ, IL–17, IL–4, LPS, IFNγ + LPS or TNFα stimulation.
Roman numbers for networks correspond to numbers of clusters in Fig 2.9. A. HCK
and FGR participate in networks containing genes upregulated in response to IL–4
(C-I, C-II and C-III). B. HCK also participates in network N-V, containing genes
upregulated in response to IFNγ. C. Expanded networks from clusters I-V contain
genes particular for each network as well as genes that are shared. The overlap among
networks indicates the presence of core genes that are used for both, anti–inflammatory
(N-I, N-II and N-III) and pro–inflammatory (N-IV and N-V) processes.
for anti–inflammatory and tissue repairing [116, 117] programing of macrophages
(Fig. 2.13A-B). Furthermore, tyrosine phosphorylation of IKBKG by FGR (Fig.
2.13A), leads to suppression of NFKB activation [118], which positions FGR as an
anti–inflammatory kinase(interaction of FGR but not HCK with NCOA6, NR1I2 and
IKBKB respectively in [119–121]).
HCK on the other hand, mediates the activation of macrophages in response
to LPS [122, 123] and IFNγ [124, 125] and was found to interact inside its network
with proteins that promote inflammation, including (i) NCL which regulates the po-
larization of macrophages in response to LPS stimulation [126]; (ii) CREBBP, which
cooperate with NFKB and STAT1 to mediate inflammatory gene expression upon
IFNγ stimulation [127] and (iii) BTK a negative regulator of alternative activation
in macrophages [128, 129] (interactions of HCK, not FGR, with NCL, CREBBP and
BTK respectively in [130–132]).
In addition, tyrosine phosphorylation of p73 (TP73) by Hck represses its tran-
scriptional activity [133], which is required for alternative activation of macrophages
and macrophage induced resolution of inflammation [134]; arguing for a proinflam-
matory role of HCK in macrophage function.
It is therefore likely that besides their overlapping role in macrophage chemo-
taxis, Hck and Fgr have divergent roles to promote pro–inflammatory and wound
healing processes, respectively. However, HCK was included in Networks N-I, N-II
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2.13B and 2.12). In these networks, HCK interacts with PI3K and its p85 regulatory
subunit [130, 135], which are crucial for alternative activation of macrophages [55].
In addition, similar to FGR, HCK activates STAT3, to induce anti–inflammatory
macrophage activation programs [82, 115] (Fig. 2.13B). Moreover, inhibition of Src
tyrosine kinases has been demonstrated to block the activation of STAT6 [136], which
is critical for alternative activation of macrophages [116, 117]. Similarly, Src tyrosine
kinase dependent phosphorylation of SHIP triggers its polyubiquitination and degra-
dation within the proteasome [137], which is required for alternative activation of
macrophages by IL–4 [138].
It is therefore conceivable that HCK mediates both pro–inflammatory and tissue
repairing programs in macrophages, in a context dependent fashion, implying that
HCK deficiency might skew the balance of macrophage function towards both pro–and
anti–inflammatory directions.
Figure. 2.13. First neighbors of FGR and HCK, in Network N-III. Expan-
sion of cluster C-III resulted in network N-III (see also Fig. 2.9). Shown here are
HCK, FGR and their first interactor neighbors (orange labels for FGR interactors,
blue, for HCK and FGR interactors, purple for HCK interactors). FGR, but not HCK,
interacts with transcription factors that control the expression of anti–inflammatory
genes (NCOA6 [111], NR1I2 [112–114]). Tyrosine phosphorylation of IKBKG by
FGR, leads to suppression of NFKB activation [118]. STAT3 is activated by both,
FGR (A) and HCK (B) [115]. Interactions of FGR, but not HCK, with NCOA6,
NR1I2 and IKBKG in References: [119–121]. See text for further details.
2.5 Discussion
This chapter presents conclusive evidence that demonstrates that Hck/Fgr–deficiency
leads to reduced atherosclerotic lesion formation with concomitant reduction in macro-
phage accumulation and lesion stability due to impaired adhesion to the endothelium,













Figure. 2.14. First neighbors of HCK, in network N-IV. Expansion of clus-
ter C-IV resulted in network N-IV (see also Fig. 2.9). Shown here is HCK and its
first interactor neighbors (orange labels). HCK, interacts with transcription factors
that control the expression of pro–inflammatory genes (NCL [126], CREBBP [127],
BTK [128, 129]). Tyrosine phosphorylation of TP73 by Hck represses its transcrip-
tional activity [133], which is required for alternative activation of macrophages and
macrophage induced resolution of inflammation [134]. Interactions of HCK but not
FGR, with NCL, CREBBP, BTK and TP73 in References: [130–133]. See text for
further details.
pro–inflammatory phenotype.
As a first hallmark of Hck/Fgr–deficiency, atherosclerotic lesions displayed re-
duced amounts of macrophages despite higher availability of circulating Ly6chi mono-
cytes, a subset known for its hypermigratory and inflammatory profile, and selective
accumulation in atherosclerosis [57, 58].
Intravital microscopy of circulatory leukocytes, including monocytes and granu-
locytes; and chlodronate liposome labeling of Ly6chi demonstrated reduced myelocyte
adhesion to the endothelium and extravasation into atherosclerotic lesions, in Hck/Fgr
dKO chimeras. In addition, Hck/Fgr–deficient macrophages displayed impaired mor-
phological polarization, deficient adhesion to the endothelium and disrupted two and
three dimensional migration. Furthermore, dKO macrophages were unable to form
filopodia and lamellipodia, which is critical for those cells to adhere and establish lead-
ing and trailing poles that direct their mobilization towards higher concentrations of
chemoattractants [139]. Taken together, these results imply that Hck/Fgr–deficiency
caused reduced adhesion on the endothelium and therefore reduced extravasation of
circulating monocytes and accumulation of macrophages in atherosclerotic lesions.
The three–dimensional mesenchymal migration of macrophages depends on the
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cellular degradation of the extracellular matrix [90]. In-vitro, dKO macrophages had
impaired localized degradation of the extracellular matrix by disrupted formation of
podosome rosettes, and mesenchymal migration. Considering the transformation of
monocytes from amoeboid to mesenchymal migrating cells upon extravasation into
peripheral tissues and differentiation into macrophages [140] this result indicates that
Hck/Fgr–deficiency might have caused reduced macrophage mesenchymal migration
across lesional fibrous caps, contributing this way to the reduced accumulation of
macrophages observed in lesions of dKO chimeras.
A second striking hallmark of Hck/Fgr–deficiency was the high susceptibility to
apoptosis induction that dKO macrophages displayed, and the expansion of necrotic
cores observed in Hck/Fgr deficient, atherosclerotic mice. This, together with the
inability of dKO macrophages to migrate suggest that intra–lesion phagocytes might
have been unable to migrate towards apoptotic cell ”eat me signals”, leading to poor
efferocytosis of death cells with subsequent expansion of necrotic cores.
Reduced fibrosis, VSMC accumulation and collagen deposition were also ob-
served in atherosclerotic lesions of atherosclerotic mice recipients of dKO bone mar-
row cells. One likely explanation for this phenotype, is that reduced adhesion and
homing of circulatory monocytes into atherosclerotic lesions might have caused re-
duced accumulation of fibrocytes. In fact, Lessened fibrocyte contents correlate with
atherosclerotic lesion instability and reduced deposition of collagen and secretion of
TGFβ [141,142]. In addition, blood monocytes are known to differentiate into fibro-
cytes [143] that express Hck and Fgr [144] and accumulate in atherosclerotic fibrous
caps [142], suggesting that Hck–Fgr deficiency would not also lead to reduced macro-
phage accumulation but also reduced numbers of lesion fibrocytes; a point that could
be addressed by staining atherosclerotic lesions from Hck–Fgr deficient chimeras for
markers that discriminate between monocytes, macrophages, fibrocytes, fibroblast
and SMCs [144].
It is also likely that Hck and Fgr have a role in macrophage tissue repairing
functions. In agreement with this notion, we demonstrated that Hck/Fgr–deficient
macrophages inhibited VSMC extracellular matrix collagen and non–collagenous pro-
tein deposition. Similarly, ear excision wounds treated with Src tyrosine kinase in-
hibitors display reduced accumulation of collagen and wound healing [145]. Further-
more, Hck/Fgr–deficient chimeras displayed Ly6chi blood monocytosis, which cor-
relates with higher Ly6chi monocyte infiltration into atherosclerotic lesions [57, 58],
lesion vulnerability [59–61] and reduced accumulation of anti–inflammatory and tissue
repairing macrophages [59,61,146].
Transcriptome and network analysis of microarray datasets indicated the in-
volvement of HCK and FGR in human atherosclerosis (Appendix A. Fig. A.10) and
gene networks that regulate inflammation and control the induction of tissue repair by
macrophages. In agreement with these results, FGR has been reported to block the
activation of NFKB [118] and activate STAT3 [115], which induces the expression of
wound healing genes, including TFG-b and IL-10 [117,147]. Fgr deficiency therefore,
would be expected cause inflammation and extracellular matrix degradation.
Hck on the other hand, participates in divergent gene networks that drive ma-
crophage pro–inflammatory and extracellular matrix degrading or anti–inflammatory
and wound–healing functions, depending on the molecular network it is embedded in.













ization, and implicates that the effect of Hck deficiency would be context dependent.
Taken as a whole, the results obtained by computational analysis indicate that
Hck and Fgr double deficient macrophages would be expected be pro–atherogenic and
induce reduced deposition of collagen, as observed in the experiments here presented.
This sets the basis for further experimentation, to corroborate the dual and context
dependent role of Hck and the function of FGR as anti–inflammatory kinase that
positively regulates wound healing and tissue repair.
The prominent involvement of Hck/Fgr in extravasation and alternative acti-
vation of macrophages, shifts the paradigm of macrophage accumulation as prime
responsible factor of lesion vulnerability towards the notion of intra–lesion macro-
phage phenotype as crucial determinant of plaque stability. The role of Hck and Fgr
in chemotaxis and that of Fgr in wound healing and tissue repair, raises a note of
caution against the use of Src kinase inhibitors for the treatment of atherosclerosis,
where reduced macrophage accumulation with simultaneous increased tissue repair
and deposition of collagen are desired to attain a stable plaque profile. However, the
novel application of Src Kinase inhibitors as anti–fibrotic therapy in systemic scle-
rosis [148, 149] and the results here described, support their potential to treat the
fibroplastic vasculopathy of restenosis and disorders where simultaneous reduction
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”...society will need to shed some of its obsession for causality in
exchange for simple correlations: not knowing why but only what”.
V. Maker & K. Cukier, Big Data
3.1 Abstract
Background: Besides its presumed cytokine function, NAMPT is a rate limiting
enzyme in the NAD+/NADH biosynthesis salvage pathway. NAMPT confers resis-
tance to apoptosis and oxidative stress, and has been implicated in inflammatory
processes and upregulation genes involved in macrophage differentiation and choles-
terol. Herein, the role of NAMPT in atherosclerosis was addressed.
Methods and Results: NAMPT was progressively over expressed in human
carotid artery atherosclerotic lesions and upregulated in peripheral blood mononuclear
cells from stroke patients. LDLr−/− mice with hematopoietic intracellular NAMPT
over expression (iNAMPThi) showed attenuated plaque burden with features of le-
sion stabilization such as reduced apoptotic cell and macrophage contents and lessened
necrotic core formation. No significant differences in smooth muscle cells and collagen
contents where observed in iNAMPThi LDLr−/− chimeras. Similarly, no differences
were observed in plasma cholesterol, triglyceride and inflammatory cytokine levels,
including NAMPT. However, over expressing iNAMPT chimeric mice had reduced
circulating monocytes, which were Ly6clo skewed. In addition, induction of NAMPT
over expression upregulated SIRT1, ABCA1 and ABCG1 leading to reduced foam
cell formation, and alternative macrophage polarization. Furthermore, iNAMPT in-
hibited monocyte stromal egress and extravasation in a PPARγ dependent manner
by quenching CCR2 expression and migratory capacity. The cross talk between iN-
AMPT and PPARγ was corroborated in human carotid atherosclerosis, showing a
correlation between iNAMPT and PPARγ in atherosclerotic but not healthy arteries.
Conclusions: These findings unveil a critical role for the iNAMPT–PPARγ axis
in atherosclerosis, which regulates monocyte egress and migration and macrophage
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3.2 Introduction
Nicotinamide Phosphoribosyl Transferase (NAMPT) or Visfatin was originally re-
ported in 1994 as a pre–Bcell colony enhancing factor (PBEF), secreted protein
by activated lymphocytes in bone marrow stroma, suggesting a cytokine like func-
tion [152,153].
In mammals, NAMPT catalyzes a rate limiting first step in the salvage pathway
of nicotinamide adenine dinucleotide (NAD+) synthesis [154], a key factor in cellular
energy metabolism and redox homeostasis [155], and cytoprotection. In addition,
NAD+ acts as cofactor for the silent mating type information regulation 2 homolog
1 (SIRT1) [156], which is closely involved in the epigenetic regulation of Peroxisome
Proliferator Activated Receptor–γ (PPARγ), Nuclear Factor–κB (NFκB), p53, FOXO
transcription factors, and endothelial nitric oxide synthase [157–159]. Moreover, a
recent study has implicated NAMPT in the control of granulocyte colony stimulating
factor (G–CSF) induced granulopoiesis in healthy subjects and in individuals with
severe congenital neutropenia, largely by promoting SIRT1 dependent G–CSF activity
[160]. These new studies have considerably widened its potential biological activities
beyond that of being a growth factor for B cells.
NAMPT not only acts intra- but also extra–cellularly. Although the physiolog-
ical role of the extracellular NAMPT (eNAMPT) is still controversial, some studies
have imputed eNAMPT pro–inflammatory activity in monocytes, neutrophils, and
macrophages. Accordingly, various inflammatory stimuli such as IL–1β, IL–6, TNFα,
LPS, IL–8, and oxidized LDL (oxLDL) were seen to induce eNAMPT in CD14+
monocytes [161]. Of note, increased plasma levels of eNAMPT following mechani-
cally induced plaque rupture (i.e., percutaneous coronary intervention) are observed
in patients with coronary artery disease. Similarly, enhanced expression of NAMPT is
present in unstable atherosclerotic carotid lesions, primarily located to foam cell ma-
crophages [162]; which suggest that both extracellular and iNAMPT may be involved
in certain inflammatory disorders such as atherosclerosis.
The latter finding, combined with the reported role of NAMPT in regulating
redox homeostasis, apoptosis, and immune responses, all key processes in the lipid
driven chronic inflammatory disorder of atherosclerosis, pleads for a contributory
role of NAMPT in the progression of this disease. However, despite the wealth of
circumstantial evidence, the role of NAMPT in atherosclerotic plaque development
has not yet been investigated.
This study demonstrates upregulation of intracellular NAMPT in peripheral
blood mononuclear cells (PBMC) of patients with ischemic stroke as well as in human
atherosclerotic arteries. Moreover, supraphysiological human iNAMPT expression in
hematopoietic cells of LDL receptor deficient (LDLr−/−) mice was seen to lead to in-
creased myeloid cell survival and impaired stromal egress with concomitant reduction
of circulatory monocytes, which translated in delayed atherosclerotic plaque develop-
ment. The observed phenotypic effects of iNAMPT on monocytes were demonstrated
to proceed in a PPARγ dependent manner. Thus, this study identify the iNAMPT
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3.3 Materials and Methods:
PBMC Isolation: PBMC from patients with symptomatic carotid atherosclerosis
and healthy controls, recruited from the same area of Norway, were isolated from
heparinized blood by Isopaque–Ficoll (Lymphoprep; Nycomed, Oslo, Norway) gradi-
ent centrifugation.
Tissue Sampling from Atherosclerotic and non Atherosclerotic Vessels: Atheros-
clerotic carotid arteries were obtained from patients undergoing carotid endarterec-
tomy (Maasland Hospital, Sittard, The Netherlands and Oslo University Hospital
Rikshospitalet, Oslo, Norway) or at autopsy (Department of Pathology, Academic
Hospital Maastricht, Maastricht, The Netherlands) as previously described [162,163].
Lesions obtained in The Netherlands, were scored according to the criteria of Vir-
mani and coworkers [95]. Intimal thickening was classified as early, thick fibrous cap
atheroma as advanced, and thin cap fibroatheroma with features of cap break, mural
thrombi, plaque dissection and/or intraplaque hemorrhage were regarded as ruptured
lesions. Non atherosclerotic vessels were obtained from common iliac artery of organ
donors (Oslo University Hospital Rikshospitalet, Oslo, Norway) and the samples were
handled and stored following the same protocol as that used for the atherosclerotic
vessels.
Animals: Female and male LDLr−/− mice, on C57/Bl6 background, were obtained
from the local animal breeding facility at University of Maastricht. Mice were fed a
regular chow diet (SDS, Essex, UK). Female LysM–Cre–PPARγflox/flox bones were
kindly provided by Prof. Nagy (University of Debrecen, Hungary). Drinking water
and food were provided ad–libitum. Experiments were performed at the animal facility
of the University of Maastricht. Male LDLr−/− mice were used as donors for bone
marrow transplantations and in vitro assays. All study protocols involving animal
experiments were approved by the Animal Care and Use Committee of the University
of Maastricht and were performed according to official rules formulated in the Dutch
law on care and use of experimental animals.
Lentivirus Production and Transfection: Plasmids encoding NAMPT, pRRL–PGK–
hNAMPT and pRRL–PGK–Empty Lentivirus vectors were used. Human NAMPT
(GenBank accession number NM005746.2) complementary DNA (cDNA) was poly-
merase chain reaction (PCR) amplified, sequenced, and subcloned into pRRL–PGK
Lentivirus vector. Plasmids for lentiviral packaging, pMDLg/pRRe, pRSV–REV,
and pMD2G were obtained from Addgene (Cambridge, USA). Recombinant lentivi-
rus were produced by transfecting lentivector and packaging vectors into 293T cells
(Invitrogen, Paisley, UK).
Bone Marrow Transplantation: Female LDLr−/− (n = 50) mice were lethally irra-
diated with a single dose (9 Gy; 0.5 Gy/min; MU 15F/225 kV; Philips) to induce bone
marrow aplasia one day before transplantation. Mice were maintained in filter–top
cages and given water containing 60,000 U/l polymyxin B sulfate (Invitrogen) and
100 mg/l neomycin (Invitrogen) starting 1 week before bone marrow transplanta-
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and tibiae. Bone marrow cells were plated (107/well) in DMEM supplemented with
10% FCS, L–glutamine, penicillin/streptomycin, and 10µg/ml DEAE–dextran, and
infected either with empty or NAMPT containing lentiviral particles (multiplicity
of infection, MOI=15:1) for 24 h [164]. The next day, irradiated recipients received
an intravenous tail vein injection with a total of 5x106 infected bone marrow cells
per mouse. Drinking water supplemented with antibiotics as indicated above was
provided ad libitum for 6 weeks post–transplantation. Thereafter, control and iN-
AMPT chimeras (mice transplanted with bone marrow transfected with either empty
or hematopoietic iNAMPT containing vector (iNAMPThi)) were fed WTD, contain-
ing 0.25% cholesterol and 15% cacao butter (SDS, Essex, UK) for 6 and 12 weeks and
subsequently sacrificed.
Histological Analysis: Aortic root sections were collected and then were formalin
fixed and paraffin embedded. Subsequently, 4µm thick sections were cut and stained
with haematoxylin and eosin (HE). Lesion size and necrotic core area were deter-
mined based on this staining in three to five sections per animal. Corresponding
sections on separate slides were stained with an antibodies against MAC3 (Becton
Dickinson, NJ, USA), ASMA (Sigma–Aldrich), and Caspase–3 (Cell Signaling Tech-
nology). Sirius Red staining was performed to detect collagen. Histological analyses
were performed, in a blinded manner, by an independent operator using Quantimet
with Qwin3 quantification software (Leica).
Flow Cytometry: Upon sacrifice, blood, spleen, and bones from the mice were col-
lected. Single cell suspensions were made from spleen. Erythrocytes in blood and
spleen were removed by incubation with a hypotonic buffer (8.4 g/l NH4Cl and 0.84 g/l
NaHCO3, pH 7). Non–specific Fc–receptor binding of antibodies was blocked by ad-
dition of an anti–CD16/CD32 antibody (eBioscience, San Diego, USA). To determine
lymphocyte subsets, cells were labeled with the following antibodies: CD3e–FITC,
CD8a-eFluor450, B220-PE-Cy7, CD25-APC, FoxP3-PE (all from eBioscience), and
CD4-PerCP (BD). To detect monocytes and granulocytes, the cells were labeled with
antibodies against CD11b-PerpCy5.5 (BD), Ly6G-PE (eBioscience), CXCR4-APC
(BD), CD62L-PE-Cy7 (eBioscience), and Ly6C-FITC (Miltenyi Biotec, BG, Ger-
many). After labeling, the samples were analyzed on a FACS Canto II flow cytometer
(BD). Samples and buffers were kept on ice throughout the experiments.
Colony Forming Units Assay: Bone marrow cells were isolated from one tibia and
one femur per mouse, as previously described [83]. Cells were counted twice manually
using a count chamber and the concentration was calculated for each sample. Per
well, 10.000 bone marrow cells were added to 2 ml methyl cellulose medium with re-
combinant cytokines (MethoCult Medium, StemCell Technologies, Grenoble, France).
After incubation for 7 days, at 37oC and 5% CO2, the total number of colonies was
quantified by an independent operator. Besides total number of colonies, GM–CFU,
G–CFU, and M–CFU colonies were specified based on morphology.
Macrophage Culture: Bone marrow cells were isolated from control and iNAMPThi
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RPMI (Invitrogen) containing 10% heatinactivated fetal calf serum, 100 U/ml peni-
cillin, 100 g/ml streptomycin, 2 mM L–glutamine, 10 mM Hepes, and supplemented
with 15% L929–conditioned medium to generate bone marrow derived macrophages
(BMDMs) [165]. Medium was replaced every three days and differentiated BMDMs
were used for in vitro assays seven to eight days after isolation.
M1/M2 Polarization: BMDM polarization was obtained by removing the culture
medium and culturing cells for an additional 24 h in RPMI (Invitrogen) supplemented
with 10% FCS and 100ng/ml LPS plus 20ng/ml IFNγ (for M1 polarization) or 20
ng/ml IL–4 (for M2 polarization). Quantitative gene expression of cytokines, M1,
and M2 macrophage markers were analyzed as previously described [166, 167]. To-
tal RNA was isolated from BMDMs using Tri–Reagent (Sigma), according to the
manufacturer’s protocol. RNA concentration was measured in a NanoDrop spec-
trophotometer (Witec AG, Switzerland). One microgram total RNA was used to
obtain cDNA (iScript, BioRad), according to the manufacturers protocol. The qPCR
Mastermix Plus kit for SYBR green (Eurogentec) was used on 10ng cDNA. Analysis
was performed on an iCycler IQ5 (BioRad). The reference genes 18s and β–actin
were used to correct for RNA concentration differences between samples. Primers
were designed based on PRIMER3.0. Primer sequences can be found in Table 3.1.















Table 3.1. Primers Used for M1/M2 macrophage polarization in iNAMPT
over expressing BMDM.
Migration Assay: In wound healing assays, BMDM were cultured to confluence on
tissue culture plates. An in vitro wound generated by scratching with the blunt end
of a 200µl plastic pipette tip, was created and the edge of the wound was marked.
Cell migration was observed by phase contrast microscopy. Complete medium, in-
cluding 500 nM of NAMPT inhibitor (FK866, Cayman Chemical), was added to the
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N–formyl–methionyl–leucyl–phenylalanine (fMLP, Sigma) was used (1 nM) as a pos-
itive control. The number of cells that had completely migrated to the wound side
was scored.
LDL Isolation and Modification; Fresh blood (obtained from healthy volunteers)
was incubated for 30 min at 37oC followed by 30 min at 4oC in 50 ml Falcon tubes.
Subsequently, the blood was centrifuged at 4,000 rpm for 10 min to isolate the serum.
The serum was brought to a density of 1.21 g/ml with KBr and put in a NaCl
gradient in 25x89 mm Ultratubes and centrifuged at 25.000 rpm in a Beckman SW28.1
rotor for 18 h at 4oC. The LDL fraction was isolated and treated with 25µM CuSO4
at 37oC overnight to be oxidized. Oxidation was stopped by adding 50µM EDTA.
This protocol was adapted from [87]. All lipoproteins were dialyzed against PBS
containing 10µM EDTA, and stored at 4oC under N2 for a maximum of 2 weeks.
Concentration was measured using the BioRad BCA protein assay kit (Pierce, USA).
Samples containing serum, LDL or oxLDL were tested for endotoxins using a Limulus
Amebocyte Lysate (LAL) assay (HyCult Biotech, The Netherlands) according to the
manufacturer’s protocol. Endotoxin concentration of all samples was below 5 pg/ml.
Apoptosis Assay: BMDM were cultured as described above and plated in 48-wells
plates (Corning, Lowell, MA, USA). Cells were incubated for 18 h in plain medium
or medium supplemented with camptothecin (CPT, 500µM) or oxLDL (50µg/ml)
to induce apoptosis. Cells were labeled with Annexin-V Alexa-488 (Invitrogen) and
stained with propidium iodide to detect apoptosis and necrosis, respectively. Pictures
were made using a Leica microscope (Leica) with Qwin software. Subsequently over-
lays were analyzed with ImageJ Software to quantify the number of apoptotic and
necrotic cells per field.
Lipid Uptake Assay: LDL was labeled by adding 150µl of 3mg/ml 1,1’–dioctade-
cyl–3,3,3’,3’–tetra–methyl–indocarbocyanine–perchlorate (DiI) in DMSO to 3 ml LDL
(0.5 mg/ml) overnight. After labeling, the unbound DiI was removed using a PD10
column (Amersham Biosciences). BMDM were incubated with 50µg/ml labeled
oxLDL for 3 h, with and without 500 nM of NAMPT inhibitor (FK866). As a con-
trol, BMDM were also incubated with DMSO. Cells were lifted from the culture dish
and washed 3 times with PBS. Finally, the cells were resuspended in 200µl PBS and
analyzed using flow cytometry in a FACS Canto II (BD Biosciences).
Lipid Extraction and TLC: BMDM were scraped from plastic 6-well plates, sus-
pended in 200µl PBS and frozen at 20oC. The cells were defrosted and repeatedly
passed through a syringe to fully lyse them. Cell lysates were further treated for lipid
analysis as described before [88].
Ethics: The human parts of the study were approved by the local ethical commit-
tee and conducted according to the ethical guidelines outlined in the Declaration of
Helsinki for use of human tissue and subjects. Informed written consent was obtained
from all subjects. All animal experiments were carried out in accordance with insti-













Animals published by the US National Institutes of Health (NIH Publication No.
85-23, revised).
Cholesterol Measurements: Blood samples of mice were collected upon sacrifice
and plasma (100µl) was stored at 80oC for further use. Plasma cholesterol levels were
measured using a colorimetric assay (CHOD–PAP, Roche, Mannheim, Germany).
NAD+ and Cytokine Determinations: Intracellular NAD+ concentrations were de-
termined by an enzymatic cycling assay. Cells were lysed in NAD+ extraction buffer
containing 100 mM Na2CO3 and 20 mM NaHCO3. Samples (20µl) were mixed with
a cycling buffer (160µl) containing 125 mM Tris HCl pH 8.8, 1.25 mM phenazine
ethosulfate, 0.625 mM thiazolyl blue tetrazolium bromide (MTT), 0.25 mg/ml al-
cohol dehydrogenase, and 1.25% BSA (all from Sigma). The cycling reaction was
initiated by adding 20µl of ethanol 6 M. After sample incubation for 10 min at 37oC,
the optical density at 570 nm was measured using an ELISA plate reader. Serial di-
lutions of NAD+ were used as a standard. NAD+ concentrations were normalized to
protein concentrations. Cytokines were determined in plasma by using the Bio–Plex
Pro mouse cytokine 23–plex immunoassay (BioRad) according to the manufactures
protocol.
Statistical Analysis: Data are expressed as mean±SEM. A two tailed Students t–test
was used to compare individual groups. Non–parametric data were analyzed using
Mann–Whitney U test. Correlations were analyzed by Spearman rank test, while
distribution variances were analyzed by F–test. All analyses were performed using
GraphPad Prism 5 software (GraphPad Software Inc, La Jolla, CA, USA) and MAT-
LAB. P–values below 0.05 were considered to be statistically significant.
3.4 Results
NAMPT is Upregulated in Circulating Leukocytes and Atherosclerotic Lesions of
Patients with Carotid Atherosclerosis Increased expression of NAMPT in carotid
lesions of patients with symptomatic disease (i.e., stroke or transient ischemic attack)
has been previously reported [162]. In the present study, these findings were extended
by demonstrating that these patients also show a profound upregulation of NAMPT
gene expression in PBMC (Fig. 3.1A). In addition, NAMPT was also upregulated in
human atherosclerotic samples obtained during carotid endarterectomy. Furthermore,
the relative gene expression levels of NAMPT increased progressively from early stable
lesions to advanced and ruptured plaques (Fig. 3.1B).
Hematopoietic Human iNAMPT Over Expression Attenuates and Stabilizes Athe-
rosclerotic Lesions in LDLr−/− Atherosclerotic Mice The functional implications of
dysregulated NAMPT expression on plaque development were next addressed, consid-
ering that it is a characteristic trait underlying the pathophysiology of cardiovascular
diseases. To approach this, chimeric LDLr−/− mice over expressing human iNAMPT
(iNAMPThi) in the hematopoietic compartment were generated, by reconstitution of
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Figure. 3.1. Expression of NAMPT in PBMCs and atherosclerotic plaques
from patients with Cardiovascular Disease; and bone marrow cells from LDLr−/−
mice recipients of bone marrow cells transfected with lentivirus encoding iNAMPT. A.
NAMPT is over expressed in PBMCs obtained from patients with ischemic stroke and
transient ischemic attack (TIA) compared to healthy subjects. B. NAMPT mRNA
expression is higher in human carotids with advanced and ruptured atherosclerotic
plaques, compared to early lesions. C-D. NAMPT mRNA expression and intracellular
NAD+ were determined in bone marrow cells from irradiated LDLr−/− recipients
reconstituted with LV.CTR (Empty vector) (black bars) or LV.NAMPThi (open bars)
infected bone marrow cells from LDLr−/− donors (n=12). Data as mean ±SEM .
∗P ≤ 0.05, ∗ ∗ P ≤ 0.01, ∗ ∗ ∗P ≤ 0.001.
Chimeric mice with the empty vector control PGK were also generated, to serve
as control for the experiments. After recovery from BMT for 6 weeks, mice were
fed a WTD for 6 and 12 weeks for analysis of early and advanced lesion develop-
ment, respectively. Hematopoietic iNAMPT over expression did not influence body
weight (Appendix B. Fig. B1A) nor total plasma cholesterol or triglyceride levels (Ap-
pendix B. Fig. B1B-C) in WTD–fed chimeric mice. At sacrifice, bone marrow cells of
the iNAMPThi chimera displayed supraphysiological expression of iNAMPT (+65%,
P ≺ 0.01; Fig. 3.1C), an effect that was accompanied by almost 2-fold increased
intracellular NAD+ levels (Fig. 3.1D).
Early lesion development (6 weeks of WTD) in the aortic roots did not differ
between the iNAMPThi and control chimeras (Fig. 3.2A). In contrast, plaque area
was significantly diminished in the iNAMPThi chimera at 12 weeks of WTD feeding
(Fig. 3.2B). At this point, necrotic core size (Fig. 3.2B) and plaque macrophage
contents (Fig. 3.2C) were more than 50% decreased in the iNAMPThi chimera. The
proportion of intimal apoptosis as assessed by activated Caspase-3 was also reduced
(Fig. 3.2D). Of note, neutrophil (Appendix B. Fig. B2A), T–lymphocytes (Appendix
B. Fig. B2B), and VSMC (Appendix B. Fig. B2C) numbers, as well as collagen
contents (Appendix B. Fig. B2D) were similar in the plaque of the iNAMPThi and
control chimeras.
Hematopoietic Human iNAMPT Over Expression Acts Cytoprotective and In-
creases Medullar Myelopoiesis Assessment of the susceptibility to apoptosis in-
duction indicated that over expression of iNAMPT acted cytoprotective. In fact,













Figure. 3.2. Hematopoietic iNAMPT over expression attenuates atheros-
clerotic lesion development in LDLr−/− mice. Bone marrow of irradiated LDLr−/−
recipients was reconstituted with LV.CTR (Empty lentivirus vector) or LV.NAMPThi
(NAMPT expressing vector) infected bone marrow cells from LDLr−/− donors. Athe-
rosclerotic lesion size was not altered 6 weeks after introduction of atherogenic diet
(A) but was significantly reduced 12 weeks on atherogenic diet (B) when necrotic core
(B), macrophage (C) and apoptotic cell (D) contents, relative to lesion area, were
reduced (n=12). Middle and right panels in A-D display representative pictures of
HE (A-B), Mac-3 (C) and activated Caspase-3 (D) stainings used for quantification
of LV.CTR (middle panel) and LV.NAMPThi (right panel) chimeras. Data as mean
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induced cytotoxicity. (Fig. 3.3A). In addition, analysis of bone marrow cells obtained
from iNAMPThi mice demonstrated increased levels of total colony forming units
(CFU), compared to the controls (Fig. 3.3B). This effect could be almost entirely
ascribed to an increased frequency of CFU-GM, CFU-G, and CFU-M (Fig. 3.3C),
suggesting a myeloproliferative response to hematopoietic iNAMPT over expression.
Figure. 3.3. Hematopoietic iNAMPT over expression modulates the survival
of myeloid cells and increases bone marrow myelopoiesis in LDLr−/− Mice. Bone
marrow of irradiated LDLr−/− recipients were reconstituted with LV.CTR (Empty
vector) or LV.NAMPThi infected bone marrow cells from LDLr−/− donors. A. Apop-
tosis quantification by flow cytometry (Annexin V and PI staining) in bone marrow
derived macrophages (BMDM) obtained from mice chimeras after 24 h incubation with
CPT (1 nM) or oxLDL (50µg protein/ml). Representative pictures of flow cytometry
analysis after CPT incubation are shown in the right part of the panel. B-C. Quantifi-
cation of colony forming units (CFU) in BMC from LDLr−/− recipients reconstituted
with LV.CTR or LV.NAMPThi infected BMC from LDLr−/− donors. Total CFU (B)
granulocyte and macrophage (GM), granulocyte (G) and macrophage (M) CFU (C)
were increased in NAMPT over expressing chimeras (n=12). Data as mean ±SEM .
∗P ≤ 0.05, ∗ ∗ P ≤ 0.01, ∗ ∗ ∗P ≤ 0.001 compared to the control chimera.
Hematopoietic Human iNAMPT Over Expression Alters Myeloid Stromal Egress
Granulocyte and monocyte numbers in bone marrow and blood of chimeric mice
were quantified to assess the systemic effect of iNAMPT induced myeloproliferation.
Relative bone CD11b+Ly6G+ granulocyte and CD11b+Ly6G− monocyte counts were
slightly but significantly augmented in iNAMPThi chimeras (Fig. 3.4A-B). However,
granulocyte levels in the bloodstream were unchanged by hematopoietic iNAMPT













the iNAMPThi chimeras (Fig. 3.4D).
Similar discrepancies in bone marrow and blood homeostasis were observed
for activated granulocytes and monocyte subsets. In fact, the relative proportion
of CD62LloCXCR4hi granulocytes within the total granulocyte population was un-
changed in the bone marrow (Fig. 3.4E), where higher levels of Ly6clo monocytes were
observed, leading to a lower Ly6Chi/Ly6clo ratio (Fig. 3.4F). In contrast, circulatory
CD62LloCXCR4hi granulocyte numbers were reduced in NAMPT over expressing chi-
meras (Fig. 3.4G) and a marked enrichment in anti–inflammatory Ly6clo monocytes
was observed (Fig. 3.4H).
Consistent with an inhibitory role of iNAMPT in bone marrow monocyte mo-
bilization, LDLr−/− mice that were intraperitoneally injected with the NAMPT in-
hibitor FK866 exhibited a reduction in stromal bone marrow monocyte content (Ap-
pendix B. Fig. B3A) and increased numbers of circulating monocytes (Appendix B.
Fig. B3B). No changes in the number of circulatory CD3−B220+, CD3+CD4+ or
CD3+ CD8+ lymphocytes, and splenic granulocytes or monocytes were detected in
the iNAMPThi versus control chimeras (data not shown).
One of the key regulatory pathways in stromal egress of monocytes has been
reported to be the CCR2–CCL2 axis [168]. Compatible with this notion, gene expres-
sion analysis of CCR2 and its ligand CCL2 in BMDM from the iNAMPThi chimera
revealed a strong downregulation of the former, whereas CCL2 expression remained
unaltered (Fig. 3.5A). Thus, these findings suggest that iNAMPT is a negative regu-
lator of CCR2–dependent monocyte mobilization. In agreement with this notion, non
treated and fMLP elicited cell motility was sharply reduced in BMDM of iNAMPThi
versus control chimeras. Conversely, the motile capability of BMDM from FK866
treated mice was augmented (Fig. 3.5B). These findings therefore suggest that iN-
AMPT over expression might have caused interrupted chemotaxis and reduced mono-
cyte extravasation into atherosclerotic lesions .
iNAMPT Acts Anti–Inflammatory Partly Via PPARγ We next assessed whether
PPARγ acted downstream of iNAMPT, as it has been reported to be targeted by
SIRT1 [169], an effector enzyme activated by iNAMPT [170], which was recently
attributed a variety of anti–inflammatory actions [171]. Genetic loss of function ap-
proaches, using BDMDs derived from conditional PPARγ knockout mice LysM–Cre-
PPARγflox/flox [172] were used to determine to what extent the aforementioned iN-
AMPT effects were mediated via PPARγ. Conditional PPARγ deficient BMDM were
then infected with PGK–NAMPT or PGK–Empty lentivirus to generate LysM–Cre-
PPARγflox/flox iNAMPThi BMDM.
CCR2 and CCL2 were upregulated in BMDM of LysM–Cre–PPARγflox/flox
(Fig. 3.5C). In addition, iNAMPT over expression completely failed to suppress
CCR2 expression in PPARγ deficient BMDM. However, over expression of iNAMPT
brought the expression of CCL2 back to the level observed in control and iNAMPThi
BMDM (Fig. 3.5C). Moreover, iNAMPT over expression had no effect on PPARγ
deficiency associated increase in BMDM migratory capacity (Fig. 3.5D). iNAMPThi
chimeras also featured upregulated expression of PPARγ (+60%, P ≺ 0.01) and of
its regulator SIRT1 (+28%, P ≺ 0.05) in bone marrow cells, reflective of complex
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Figure. 3.4. Hematopoietic iNAMPT over expression perturbs stromal
and circulatory leukocyte homeostasis in LDLr−/− mice. Bone marrow of irradi-
ated LDLr−/− recipients was reconstituted with donor LV.CTR (Empty vector) or
LV.NAMPThi infected bone marrow cells. Relative granulocyte (A,C) and monocyte
(B,D) contents in bone marrow (A-B) and blood (C-D) of LDLr−/− chimeras, (corre-
sponding graphs of flow cytometry analysis of monocytes and granulocytes are depicted
in the right side of the panels). Relative fraction of activated granulocytes (E,G) and
Ly6chi/Ly6clo ratio (F,H) in bone marrow (E-F) and blood (G-H) of LDLr−/− .
(Data as mean ±SEM . ∗P ≤ 0.05, ∗ ∗ P ≤ 0.01, ∗ ∗ ∗P ≤ 0.001 compared to the













Figure. 3.5. Hematopoietic iNAMPT over–expression impairs the migra-
tory response of BMDM via PPARγ and upregulates the expression of SIRT1 and
PPARγ. Bone marrow of irradiated LDLr−/− recipients was reconstituted with
LV.CTR (Empty vector) or LV.NAMPThi infected bone marrow cells from LDLr−/−
donors. A. CCR2 and CCL2 mRNA expression in bone marrow derived macrophages
(BMDM) of LDLr−/− chimeric mice recipient of lentivirus transduced bone marrow
cells. B. Migration index of BMDM after incubation with fMLP (1 nM) in the ab-
sence or presence of FK866 (500 nM). (C) CCR2 and CCL2 mRNA expression in
PPARγdeficient BMDM infected with LV.CTR (sky blue bars) or LV–NAMPThi (dark
blue bars) lentivirus. (D) Migration index of PPARγ deficient BMDM infected with
LV.CTR (sky blue circles) or LV–NAMPThi (dark blue circles) lentivirus after incu-
bation with fMLP (1 nM). (E) SIRT1 (top panel) and PPARγ (bottom panel) mRNA
expression in BMC. Data as mean ±SEM . ∗P ≤ 0.05, ∗ ∗P ≤ 0.01, ∗ ∗ ∗P ≤ 0.001.
Hematopoietic Human iNAMPT Over Expression Favors Alternatively Activated
Macrophage Polarization Classically activated macrophages (CAM) are deemed to
be derived from Ly6chi monocytes [173,174] and recruited into inflamed tissues partly
via CCR2 [175]. CCR2–dependent retention of monocytes in the bone marrow ren-
dered Ly6clo monocytes, the dominant subset in iNAMPThi chimeras. We therefore
hypothesized that iNAMPT over expression caused macrophage differentiation skew-
ing towards alternatively activated M2 macrophages, known for their wound healing
and resolution of inflammation activities [176, 177]. In agreement with this hypoth-
esis, iNAMPThi BMDM, polarized with IFNγ and LPS (M1) or IL–4 (M2), showed
attenuated or increased expression, respectively, of established M1 (TNFα, IL–6, and
iNOS) and M2 (IL–10, ARG1, and to a lesser extent MRC1) markers, relative to
control BMDM (Fig. 3.6A).
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Figure. 3.6. Hematopoietic iNAMPT over expression favors BMDM alter-
native anti–inflammatory differentiation. Bone marrow of irradiated LDLr−/− recip-
ients was reconstituted with LV.CTR (Empty vector) (black bars) or LV.NAMPThi
(black bars) infected bone marrow cells from LDLr−/− donors. Bone marrow derived
macrophages (BMDM) obtained from chimeric mice was used for further analysis. A.
TNFα, IL–6, and iNOS were downregulated in M1 polarized LV.NAMPThi BMDM
(gray bars, top panel). IL–10, MRC, and ARG1 mRNA were in contrast upregulated in
M2 polarized LV.NAMPThi BMDM (light gray bars, bottom panel). B. TNFα, IL–6,
and iNOS mRNA expression is conversely upregulated in PPARγ deficient BMDM
infected with LV.CTR (sky blue bars). Infection of those cells with LV.NAMPThi
(dark blue bars) lentivirus, dampens this effect. C-E. PPARγ (C), ABCA1 (D), and
ABCG1 (E) mRNA expression is upregulated in LV.NAMPThi BMDM after 24 h
incubation with oxLDL (50µg protein/ml). PPARγ deficiency block this upregulation.
Data as mean ±SEM . ∗P ≤ 0.05, ∗ ∗ P ≤ 0.01, ∗ ∗ ∗P ≤ 0.001, n =4.
recent finding that this nuclear receptor is a key positive regulator of alternative
macrophage polarization [178], suggested the involvement of PPARγ on iNAMPT
associated M2 skewed macrophage polarization. As expected, macrophage deficiency
in PPARγ (LysM–Cre–PPARγflox/flox) translated in a profound increase in expres-
sion of M1 markers; however, unlike control BMDM, iNAMPT over expression did
not alter M1 marker gene expression patterns in LysM–Cre–PPARγflox/flox BMDM
(Fig. 3.6B). From these results, PPARγ was demonstrated to be a downstream ef-
fector of iNAMPTmediated macrophage reprogramming towards M2–type cells. It is
worth noting that hematopoietic iNAMPT over expression did not confer systemic
anti–inflammatory effects, as judged by the unaltered plasma cytokine patterns ob-













Hematopoietic Human iNAMPT Over Expression Promotes PPARγ–Responsive
Gene Transcription with Functional Consequences in Macrophages The tight in-
terplay between iNAMPT and PPARγ, a master regulator of lipid handling in ma-
crophages [179, 180] and the iNAMPT associated induction of intracellular levels of
NAD+, which may impact lipid metabolism as well [181,182], hinted towards an effect
of iNAMPT over expression on macrophage lipid handling. In line with the afore-
mentioned iNAMPT–induced upregulation of PPARγ in BMC, iNAMPThi BMDM
had roughly 30% higher PPARγ mRNA expression in comparison to control BMDM
(Fig. 3.6C). LysM–Cre–PPARγflox/flox BMDM showed intrinsically reduced PPARγ
mRNA expression, which was not affected by iNAMPT over expression (Fig. 3.6C).
Of note, iNAMPT augmented oxLDL induced PPARγ upregulation in BMDM (Fig.
3.6C).
ABCA1/ABCG1 gene expression patterns essentially mirrored that of PPARγ,
with strong iNAMPT over expression associated upregulation in control but not
LysM–Cre–PPARγflox/flox BMDM (Fig. 3.6D-E). Consistent with this, BMDM of
iNAMPThi chimeras accumulated less cholesterol ester than BMDM of control chime-
ras in either the absence or presence of oxLDL (Fig. 3.7A); however, free cholesterol
remained at similar levels in control and iNAMPThi BMDM after oxLDL administra-
tion (Fig. 3.7B). The uptake of DiI–oxLDL was enhanced in BMDM over expressing
iNAMPT, an effect that was profoundly diminished in the presence of the NAMPT in-
hibitor FK866 (Fig. 3.7C), similarly to the lack of effect in LysM–Cre–PPARγflox/flox
BMDM. These findings demonstrate for the first time, that the iNAMPT–PPARγ axis
is strongly involved in the modulation of the macrophage lipid homeostasis.
Figure. 3.7. iNAMPT modulate lipid homeostasis in macrophages via
PPARγ. A-B. Cholesterol ester (A) and free cholesterol (B) accumulation in BMDM
over expressing iNAMPT, after 24 h incubation with oxLDL (50µg protein/ml).
C. Quantification of DiI–oxLDL uptake by PPARγ deficient BMDM infected with
LV.CTR (sky blue) or LV.NAMPThi (dark blue) lentivirus. DiI+ cells were quanti-
fied after 24 h incubation with FK866 (500 nM). Data as mean ±SEM . ∗P ≤ 0.05,
∗ ∗ P ≤ 0.01, ∗ ∗ ∗P ≤ 0.001, n =4.
iNAMPT and PPARγ Expression Are Tightly Correlated in Human Atherosclerosis
To verify whether the disclosed mutual interaction between iNAMPT and PPARγ is
also relevant in the context of human disease, PPARγ expression levels were assessed
in atherosclerotic and non–atherosclerotic vessels obtained from carotid lesion and
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taining early, advanced, and ruptured carotid plaque segments. The results of this
analysis revealed a tight correlation between NAMPT and PPARγ expression in athe-
rosclerotic (Appendix B. Fig. B5A) but not healthy arteries (Appendix B. Fig. B5B).
In addition, a strong relationship between NAMPT and PPARγ expression changes
with progressive atherosclerotic disease was observed (Appendix B. Fig. B5C).
3.5 Discussion
In this study the role of iNAMPT in the genesis and development of atherosclerosis
was addressed. Using a gain of function approach, the over expression of iNAMPT
was demonstrated to confer protection against atherosclerosis by various mechanisms:
first, by attenuating monocyte intravasation and migration in response to chemotactic
signals; second, by reducing apoptosis of macrophages in response to oxLDL; third,
skewing monocyte and macrophage differentiation into an anti–inflammatory M2 phe-
notype, and fourth; inducing over expression of genes involved in cholesterol efflux
and attenuating lipid accumulation in macrophages. Taken together, the results in-
dicate that iNAMPT participate in three hallmarks of atherosclerosis, i.e., leukocyte
homeostasis, inflammation and lipid accumulation.
Overall, the effects imposed by over expressing of NAMPT, led to a signifi-
cant decrease in plaque burden and delay in plaque progression in the aortic roots of
LV.iNAMPThi chimeras, which however displayed equivalent plasma cholesterol and
triglyceride levels, compared to control mice. In fact, lesions in iNAMPThi mice did
not progress beyond a fatty streak stage, which was characterized by aortic lesions
with low content of macrophages and marginal size of necrotic cores. The common
pathway of apoptosis was minimally activated in aortic root lesions of iNAMPThi
chimeras, indicating a protecting anti–apoptotic effect of NAMPT on lesion macro-
phages.
In agreement with these results, supra physiological iNAMPT levels, as induced
by lentiviral gene transfer, caused increased levels of intracellular NAD+ and resis-
tance to apoptosis induction in macrophages upon exposure to oxLDL. In agreement
with these findings, monocyte derived macrophages confronted with hypobaric hy-
poxia have been reported to display up–regulated expression of NAMPT [179].
Various molecular mechanism may be responsive for the protection from apop-
tosis observed upon NAMPT over expression: at the molecular level, NAMPT in-
hibits apoptosis by catalyzing the condensation of nicotinamide with 5–phosphoribo-
syl–1–pyrophosphate to yield nicotinamide mononucleotide, an intermediate in the
biosynthesis of NAD+; which in turn inhibits apoptosis through several mechanisms
(Reviewed in [155]). over expression of NAMPT led to increased intracellular le-
vels of NAD, likely causing increased intracellular NAD+ dependent protection from
apoptosis in atherosclerotic lesions of iNAMPThi chimeras.
Increased expression of SIRT1 and ATP binding cassette transporters (ABCA1
and ABCG1), as observed upon induction of NAMPT over expression, might have
contributed to the resistance to apoptosis observed in macrophages of iNAMPThi chi-
meras, by increasing the deacetylation of p53 [183]; which has been demonstrated to
promote survival through induction of autophagy [184,185] and induced reverse choles-
terol transport thereby reducing the intracellular content of cytotoxic lipids, including













dase NOX2, following exposure to oxidized phospholipids, which is known to induce
programmed cell death [187]. In agreement with this, iNAMPT over expressing ma-
crophages presented reduced accumulation of cholesterol esters and free cholesterol in
vitro.
Reduced contents of macrophages were observed in atherosclerotic lesions of
chimeric mice over expressing iNAMPT in hematopoietic cells. Mechanistically, iN-
AMPT over expression in macrophages causes PPARγ dependent downregulation of
CCR2 and reduced extravasation, in agreement with the negative regulation that
PPARγ has been reported to exert on CCR2 expression and chemotaxis [38, 188,
189] and the role of CCR2 in macrophage mobilization [190]. over expression of
NAMPT also increased the expression of ATP binding cassette transporters ABCA1
and ABCG1 thereby reducing the intracellular accumulation of cholesterol esters and
free cholesterol, in agreement with previously published data [191–195]. This effect
of NAMPT over expression likely attenuated the formation of foam cell macrophages
contributing to the delayed progression observed in atherosclerotic lesion of NAMPT
over expressing chimeric mice.
Increased levels of myelocyte colony forming units were observed in bone marrow
of iNAMPThi chimeras indicating increased myeloproliferation. In addition, absolute
bone marrow monocyte counts were slightly increased upon NAMPT over expression.
However circulating monocyte numbers were lower. Since iNAMPThi macropha-
ges downregulated the expression of CCR2, which is critical for monocyte intrava-
sation [190], these results suggest stromal sequestration causing reduced availability
of circulatory monocytes to extravasate into atherosclerotic lesions in NAMPT over
expressing chimeras. In agreement with this, administration of the NAMPT inhi-
bitor FK866 [196], boosted resident bone marrow monocyte release and circulating
monocyte numbers.
BMDM from iNAMPThi chimeras were hyporeactive to inducers of M1 differ-
entiation and displayed stronger alternative activation in response to M2 stimulants
by activation of PPARγ in-vitro and upregulation of PPARγ, SIRT1 ABCA1 and
ABCG1, which likely induced lesion stabilization by modulation of macrophage differ-
entiation [186,197–200]. PPARγ in particular inhibits the proinflammatory activation
of macrophages in atherosclerosis [201,202], and positively regulates their alternative
polarization [203,204].
In addition, hematopoietic NAMPT over expression caused a marked shift in cir-
culatory monocyte subset balance characterized by lower CD11b+Ly6chi and higher
CD11b+Ly6clo monocyte counts, which might have further reduced the M1/M2 ma-
crophage ratio in atherosclerotic lesions as result of increased availability of Lyc6lo
monocytes to home into atherosclerotic lesions to differentiate into alternative acti-
vated macrophages (AAM) [205]. The upregulated expression of ABCA1 and ABCG1
upon NAMPT over expression observed might have also contributed to a higher Ly6clo
to Ly6chi monocyte ratio, by negative regulation of hematopoietic stem cell progen-
itor extravasation and extramedullary hematopoiesis [206]; since hematopoietic stem
cell progenitors constitute a source of CD11b+Ly6chi monocytes in atherosclerosis
upon extravasation out of the bone marrow and differentiation in the spleen [66].
Collectively, these results suggest that besides reduced macrophage accumula-
tion due to impaired monocyte extravasation and stromal sequestration, iNAMPThi
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clerotic lesions; likely contributing to the delayed progression and features of lesion
stabilization observed, for M2 macrophages mediate wound healing and resolution of
inflammation [207].
Surprisingly however, mRNA coding for NAMPT, displays a expression pattern
characteristic of inflammatory monocytes [161, 162, 208] and CAM [179]. Besides,
NAMPT is part of a cluster of human genes upregulated upon IFNγ and LPS stim-
ulation and downregulated in response to IL–4 (Cluster C-IV, Fig. 2.9A-C, Page
36 in Chapter 2) whose expression is controlled by transcription factors linked to
pro–inflammatory macrophage differentiation (Fig. 2.11, Page 38 in Chapter 2).
In addition, NAMPT and PPARγ were here demonstrated to be progressively
upregulated in human atherosclerotic lesions and PBMCs obtained from patients with
symptomatic carotid atherosclerosis. Furthermore, NAMPT expression is increased
in unstable atherosclerotic carotid lesions, primarily in foam cell macrophages [162].
Similarly, NAMPT serum levels are significantly associated with higher intima–media
thickness and advanced carotid atherosclerosis in patients with type 2 diabetes [209];
which suggest, contrary to our results, that NAMPT has pro–inflammatory and
atherogenic functions.
Various reasons could be responsible for this paradox. First, the positive associ-
ation between NAMPT and PPARγ upregulation in the context of human atheroscle-
rotic lesion progression/vulnerability might be due to correlation without causation.
In fact, studies using PPARγ activators in the clinical context have not provided
conclusive evidence that they reduce cardiovascular morbidity and mortality, which
may be related to adverse effects of PPARγ activation in human atherosclerosis [210];
despite activation of PPARγ has favorable effects on measures of adipocyte function,
insulin sensitivity, lipoprotein metabolism, and vascular structure and function in
experimental animals [201]. This suggest interspecies variation and indicates that
further experimentation would be needed to investigate the relevance of the results
here presented in the human context.
Another possibility is that PPARγ and NAMPT could be functional in gene net-
works that as a whole favor lesion progression and destabilization in advanced human
atherosclerosis, despite they both participate in gene networks with anti–atherogenic
functions. The fact that NAMPT and PPARG interact with genes having both func-
tions, being part of networks N-I, N-II, N-III and N-IV (See Fig. 2.12, Page 39)
argues for this possibility. Genes can contribute their molecular activities in mul-
tiple or even antagonistic biological processes due to their ability to interact with
other genes in networks that as a whole execute cell processes and display emergent
properties beyond single molecular functions of their particular constituents.
In conclusion, here we demonstrated that over expression of NAMPT in hemato-
poietic cells confers protection against high fat diet induced atherosclerosis in LDLr
deficient mice. NAMPT acts upstream of PPARγ to upregulate ABCA1/ABCG1,
thereby increasing macrophage lipid efflux, reducing apoptosis and inhibiting foam
cell formation, while impairing extravasation and mobilization of monocytes out of the
bone marrow and emulating PPARγ, SIRT1 and ABCA1/ABCG1 anti–inflammatory
functions. These effects translated into delayed atherosclerotic lesion progression,
reduced macrophage accumulation and features of lesion stability in atherosclerotic
mice over expressing iNAMPThi, which contrasted to increased expression of NAMPT








































Lesions in LDLr−/− Mice































”Abundant death, often cataclysmic in its onslaught, is just part
of development in many animals...”
J. W. Saunders, Death in Embryonic Systems.
4.1 Abstract
Background: Previous studies have indicated that induction of macrophage apop-
tosis might lead to lesion destabilization in atherosclerosis. These studies however
have caused simultaneous depletion of other myelocytes important for the develop-
ment and progression of atherosclerosis, including monocytes and dendritic cells. In
addition, no study has addressed the effect of recovery from induction of macrophage
ablation in atherosclerosis, which is prime importance to assess the feasibility to trans-
late preclinical results into clinical applications. In this study a more specific system
allowed the induction of CD169+ macrophage apoptosis on advanced atherosclerosis
for assessment of its effect both at baseline, and after recovery.
Methods and Results: Female LDLr/ mice were lethally irradiated and re-
constituted with bone marrow from syngeneic CD169–DTR donors expressing the
human receptor for diphtheria toxin (DT), under CD169–promoter mediated tran-
scriptional control. After recovery and 8 weeks of Western type diet, animals were
injected with DT or inactive DT mutant (DTM) to ablate CD169+ macrophages dur-
ing 2 weeks. Mice were sacrificed, either 3 days (baseline) or two weeks after the
last DT–injection (recovery) and lesions were analyzed. No differences in plasma cho-
lesterol levels were observed between treated and control groups neither at baseline
nor after recovery. DT induction of CD169+ macrophage apoptosis caused increase
in circulatory myelocytes and proinflammatory cytokines at baseline, but their levels
recovered to normal after two weeks. CD169+ cell depletion induced plaque expan-
sion and increased lesion apoptotic cell content with concomitant increase in relative
necrotic core areas at baseline. However these variables normalized upon recovery.
In addition, DT treatment led to a significant reduction in macrophage content at
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crophages. DT treatment had no effect on minimal fibrous cap thickness nor collagen
and smooth muscle cell content at baseline. In sharp contrast, significant increases in
collagen, fibrous cap thickness and SMC content were observed upon recovery from
macrophage depletion.
Conclusions: Ablation of CD169+ macrophages in advanced atherosclerosis
leads to reduced macrophage contents with simultaneous collagen and smooth muscle
cell accumulation and fibrous cap enlargement after recovery from acute induction
of macrophage apoptosis, changes that are generally deemed beneficial for plaque
stability.
4.2 Introduction
In developed countries, cardiovascular diseases have become an important problem,
representing the principal cause of disability and death [1]. Atherosclerosis is the lead-
ing cause of cardiovascular diseases [2]. It is a chronic, inflammatory vasculopathy
typified by the progressive accumulation of cholesterol and monocyte derived macro-
phages in the arterial wall [211, 212]. Lesion macrophages ingest oxidized cholesterol
to become foam cells that undergo various forms of programmed cell death, including
apoptosis and necroptosis [49], leading either to non inflammatory cell turnover upon
efferocytosis by neighboring cells in early lesions [52], or to necrotic core formation in
more advanced atherosclerosis [52, 213].
The transition of stable asymptomatic atherosclerotic lesions, to unstable ones,
prone to rupture and clinical events such as acute myocardial and cerebral infarction
and sudden death, is mediated by the formation of necrotic cores [52] and the erosion
and rupture of lesion fibrous caps [214]. Necrotic cores form by accumulation of cells
that committed to necroptosis [49] or when apoptotic macrophages were not removed
before their membrane lost its integrity, leading to cell necrosis [213].
Necrotic cells leak lytic enzymes, oxidants, proinflammatory and thrombogenic
intracellular contents in pools that enter the circulation upon fibrous cap fissure and
rupture [45,213]. Then, thrombogenic components of the lesion react with with blood
clogging factors causing the formation of clots and resulting in vascular occlusion with
subsequent hypoxia of downstream tissues [214], which in few minutes causes tissue
infarction and death [215].
Current treatment strategies to control atherosclerosis include blood pressure
stabilizers, anticoagulants, HMG–CoA reductase inhibitors and anti–inflammatory
medicines. Cholesterol–lowering therapy leads to lesion regression and reduced macro-
phage content in human atherosclerosis [216]. Similarly, various methods of induction
of advanced atherosclerotic lesion regression in mice and rabbits, including choleste-
rol withdrawal [217], phototherapy [218] and genetic complementation of mice with
genetic deficiencies that cause atherosclerosis [69, 219], induce lesion stabilization.
The mechanisms behind those phenotypic changes can proceed independently
of phagocyte efflux out of lesions, converging at reduced monocyte recruitment cou-
pled to lesion macrophage turnover by apoptosis [69, 217, 218, 220–224]. In addition,
induction of apoptosis with simultaneous induction of lesion regression by cholesterol
withdrawal induces collagen deposition and higher contents of smooth muscle cells
than those observed in atherosclerotic lesions of mice under cholesterol withdrawal













duce cell turnover and lesion regression, as promising mechanism to develop novel
and improved therapies for atherosclerosis.
However, the long term effect of induction of macrophage apoptosis on athe-
rosclerotic lesions has not been explored. In addition, it’s short term effect has been
difficult to elucidate because off target induction of apoptosis in other leukocytes. In
fact, systemic induction of CD11b+ myelocyte apoptosis has been reported to have
no effect on atherosclerotic lesion phenotype, likely due to simultaneous ablation and
reduced availability of circulatory monocytes [225]. Similarly, systemic induction of
CD11c+ dendritic cell and macrophage apoptosis has no effect on lesion macrophage
contents, but results in advanced atherosclerotic lesion expansion, with simultaneous
depletion of dendritic cells and increased plasma cholesterol levels, that might be
responsive for the accelerated development of atherosclerotic lesions observed [23,25].
This study, used a macrophage specific promoter to evaluate the effect of induc-
tion of CD169+ macrophage apoptosis in atherosclerosis without off target ablation of
monocytes and dendritic cells. Atherosclerotic lesion size and composition were eval-
uated at finalization and recovery from systemic induction of CD169+ macrophage
apoptosis. The results here presented indicate that despite signs of lesion vulnerability
three days after induction of macrophage apoptosis, a short period of recovery allows
macrophage turnover and lesion stabilization, which has tremendous implications for
the development of treatments aiming at lesion stabilization involving macrophage
turnover.
4.3 Methods
Bone Marrow Transplantation and Atherosclerosis Bone marrow transplantation
experiments were approved by the regulatory authorities of the University of Lei-
den, and performed in accordance with the Dutch Government guidelines. Female
LDLr/ recipient mice were obtained from the local animal breeding facility at Lei-
den University. Animals were exposed to a single dose of 9Gy total body irradiation
(0.19Gy/min, 200kV, 4mA) using an Andrex Smart 225 Rontgen Source (YXLON
International, Copenhagen, Denmark) one day before reconstitution with bone mar-
row cells from CD169–DTR transgenic mice in which CD169 macrophages could be
specifically ablated [226]. Drinking water with antibiotics (83 mg/l ciprofloxacin and
67 mg/l Polymixin) and 5g/l sucrose was introduced one week before irradiation and
supplied during the experiment. Eight weeks after bone marrow transplantation mice
were put on WTD composed of 0.25% cholesterol and 15% cacao butter (Special
Diet Services, Witham, Essex, UK) fed during 11 weeks (baseline group) or 13 weeks
(recovery group) until sacrifice. Diphteria toxin, and diphteria toxin mutant (MBL,
International corporation RK-01-515 and RK-01-517) were injected intraperitoneally
(1ng/µl to achieve a dose of 10ng/g body weight every 3rd day).
Bone marrow transplantation efficiency was assessed as previously described [83]
by qPCR of gDNA obtained from bone marrow cells extracted at sacrifice (PureLink
Genomic DNA Purification Kit, Invitrogen). Real time PCR reactions (MyIQ Icycler,
Biorad) were carried out using 25ng of gDNA plus 0.4µl of 15µM primers and 10µl of
iQ SYBR R©Green Supermix (Biorad) in a total volume of 20µl. Primer sequence sets
were: LDLr-forward: 5’-GCTGCAACTCATCCATATGCA-3’ and LDLr-reverse: 5’-
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ACTTCATGTGACTAA-3’ and P50-reverse: 5’-GCACCAGAAGTCCAGGATTAT-
AGC-3’. PCR conditions were: 3 min 95oC, 40 2-step cycles: 10 sec 95oC, 45 sec
60oC and 1 min at 95oC. Samples were run in duplicate and CT values compared to
CT values obtained from a standard curve of a dilution series mix of 100% : 0% to
0% : 100% of LDLr−/−:LDLr+/+ genomic DNA.
Cholesterol and Triglyceride Levels Blood samples were taken by tail bleeding one
day before the introduction of WTD, five weeks after introduction of WTD and at sac-
rifice. Total cholesterol and triglyceride and phospholipid content was measured spec-
trophotometrically using enzymatic digestion of plasma (Roche Diagnostics, Almere,
The Netherlands).
Blood Cell Analysis and Flow Cytometry: Whole blood samples were analyzed
on a Sysmex blood cell analyzer (XT-2000i, Sysmex Europe GmbH, Norderstedt,
Germany) for absolute quantification of leukocyte counts. Single cell suspensions
of blood, bone marrow and peritoneal cells harvested at sacrifice were stained with
fluorescent label conjugated antibodies after lysis of erythrocytes in ice cold NH4Cl
(8.4g/l) NaHCO3 (1g/l) EDTA (37mg/l) during 3 minutes. Antibodies (eBioscience:
B220 (25-0452-82, 1:150), CD11b (57-0112-82, 1:40), CD3e (45-0031-82, 1:50 or 11-
0031-82, 1:300), CD19 (45-0193-82, 1:100 or 12-0193-83, 1:100), BD Pharmingen:
Ly6G (551461, 1:100), CD11c (558079, 1:400), B220 (553089, 1:100), CD11b (552858,
1:300) and Miltenyi: Ly6c (130-093-134 or 130-093-136, 1:10)) were used after Fc
receptor blockage with CD16/32 blocking antibody (eBioscience 14-0161-85, 1:100). A
FACSCanto II (BD Biosciences) flow cytometer coupled to the FACSdivaTM software
was used for acquisition and analysis of data.
Analysis of Plasma Cytokine Levels The Luminex 100 Bio-Plex cytokine assay (Bio-
Rad Laboratories, Inc; Hercules CA, USA) was used to determine cytokine expression
in serum samples; cytokines investigated were: IL–1α, IL–1β, IL–2, IL–4, IL–5, IL–6,
IL–10, IL–12(P40), IL–12(P70), IL–17, Eotaxin, Keratinocyte chemoattractant (KC),
Monocyte chemoattractant protein–1 (MCP–1), Monocyte inflammatory protein–1α
(MIP–1α) and Tumor Necrosis Factor–α (TNFα). Statistical analysis was performed
for the cytokines that reached the limit of detection (IL–1β, Eotaxin, KC, MCP1 and
MIP–1α)
Tissue harvesting, Immunohistochemistry and Plaque Morphometry Mice were
anesthetized, sacrificed and exsanguinated. Samples of organs were snap-frozen in
liquid nitrogen and stored at -80oC. Animals were perfused with PBS followed by
4% formaldehyde before dissection of heart, aorta, common carotid arteries, spleen,
thymus, omentum and liver. Organs were stored in 4% formaldhehide overnight (4.5
times diluted Zinc Formal-Fix, Thermo Electron Corporation, Breda, The Nether-
lands) before being embedded in (Tissue-Tek, Sakura Finetek). Immunohistochem-
istry of aortic roots was performed for Moma–2 (1;50, Serotec, Cat. no. MCA 519),
activated Caspase-3 (1:100, Cell signaling Cat. nl. 9661L), anti–α-Smooth Mus-
cle Actin (ASMA) fluorescein-isothyocyanate (FITC) conjugated antibody (1:3000,
Sigma, Cat. F3777). HE and sirius red stainings were used for morphometric anal-













counterstain of activated Caspase-3 staining and hematoxilin for all other stainings.
Sections were analyzed using a Leica Quantimet coupled to Qwin Image Analysis
Software, or ImageJ.
Statistical Analysis All data was analyzed by non-parametric Mann-Whitney U test
or t-test, as appropriate, using MatLab Software. P values < 0.05, two sided, were
considered significant. Data are presented as mean±S.E.M. Multiple comparisons
were analyzed by one-way ANOVA, followed by Bonferroni multi-comparison test.
4.4 Results
Effects of Systemic Induction of CD169+ Macrophage Apoptosis in Atheroscle-
rosis CD169 (also known as Sialoadhesin or Siglec-1) is expressed by macrophages
homing to inflammation loci in autoimmune diseases [227, 228] and regions of the
arterial intima predisposed to atherosclerosis [229]. CD169 is not present in circula-
tory monocytes [230] although it is expressed by stromal macrophages present in the
bone marrow, as well as by macrophages resident in the spleen marginal zone and
lymph node sinus [231], where they trap blood and lymph-born antigens respectively,
to induce T-cell mediated responses [232–234]. In addition, CD169 functions as an
endocytosis receptor that binds and internalizes sialoadhesin carrying pathogens to
increase the humoral response against internalized antigens [235]. However, CD169+
macrophages mediate tolerance to apoptotic cell carried antigens upon phagocyto-
sis [226].
CD169-DTR mice, expressing the human receptor for diphtheria toxin (hDTR)
under regulation of the promoter for CD169, were previously developed for time
controlled induction of CD169+ macrophage apoptosis [226]. In these mice, ad-
ministration of diphtheria toxin (DT) results in depletion of CD169+ macrophages.
CD169-DTR mice donor of bone marrow were used to reconstitute lethally irradi-
ated LDLr−/− recipients, thereby generating chimeric CD169–DTR–LDLr−/− mice
prone to development of atherosclerosis and susceptible to DT controlled induction of
CD169+ macrophage apoptosis. 92.2% of circulatory white blood cells were of donor
origin after bone marrow transplantation, indicating successful engraftment.
Bone marrow transplantation using CD169-DTR donors and induction of macro-
phage apoptosis did not lead to any differences in total body weight along the experi-
ment, nor did it affect total plasma cholesterol and triglyceride levels before and after
introduction of WTD (Table. 4.1). Similarly, no differences were found in plasma
cholesterol levels upon transient induction of macrophage apoptosis by administra-
tion of diphtheria toxin (DT) both at the end of the treatment and after two weeks
of recovery (Table. 4.1).
Previous studies have assessed the effects of short term induction of macro-
phage apoptosis on atherosclerotic lesion size and apoptotic cell accumulation [25,
217, 225, 236], but the effect of recovery from induction of macrophage ablation on
disease progression and phenotype, have not been reported. We therefore evaluated
atherosclerotic lesions obtained from CD169–DTR–LDLr−/− mice at day 3 (baseline)
and day 14 (recovery) after DT administration during two weeks to induce CD169+
macrophage ablation.
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Time Group TC (mg/dl) TG (mg/dl)
Before WTD DTM 225± 9 70± 8
DT 250± 14 83± 10
After WTD DTM 1328± 14 295± 12
DT 1426± 15 276± 12
Baseline DTM 1587± 14 286± 9
DT 1625± 13 291± 7
Recovery DTM 1735± 14 274± 8
DT 1644± 13 269± 8
Table 4.1. Plasma Cholesterol and Triglyceride concentration in
CD169–DTR–LDLr−/− chimeric mice. Concentrations were measured one day be-
fore the introduction of WTD (Before WTD), five weeks after introduction of WTD
(After WTD), at sacrifice (Baseline) and upon recovery from induction of apoptosis
(Recovery), in DTM and DT treated in CD169–DTR–LDLr−/− chimeric mice.
clerosis increased lesion burden (+26%, P ≺ 0.001) and necrotic core area (+23%,
P ≺ 0.01), relative to total lesion area (Fig. 4.1A). Simultaneous increase in apop-
totic cell density (4.5 fold, P ≺ 0.001, Fig. 4.1B) without changes in lesion cellularity
(Fig. 4.1B) and reduction in macrophage contents (−57%, P ≺ 0.01, Fig. 4.1C) were
observed, indicating successful induction of lesion macrophage apoptosis.
No differences were observed in plaque VSMC content (Fig. 4.2A), collagen
deposition and fibrous cap area (Fig. 4.2B) upon DT treatment. Taken together,
these results indicated that short term induction of CD169+ macrophage apoptosis
solely caused augmented macrophage turnover with increase in lesion burden and
necrotic content, without signs of lesion vulnerability, nor reduced contents of VSMC
or degradation of the extracellular matrix.
Macrophage apoptosis and the ability of phagocytes to clear apoptotic remnants
are important processes that control the balance between lesion inflammation and
necrotic core formation versus silent disposal of apoptotic corpses in advanced atheros-
clerosis. In fact, increased apoptosis of macrophages coupled to defective phagocytosis
of death cells causes secondary necrosis leading to expansion of plaque necrotic cores,
inflammation, and lesion susceptibility to rupture [54]. In addition, DT mediated
induction of CD11c+ macrophage and dendritic cell apoptosis causes increased levels
of small inducible cytokines in atherosclerotic lesions [25]. We therefore hypothesized
that treatment of CD169–DTR–LDLr−/− mice with DT besides causing macrophage
apoptosis and expansion of necrotic cores might have triggered a pro-inflammatory
response.
To test this hypothesis, we evaluated whether the induction of CD169+ macro-
phage apoptosis elicited systemic inflammation in DT treated CD169–DTR–LDLr−/−
mice. As seen in Figure 4.3A, plasma levels of MCP-1 and IL–1β were increased three
fold at baseline although no significant differences in Eotaxin, KC and MIP–1α were
observed (Fig. 4.3A). Interestingly, plasma cytokine levels returned to normal upon
recovery (Fig. 4.3B). Similarly, absolute levels of circulatory monocytes and neu-













Figure. 4.1. Lesion expansion, higher necrosis and macrophage apop-
tosis, upon induction of CD169+ macrophage apoptosis in atherosclerotic mice.
CD169–DTR–LDLr−/− chimeric mice fed WTD during eight weeks were treated with
diphtheria toxin (DT) for two weeks, to induce CD169+ cell apoptosis. Diphtheria
toxin mutant (DTM) treated mice were used as control. Three days after the last in-
jection of DT, animals were sacrificed and aortic root sections analyzed for lesion size
(A) and necrotic core area using HE stained sections. B. Activated Caspase-3 staining
was used for quantification of apoptotic cells and cell density. C. Moma–2 staining
was used for quantification of macrophage contents. The induction of CD169+ cell
apoptosis leads to increased lesion burden, expansion of necrotic cores (A) and in-
crease in apoptotic cell content (B), with concomitant reduction in macrophage area
(C). No difference was observed in lesion cellularity (B). Central and right panels in
A-C, display pictures of sections obtained from DTM (central panel) and DT (right
panel) treated mice and stained with HE (A) or antibodies against activated Caspase–3
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Figure. 4.2. Lesion phenotype at baseline upon induction of CD169+ macro-
phage apoptosis. CD169–DTR–LDLr−/− chimeric mice fed WTD during eight weeks
were treated with diphtheria toxin (DT) for two weeks, to induce CD169+ cell apopto-
sis. Diphtheria toxin mutant (DTM) treated mice were used as control. No differences
were observed in SMC VSMC (A) and collagen (B) contents three days after the last
injection of DT. Fibrous cap areas were similar in DT treated and control mice (B).
Central and right panels in A-B, display pictures of α − SMC (A) and Sirius Red
(B) staining in sections of DTM (central panel) and DT (right panel) treated mice.
changes in lymphocyte levels were observed at this time point (Fig. 4.4C). However,
circulatory monocyte and neutrophil percentages returned to basal levels after reco-
very (Fig. 4.4D-E), indicating that the induction of CD169+ cell apoptosis caused
transient elevation of inflammatory cytokines and expansion of circulatory myelo-
cytes. Lymphocyte levels remained not altered at recovery (Fig. 4.4F). No changes
in absolute circulatory Ly6c monocyte subsets were observed, both at baseline and
upon recovery (data not shown).
Interestingly, induction of CD169+ macrophage apoptosis has been reported
to induce increased egress of bone marrow stem cell progenitors to the circulation
[237]. In addition, monocytes infiltrating atherosclerotic lesions were recently shown
to arise also from bone marrow stem cell progenitors that egress from the medullar
niche to accumulate in the splenic red pulp, where they expand and differentiate
before intravasation and recruitment from the circulation into crescent lesions [66];
which suggested that increased spleen and/or medullar hematopoiesis might have
given rise to the increase amount of circulatory myelocytes observed in DT treated
atherosclerotic mice at baseline (Fig. 4.4A-B). In agreement with this hypothesis,













Figure. 4.3. Plasma cytokine levels at baseline and after recovery from
induction of CD169+ Macrophage apoptosis in atherosclerotic mice. A. Induction of
CD169+ macrophage apoptosis increases plasma levels of MCP–1 and IL–1β but not
of Eotaxin, KC and MIP–1α at baseline. B. Plasma concentration of these cytokines
returns to normal 2 weeks after recovery from apoptosis induction treatment. IL–1α,
IL–2, IL–4, IL–5, IL–6, IL–10, IL–12(P40), IL–12(P70), IL–17 and TNFα did not
reach the threshold of detection, neither in DT, nor in DTM treated controls. ∗P ≤
0.05.
fold, P ≺ 0.001) were observed (Fig. 4.5A-B) with reciprocal reduction in spleen
lymphocytes (Fig. 4.5C).
Reduced levels of spleen plasmacytoid dendritic cells were also observed (pDC,
−35%, P ≺ 0.01; Fig. 4.5D) upon induction of CD169+ macrophage apoptosis,
with simultaneous increase in resident dendritic cells (rDCs, two fold, P ≺ 0.01; Fig.
4.5E). No differences were found in CD8+ and CD8− rDCs in the spleen (Fig. 4.5F).
Similarly, no differences were observed in differenciated bone marrow leukocyte levels
(Appendix C. Fig. C1). 4.6,4.7
Lesions from CD169–DTR–LDLr−/− mice that were allowed to recover for two
weeks upon DT treatment had similar size and necrotic content as those observed in
DTM treated controls (Fig. 4.6A), but strikingly transitioned towards lesion stability.
In fact, while apoptotic cell contents and cell densities were similar in DT and DTM
treated mice (Fig. 4.6B), their content of macrophages was remarkably reduced upon
recovery from induction of CD169+ cell ablation (−50%, Fig. 4.6C). Simultaneously,
a two fold increase in VSMC VSMC content and collagen deposition was observed
(P ≺ 0.01, Fig. 4.7A-B) with concomitant expansion of fibrous cap areas (Fig. 4.7B),













78 Macrophage Apoptosis and Atherosclerotic Lesion Stabilization
Figure. 4.4. Effect of induction of CD169+ cell apoptosis on blood leukocyte
homeostasis. CD169–DTR–LDLr−/− chimeric mice fed WTD during eight weeks were
treated with diphtheria toxin (DT) for induction of CD169+ cell apoptosis during two
weeks. Diphtheria toxin mutant (DTM) treated mice were used as control. A-C.
Induction of CD169+ macrophage apoptosis leads to increase levels of monocytes (A)
and neutrophils (B) three days after the last injection of DT, when no differences are
observed in circulatory lymphocyte counts (C). D-F. The increase in absolute levels
of circulatory myelocytes observed, is normalized upon recovery during two weeks (D-
E). No further changes in circulatory lymphocytes are observed upon recovery (F).
∗P ≤ 0.05, ∗ ∗ P ≤ 0.01, ∗ ∗ ∗P ≤ 0.001.
4.5 Discussion
We evaluated the effects of systemic induction of CD169+ macrophage apoptosis in
atherosclerosis at baseline and following recovery and stabilization. CD169, which is
not present by circulatory monocytes [230] is expressed by macrophages in regions of
the arterial intima predisposed to atherosclerosis [229], stromal macrophages in the
bone marrow, marginal zone macrophages and macrophages resident in the lymph
node sinus.
Transient induction of macrophage apoptosis was achieved by intravenous in-
jections of diphtheria toxin to CD169–DTR–LDLr−/− chimeric mice obtained upon
transplantation of bone marrow cells from CD169-DTR mice [226] into LDLr−/−
atherosclerotic prone recipients.
Induction of macrophage apoptosis in CD169–DTR–LDLr−/− mice by adminis-
tration of DT during two weeks caused significant expansion of atherosclerotic lesions













Figure. 4.5. Effect of induction of CD169+ cell apoptosis on spleen leukocyte
homeostasis. CD169–DTR–LDLr−/− chimeric mice fed WTD during eight weeks were
treated with diphtheria toxin (DT) for induction of CD169+ cell apoptosis during two
weeks. Diphtheria toxin mutant (DTM) treated mice were used as control. A-C.
Induction of CD169+ macrophage apoptosis leads to increase levels of monocytes (A)
and neutrophils (B) three days after the last injection of DT, when no differences are
observed in spleen lymphocyte percentage (C). D-F. Reduced contents of spleen pDC
are observed (D) with concomitant increase in rDC (E). No changes in rDC subsets
are observed (F). ∗P ≤ 0.05, ∗ ∗ P ≤ 0.01, ∗ ∗ ∗P ≤ 0.001.
tion in macrophage contents, that indicated successful induction of lesion macrophage
apoptosis and overloading of the efferocytosis capacity of remaining lesion phagocytes.
In addition, induction of CD169+ cell apoptosis led to a sharp increase in abso-
lute circulatory myelocytes levels at baseline that rapidly normalized upon recovery,
reaching similar levels to those observed in DTM control mice. No differences in abso-
lute lymphocyte levels were observed both at baseline and after recovery, in agreement
with previous characterization of CD169-DTR mice that demonstrated successful de-
pletion of CD169+ macrophages without induction of apoptosis in monocytes, T and
B leukocytes and DC [226].
No differences in differentiated leukocytes were observed in the bone marrow
of DT treated CD169–DTR–LDLr−/− chimeras, but the percentage of monocytes,
granulocytes and dendritic cells was increased in the spleen at baseline, which consid-
ering (i) the increased amount of circulatory myelocytes observed, (ii) the increased
egress of hematopoietic stem cell progenitors (HSCP) to the circulation observed
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Figure. 4.6. Lesion size, necrotic core and macrophage apoptosis, upon
recovery from induction of CD169+ macrophage apoptosis in atherosclerotic mice.
CD169–DTR–LDLr−/− chimeric mice fed WTD during eight weeks were treated with
diphtheria toxin for two weeks (DT) to induce of CD169+ cell apoptosis. Diphtheria
toxin mutant (DTM) was used as control. Mice were allowed to recover for two more
weeks before sacrifice and analysis of lesion phenotype. A. HE stained aortic root
sections were analyzed for lesion size and necrotic core area. B. Activated Caspase-
3 staining was used for quantification of apoptotic cell and overall cell density. C.
Moma − 2 staining was used for quantification of macrophage content. Recovery
from induction of CD169+ cell apoptosis caused previously expanded necrotic cores to
normalize (A) (Compare with Fig. 4.1A). Similarly, the levels of apoptotic cells were
reduced in DT treated mice, reaching the same level found in DTM treated, control
mice (B) (Compare with Fig. 4.1B). The content of macrophages remained reduced in
DT treated mice (C) (Compare with Fig. 4.1C). No difference was observed in lesion













Figure. 4.7. Features of lesion stability are observed after reco-
very from induction of CD169+ macrophage apoptosis in atherosclerotic mice.
CD169–DTR–LDLr−/− chimeric mice fed WTD during eight weeks were treated with
diphtheria toxin (DT) for induction of CD169+ cell apoptosis during two weeks. Diph-
theria toxin mutant (DTM) treated mice were used as control. Mice allowed to re-
cover from induction of apoptosis displayed increased lesion SMC (A) and collagen
(B) contents, and thickening of fibrous caps (C). Central and right panels in A-B, dis-
play pictures of ASMA (A) and Sirius Red (B) staining in sections of DTM (central
panel) and DT (right panel) treated mice. ∗ ∗ ∗P ≤ 0.001
hematopoiesis observed upon depletion of CD169+ macrophages [238] and the accu-
mulation of HSC in the spleen where they expand and differentiate before intravasa-
tion and accumulation in crescent atherosclerotic lesions [66], suggest that increased
extramedullary spleen myelopoiesis might have taken place upon DT mediated induc-
tion of CD169+ cell apoptosis in LDLr−/− atherosclerotic chimeras.
In addition, analysis of plasma cytokines indicated that induction of CD169+
macrophage apoptosis caused a temporal increase in MCP1, which is known to me-
diate the accumulation of leukocytes in arterial lesions [239, 240] and IL–1β, which
expression induces secretion of other proatherogenic cytokines and correlates with the
severity of atherosclerosis [241].
Strikingly however, the transient increase in proinflammatory cytokines in the
circulation, and the expansion of blood and spleen myelocytes, although expected to
cause accelerated atherosclerosis [242], caused transient expansion of atherosclerotic
lesions that rapidly normalized upon recovery. Treatment with DT had no effect on
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The expansion of lesion burden with concomitant increase in lesion apoptosis
and reduction in macrophage contents observed upon induction of CD169+ cell apop-
tosis contrasts to the results reported by Stoneman et al. [225] who demonstrated
that acute induction of CD11b+ cell apoptosis had no effect on advanced atheroscle-
rotic lesion size despite increased apoptotic cell densities and reduction in macrophage
contents. However, induction of CD11b+ myelocyte apoptosis led to massive deple-
tion of circulatory CD11b+ myelocytes and thus reduced availability of circulatory
monocytes to extravasate into atherosclerotic lesions; making difficult to discern the
true effect of macrophage apoptosis in atherosclerosis. With our studies in contrast
no reduction in absolute circulatory monocyte counts was observed, but transient
monocytosis and increase in plasma pro-inflammatory cytokines.
Our results agree with those obtained by Gautier et al. [25], who reported that
systemic induction of CD11c+ cell apoptosis caused lesion expansion, accumulation
of apoptotic cells and increased levels of newly recruited CD11b+ macrophages in
advanced atherosclerosis. However, we observed reduction in lesion macrophages
upon DT administration to CD169–DTR–LDLr−/− mice. In sharp contrast, CD11c-
DTR mice treated with DT had similar contents of lesion macrophages, compared
to controls; which was suggested by the authors to be caused by progressive recruit-
ment of circulatory monocytes masking the lost of macrophages [25]. Although a
non–significant ablation of lesion CD68+ macrophages could not be discarded.
Induction of CD11c+ cell apoptosis as reported by Gautier et al. [25], caused
massive depletion of dendritic cells and increased plasma cholesterol levels that might
be responsive for the accelerated development of atherosclerotic lesions observed [23,
25]. With our experiments in contrast we did not observe ablation but expansion of
spleen resident dendritic cells. In addition, no differences were observed in plasma
cholesterol levels upon induction of CD169+ macrophage apoptosis in atherosclerotic
mice.
Regarding the effect of induction of CD169+ macrophage apoptosis on athe-
rosclerotic lesion stability, our results implicate that lesions from DT treated mice,
which exhibited features of instability such as increased necrotic core and apoptotic
cell densities at baseline, transitioned into a more stable phenotype characterized by
increased contents of collagen and VSMC and expansion of fibrous caps after reco-
very. Furthermore, necrotic cores and apoptotic cell contents where normalized during
recovery, reaching similar levels as those found in control DTM treated mice.
Using different strategies, Waksman et al. [218], and Secchiero et al. [243], re-
ported that induction of cell apoptosis in advanced atherosclerosis resulted in pro-
gressive reduction and stabilization of atherosclerotic lesions by sustained removal of
macropha- ges and progressive repopulation with smooth muscle cells. These results,
although dependent on a different mechanism, agree with our results that indicate
that induction of CD169+ macrophage apoptosis in atherosclerotic lesions might trig-
ger lesion stabilization.
The mechanism responsible for induction of lesion stabilization after recovery
from induction of CD169+ macrophage apoptosis remains to be fully elucidated, al-
though it is conceivable that induction of CD169+ macrophage apoptosis caused pref-
erential depletion of classically activated macrophages (CAM) skewing the balance
towards a higher M2 to M1 intra-lesion macrophage ratio, which is deemed to induce













pro-inflammatory and tissue degradative stimulus such as IFNγ, LPS and TNFα while
being downregulated by IL–4 (CD169 belongs to Cluster C-IV Fig. 2.9A-C and 2.11,
Pages 36 and 38, in Chapter 2) agrees with this hypothesis.
In conclusion, this study demonstrates for the first time that advanced atheros-
clerotic lesions follow a biphasic phenotype that transients from reduced contents of
macrophages coupled to lesion expansion and increased apoptosis and necrosis to a
phenotype with traits of improved lesion stability upon selective induction of CD169+
macrophage ablation. This opens many opportunities for future research and develop-
ment of treatment strategies to induce macrophage turnover and lesion stabilization
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”Almost everything, all external expectations, all pride, all fear of
embarrassment or failure... these things just fall away in the face
of death, leaving only what is truly important.”
Steve Jobs
5.1 Abstract
Background: Although macrophage apoptosis is deemed to induce atherosclerotic
lesion vulnerability, the actual impact of macrophage death on atherosclerosis remains
unclear, because the experimental set–up used for its evaluation has had off–target
effects on peripheral monocyte or myeloid populations. Therefore we here sought to
compare spatially restricted local induction of macrophage apoptosis in atherosclerotic
lesions versus systemic ablation, on advanced atherosclerosis.
Methods and Results: ApoE−/− mice, expressing a Macrophage Fas In-
duced Apoptosis (MaFIA) suicide gene in CD115+ myelocytes were used to address
the impact of conditional CD115+ myelocyte ablation on advanced atherosclerotic
lesions induced by perivascular collar placement. Systemic and local induction of
CD115+ myelocyte apoptosis was achieved respectively by intravenous injection or
local delivery of AP20187 using micro–osmotic pumps connected to atherosclerotic
lesions. As expected, local and systemic induction of CD115+ myelocyte apopto-
sis caused accumulation of apoptotic cells in atherosclerotic lesions, and reduced
their contents of macrophages. Local treatment caused lesion expansion, without
detectable changes in necrotic core size and features of lesion stability such as VSMC
accumulation, collagen deposition and fibrous cap thickness. In contrast systemic
induction of CD115+ myelocyte apoptosis caused marked lesion destabilization. Lo-
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homeostasis. Systemic treatment in contrast caused extramedullary myelopoiesis and
proinflammatory Ly6chi monocytosis, promoting lesion destabilization by multiple
immune–mediated mechanisms.
Conclusions: This study is the first to segregate the impact of lesion restricted
vs systemic induction of CD115+ myelocyte apoptosis in advanced atherosclerotic
lesions. Divergent effects are observed using these strategies. Local induction of ma-
crophage apoptosis causes lesion expansion but allows macrophage turnover without
lesion vulnerability. In sharp contrast, systemic induction of macrophage apoptosis
causes lesion vulnerability and disturbed leukocyte homeostasis.
5.2 Introduction
Atherosclerosis, characterized by the progressive accumulation of monocyte derived
macrophages and oxidized cholesterol in the vasculature, is the underlaying cause of
cardiovascular disease [2] and the single most important cause of death in the western
world [1].
Atherosclerotic lesions transition from asymptomatic expansion to clinical man-
ifestations such sudden death upon erosion and rupture of their fibrous caps [44]. This
causes leakage of thrombogenic components of lesions into the circulation, and incites
thrombus formation and infarction or death withing minutes of arterial occlusion.
Macrophage apoptosis coupled to impaired apoptotic cell clearance is believed
to cause lesion destabilization and fibrous cap rupture in atherosclerosis [46], as the
frequency of apoptotic macrophages and the volume occupied by necrotic cores are
higher at sites of plaque rupture than in areas of intact fibrous caps [45,244].
The percentage of apoptotic macrophages increases with the progression of athe-
rosclerotic lesions towards destabilization and rupture [244, 245], which coupled to
poor phagocytosis of apoptotic bodies fosters necrotic core formation and leads to re-
lease of pro–inflammatory cytokines with subsequent influx of circulatory monocytes,
lesion expansion [46,54] and thrombogenicity [246].
Genetic cell ablation models have indicated that higher susceptibility to apop-
tosis in macrophages delays early lesion formation [247–249], but causes lesion ex-
pansion [250–252] and instability [253, 254] in advanced atherosclerosis. Conversely,
protection from apoptosis in atherosclerosis causes early lesion expansion [250, 251]
but reduced atherosclerosis in advanced stages [255].
Collectively, these results have led to the generalized idea that macrophage
apoptosis has a biphasic effect in atherosclerosis. However, pharmacological (reviewed
by Martinet et al. [256]) and suicide gene mediated induction of cell ablation [25,225]
have afforded contradictory results regarding the impact of macrophage death on
atherosclerosis.
In fact, systemic induction of CD11b+ myelocyte apoptosis has been reported
to have no effect in atherosclerotic lesions, probably due to simultaneous ablation and
reduced availability of circulatory monocytes [225]. In addition, combined induction
of CD11c+ dendritic cell and macrophage apoptosis does not reduce lesion macro-
phage contents but results in advanced atherosclerotic lesion expansion, depletion of
dendritic cells and increased plasma cholesterol levels [23, 25].
These inconsistent outcomes might be caused not only by intra–lesion induction













off target ablation of other leukocytes, including monocytes and dendritic cells, which,
we hypothesized, would directly or indirectly disturb intra–vascular and peripheral
leukocyte homeostasis and activity, and thus complicate the interpretation of the
results reported.
In this study we tested this hypothesis and assessed for the first time the effect of
confined induction of lesion macrophage apoptosis on advanced atherosclerotic lesion
phenotype. We used ApoE−/− MaFIA+/+ mice prone to development of atheros-
clerosis and susceptible to induction of CD115+ cell apoptosis by administration of
AP20187 [257,258]. Local ablation of macrophages was achieved by continuous release
of AP20187 into atherosclerotic lesions that were evaluated and compared to those
obtained upon systemic induction of macrophage apoptosis by intravenous injection
of AP20187 in atherosclerotic mice.
Analysis of the data presented indicates that local induction of CD115+ myelo-
cyte apoptosis in advanced atherosclerosis caused massive depletion of plaque macro-
phages and lesion expansion without changes in lesion composition and circulatory
and spleen leukocyte homeostasis.
Systemic induction of CD115+ myelocyte apoptosis in contrast, led to features
of lesion instability such as reduced collagen content and thinner fibrous caps, besides
inducing lesion macrophage ablation. These effects proceeded with concurrent in-
crease in proinflammatory resident and circulatory leukocytes, deemed to to promote
atherosclerotic lesion vulnerability [7].
5.3 Methods
Mice C57BL/6J–Tg(Csf1r–EGFP–NGFR/FKBP1A/TNFRSF6)2Bck/J MaFIA+/+
male mice obtained from the Jackson Laboratories, were back crossed to ApoE−/−
mice for more than 12 generations to obtain homozygous, atherosclerotic prone,
ApoE−/− MaFIA+/+ mice. The MaFIA transgene was inherited according to Men-
delian laws as demonstrated by qPCR analysis of gDNA (PureLink Genomic DNA
Purification Kit, Invitrogen) performed in all experimental units [259].
Real time PCR reactions were performed in the 7500 Fast Real–Time PCR
System (Applied Biosystems, Warrington, UK) using 10ng of gDNA plus 0.25µl of
20µM of EGFP forward and reverse primers and 5µl of Power SYBR Green PCR
master mix (Applied Biosystems) in a total volume of 10µl. Primer sequences were: 5’-
CCACATGAAGCAGCAGGACTT-3’ forward, and 5’-GGTGCGCTCCTGGACGT-
A-3’ reverse. PCR conditions were: 10 min 95oC, 40 2-step cycles: 15 sec 95oC, 1
min 60oC and 1 min at 95oC. Samples were run in triplicate and CT values compared
to CT values obtained using gDNA of MaFIA+/+ homozygous litter mates.
Animal Experiments All experiments with ApoE−/− MaFIA+/+ mice, including
characterization of the model, perivascular collar placement and induction of apopto-
sis of CD115+ cells in-vivo were performed in accordance with the Dutch Government
guidelines for animal experiments and approved by the Institutional Animal Care and
Use Committee of the University of Maastricht. Mice were housed in filter top cages
in all experiments in-vivo. Food and water were provided ad–libitum. Drinking wa-
ter with antibiotics (83 mg/l ciprofloxacin and 67 mg/l Polymixin plus 5g/l sucrose,
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weeks before the introduction of WTD and supplied until sacrifice. (All antibiotics
were from Sigma–Aldrich, St. Louis, MO, USA).
Characterization of MaFIA Mice For assessment of the MaFIA model of induction
of CD115+ cell apoptosis, ApoE−/− MaFIA+/+ mice (n=5 to 8) fed WTD (0.25%
cholesterol and 15% cacao butter. Special Diet Services, Witham, Essex, UK) received
injections of AP20187 (1 to 10 mg/kg) diluted in vehicle (4% ethanol, 10% PEG-400,
1.7% Tween, in water) before sacrifice and analysis of blood, peritoneal and spleen
leukocyte counts. ApoE−/− MaFIA+/+ receiving only vehicle were used as controls.
Induction of CD115+ Macrophage Apoptosis in Atherosclerotic Mice Bilateral
perivascular collars were placed in male ApoE/, MaFIA+/+ mice three weeks after
introduction of WTD (0.25% cholesterol and 15% cacao butter. W. Special Diet Ser-
vices, Witham, Essex, UK) for induction of atherosclerosis [84]. ApoE/, MaFIA−/−
mice were used as control. CD115+ cell apoptosis was induced in-vivo during 2 weeks
starting 5 weeks after collar placement (Fig. 5.1A).
Systemic induction of apoptosis was achieved by 5 intravenous injections of
1mg/kg–body–weight of AP20187 diluted in vehicle (4% ethanol, 10% PEG-400, 1.7%
Tween, in water), every 72 hours. Sacrifice of experimental mice (n=15) was done 16
hours after the last injection.
Local induction of apoptosis was achieved by controlled release of AP20187 di-
luted in vehicle (4% ethanol, 10% PEG-400, 1.7% Tween, in water), using ALZET
osmotic pumps (model 2006) with micro–connector bifurcations (PlasticsOne Y Can-
nula Bifurcation 37200); connected via catheters (HelixMark R©Standard Silicone Tub-
ing 0.64 mm I.D.) to the adventitial side of perivascular collar induced atherosclerotic
lesions (Fig. 5.1B).
The concentration of AP20187 in micro–osmotic pumps and therefore, the local
concentration of AP20187 at the site of release was set at 100µM, which depending
on body weight, led to a systemic dose of 0.018 ± 0.001 mg/kg–day. Sacrifice of
experimental mice (n=15) was done 16 hours after the last injection. A baseline
group of mice (n=8) was sacrificed 5 weeks after collar placement, without induction
of apoptosis.
Plasma M-CSF, Cholesterol and Triglyceride Levels Blood samples were collected
in tubes containing 5µl 0.5M EDTA and centrifuged for 10 minutes at 2100 rpm.
Subsequently, plasma was isolated and used for M–CSF and total cholesterol mea-
surement. M-CSF was determined using the mouse M-CSF Quantikine ELISA kit
(RD Systems). Total plasma cholesterol levels were measured using a colorimetric
assay (Roche Diagnostics, Mannheim, Germany).
Colony Forming Units Assays Spleen and bone marrow cells were isolated from
respectively a fraction of the spleen, one tibia and one femur per mouse. Cells were
counted twice using a Countess automated cell counter (Sigma–Aldrich) and the con-
centration was calculated for each sample. Respectively, 10,000 and 250,000 bone
marrow and spleen cells were added separately to 2 ml methyl cellulose medium
with recombinant cytokines (MethoCult Medium, StemCell Technologies, Grenoble,













Figure. 5.1. Experimental setup for systemic and local induction of CD115+
cell apoptosis in atherosclerotic ApoE−/− MaFIA+/+ mice. A. Advanced atheroscle-
rotic lesions were induced to form by semi–constrictive perivascular collars placed
around the common carotid arteries, three weeks after introduction of high cholesterol
diet (WTD) [84]. CD115+ cell apoptosis was triggered either by intravenous injec-
tion or local release of AP20187 during two weeks, starting five weeks after collar
placement. B. Schematic representation of local induction of macrophage apoptosis in
advanced atherosclerotic lesions using micro–osmotic pumps. Catheters (green) were
used to connect osmotic pumps to the adventitial side of atherosclerotic lesions, for
continuous release of apoptosis inducer AP20187.
quantified by an independent operator. GM-CFU, E-CFU, G-CFU, and M-CFU
colonies were specified based on morphology.
Flow Cytometry Blood and peritoneal cells, and spleen tissue were harvested at sac-
rifice and single cell suspensions were prepared. Lysis of erythrocytes was performed
in ice cold NH4Cl (8.4g/l) NaHCO3 (1g/l) EDTA (37mg/l) during 3 minutes. Sin-
gle cell suspensions were stained with anti -B220, CD3e, CD25, Ly6C, Ly6G, CD11b,
CD11c, CD4, CD19, MHCII, CD86, CD40, F4/80, CD8a, FoxP3 following blocking of
the Fc receptor with CD16/32 Fc blocking antibody. Antibodies were conjugated to
fluorescein isothiocyanate (FITC), phycoerythrin (PE),phycoerythrin–Cy7 (PE–C7),
allophycocyanin (APC), peridinin cholorophyl protein (PerCP), peridinin cholorophyl
protein–Cy5.5 (PerCP–Cy5.5) or eFluo450. A FACSCanto II (BD Biosciences) cou-
pled to the FACSdivaTM software was used for acquisition and analysis of data.
BD TrucountTM tubes, were used for absolute cell counts in blood according to
the protocol supplied by the manufacturer. In short, Fc–receptor blocking antibody
was added to the Trucount tubes. Subsequently, 50µL anti–coagulated whole blood
was added and the tube was gently vortexed. After incubation for ten minutes, the
antibody cocktail was added and incubated at room temperature in the dark for an
additional 20 minutes. Finally, hypotonic lysis buffer was added and samples were
measured on a FACS Canto II flow cytometer (BD Biosciences).
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stained with biotin–conjugated antibodies against lineage markers (CD5, CD45RA
(B220), CD11b, Gr-1 (Ly6G/G), 7-4, and Ter-119; Miltenyi Biotec). Next, lineage
positive cells were depleted using streptavidin conjugated magnetic beads (Miltenyi
Biotech) and LS columns (Miltenyi Biotech). Lineage negative fractions were subse-
quently stained with antibodies for Sca-1, c-Kit (CD117), CD34, CD16/32, CD115,
and lineage markers (CD5, CD45RA (B220), CD11b, Ly6C, Ly6G, Ter-119) and mea-
sured on a FACS Canto II (BD Biosciences).
Isolation and Differentiation of Bone Marrow Derived and Peritoneal Macropha-
ges: Bone marrow derived macrophages (BMDM) were obtained from non adherent
macrophage precursors as previously described [85]. Femurs and tibia were flushed
with phosphate buffered saline (PBS) and single cell suspensions were obtained by
passing the bone marrow so obtained through a 70µm nylon cell strainer (BD Falcon,
Breda, The Netherlands). Bone marrow precursors were differentiated into macropha-
ges by culturing in 85% RPMI containing 10% FCS, 2mM glutamine, 1% pyruvate,
100U/ml penicillin, 100µg/ml streptomycin, 1% non essential amino acids and 15%
L929 LCM medium for 7 days. All in-vitro experiments with BMDM were performed
in RPMI containing 10% FCS, 2mM glutamine, 100U/ml penicillin, 100µg/ml strep-
tomycin and 15% L929 LCM medium.
Peritoneal leukocytes were isolated from mice after cervical dislocation, by in-
jecting 10 ml of sterile PBS into the caudal half of the peritoneal cavity using a
25-gauge and removing the saline containing peritoneal cells with a 19-gauge needle
after shaking the entire body for some seconds. Cells were plated in RPMI 1640 sup-
plemented with 10% FCS 50IU/ml penicillin, 50µg/ml streptomycin, 2mM glutamine,
at 0.25x106 cell/well in 8-chambers culture slides (BD Falcon, Cat. No. 354108) and
incubated for one hour at 37oC. Non adherent cells were removed by washing 5 times
with 500µl prewarmed PBS and adherent peritoneal macrophages (PEM) cells used
for induction of apoptosis in-vitro.
Apoptosis Induction in Peritoneal Macrophages Peritoneal macrophages, obtained
fromMaFIA+/+ ApoE−/− or MaFIA−/− ApoE−/− mice, were cultured with AP20187
(10nM) during 24 hours and stained for 1 hour with FLICA fluorescent polycaspase
detection reagent, to label intracellular activated caspases. Cells were thereafter in-
cubated with Hoechst (200µg/ml) to label cell nuclei, fixed with formaldehyde and
mounted with Dako fluorescence mounting medium (S3023) for analysis by fluores-
cence microscopy.
Tissue Harvesting, Immunohistochemistry and Plaque Morphometry Mice were
anesthetized, sacrificed and exsanguinated. Samples of organs were snap–frozen in
liquid nitrogen and stored at -80oC. Animals were perfused with PBS followed by 4%
formaldehyde before dissection of heart, aorta, common carotid arteries, spleen, thy-
mus, omentum and liver. Organs were stored in 4% formaldhehide overnight (4.5 times
diluted Zinc Formal–Fix, Thermo Electron Corporation, Breda, The Netherlands) be-
fore being embedded in paraffin. Immunohistochemistry of carotid arteries was per-
formed for Mac3 (1:30, BD Pharmigen Cat. 553322), anti–α–smooth–muscle–actin
(ASMA) fluorescein–isothyocyanate (FITC) conjugated antibody (1:3000, Sigma, Cat.













stainings were used for morphometric analysis and assessment of collagen contents
respectively. Sections were analyzed using a Leica Quantimet coupled to Qwin Image
Analysis Software, or ImageJ.
Bones were analyzed for the effects of dimerizer treatment on hematopoiesis.
Contralateral tibiae were fixated for 24 hours and decalcified for 2 weeks in decalcifi-
cation buffer (PBS with 0.05 mM EDTA). Buffer was replaced every 3 days to obtain
sufficient level of decalcification. Tibiae were subsequently embedded in paraffin and
4µm thick sections were cut for RUNX2 and TRAP histological analysis. All histolog-
ical analyses were performed, blinded, by two independent operators using Quantimet
(Leica) with Qwin3 Image Analysis Software (Leica), or ImageJ.
Statistical Analysis All data were tested for normality and analyzed using t–tests
or non–parametric Mann–Whitney U test, as appropriated, with MatLab Software.
P values < 0.05, two sided, were considered significant. Data are presented as mean±
S.E.M. Multiple comparisons were analyzed by one–way ANOVA, followed by Bon-
ferroni multi–comparison test.
5.4 Results
Macrophage Fas Induced Apoptosis (MaFIA) transgenic mice, designed for inducible
depletion of CD115+ cells were generated by Burnett and colleagues [257, 258]. In
those mice, a suicide protein is co–expressed with EGFP, which serves as reporter
gene. The suicide protein comprises a extracellular AP20183 binding protein motif, a
transmembrane region of the human low affinity nerve growth factor receptor and the
cytoplasmic domain of FAS. The MaFIA transgene uses for transcriptional regulation
the promoter of CSF1R, also known as CD115 or M-CSFR; which is expressed in
myeloid phagocytes, including neutrophils, monocytes and macrophages.
The MaFIA mechanism of induction of CD115+ cell apoptosis relies on admin-
istration of AP20187 to mice expressing MaFIA [257, 258]. Binding to AP20187,
cross links the extracellular domain of neighboring MaFIA transgene proteins bring-
ing this way their cytoplasmic FAS domains in close contact. This triggers activation
of the FAS–Caspase-8 extrinsic pathway of apoptosis without off target effects due to
the high specificity provided by the system [260]. MaFIA mice on C57BL/6J back-
ground were crossed to C57BL/6J–ApoE−/− mice to generate homozygous ApoE−/−,
MaFIA+/+, atherosclerotic prone mice.
A detailed characterization of ApoE−/− MaFIA+/+ mice as a model for in-
duction of CD115+ macrophage apoptosis in atherosclerosis is described in the data
supplement (Appendix D. Table D.1 and Appendix D. Fig. D1 –D5). Assessment
of expression of MaFIA in various leukocyte populations, including myelocytes and
leukocytes is included, as well as a description of cells susceptible to induction of
apoptosis by administration of AP20187.
Advanced atherosclerotic lesions were induced by bilateral perivascular col-
lar placement on common carotid arteries of WTD fed ApoE−/− MaFIA+/+ mice.
ApoE−/− MaFIA−/− mice were used as control. The effect of induction of CD115+
cell apoptosis on advanced atherosclerotic lesions was assessed using two approaches.
In the first approach, only lesion CD115+ cells were targeted for ablation by local
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induced by intravenous injection of AP20187.
CD115+ cell apoptosis was induced during 2 weeks starting 5 weeks after perivas-
cular collar placement and eight weeks after introduction of WTD. At this time point
(baseline) no significant differences in total body weight (30.27± 0.82 vs. 31.89± .91
gr, Pval > 0.05) and plasma cholesterol levels (Pval > 0.05. Appendix E. Fig. E1A)
were observed between MaFIA+/+ and MaFIA−/− control mice.
Similarly, no significant differences were observed in plaque burden, lipid core,
lesion cellularity and relative necrotic core content in MaFIA+/+ mice, compared
to MaFIA−/− controls (Appendix E. Fig. E2A-E). Furthermore, no differences were
found in cell composition (TUNEL+ apoptotic cells, MAC3+ macrophages and ASMA+
VSMC), collagen content and minimal fibrous cap thickness, as assessed by histologi-
cal quantifications (Appendix E. Fig. E3A-D). Therefore the presence of MaFIA did
not influence the development of atherosclerotic lesions, as expected.
Systemic, but Not Local Induction of CD115+ Myelocyte Apoptosis Leads to
Atherosclerotic Lesion Vulnerability Local induction of CD115+ cell apoptosis was
achieved using osmotic micropumps containing AP20187. Osmotic pumps were con-
nected to catheters whose outlets were attached to perivascular collars for topical
release of dimerizer on the adventitia of carotid artery atherosclerotic lesions (Fig.
5.1).
The concentration of AP20187 in osmotic pumps at the site of release was set
at 100µM (0.142mg/ml). The osmotic pump model with the slowest release rate
(0.15µl/hour) was chosen to minimize systemic effects due to leakage into the pe-
riphery, bringing about pharmaceutically inactive systemic doses of 0.018 ± 0.001
mg/kg–day. No significant differences in body weight (29.45 ± 0.97 vs. 28.93 ± 1.02
gr, Pval > 0.05) and plasma cholesterol levels (Appendix E. Fig. E1B) were observed
between ApoE−/− MaFIA+/+ and ApoE−/− MaFIA−/− controls.
Local ablation of CD115+ macrophages using the above experimental setup led
to a marked accumulation of apoptotic cells in atherosclerotic lesions (Fig. 5.2A).
Furthermore, the amount of lesion macrophages relative to lesion area was 57% re-
duced (Fig. 5.2B), which indicated succesful induction of lesion macrophage apopto-
sis. Minimal fibrous cap thickness and relative contents of VSMC and collagen were
not altered (Fig. 5.2C-D); indicating that local induction of CD115+ cell apoptosis
had no apparent effects on lesion stability. However, a two fold increase in lesion size
(Fig. 5.3A) was observed, with no differences in lipid core, cell density and necrotic
core area, relative to total lesion area (Fig. 5.3B-E).
Taken together, these results provided a signature of the effect of confined ma-
crophage apoptosis on lesion progression, thus allowing us to segregate local from
systemic effects by comparison to mice receiving intravenous injection of AP20187(1
mg/kg body weight, every 72 hours, for two weeks) as next detailed.
Systemic induction of CD115+ cell apoptosis caused a significant reduction in
body weight in MaFIA+/+ mice (−15.6%, Pval ≺ 0.01), not seen in MaFIA−/−
controls. Nevertheless, plasma cholesterol levels were not affected by intravenous
administration of dimerizer (Appendix E. Fig. E1C), indicating that induction of
CD115+ myelocyte apoptosis had no influence on cholesterol metabolism.
Systemic induction of CD115+ myelocyte apoptosis led to a significant accumu-













Figure. 5.2. Local induction of CD115+ macrophage apoptosis causes ad-
vanced atherosclerotic lesion expansion. A-D. Apoptotic cells (A), macrophages (B),
VSMC (C), collagen contents (D, left panel) and minimal fibrous cap thickness
(D, right panel) upon local induction of CD115+ myelocyte apoptosis in MaFIA+/+
ApoE−/− mice. MaFIA−/− ApoE−/− mice were used as control. 2.5 fold increased
accumulation of apoptotic cells (A), with concomitant 58% reduction in lesion macro-
phages (B) was observed. The total amount of VSMC (C) and collagen (D, left panel)
contents was not altered, nor was the minimal fibrous cap thickness changed (D, right
panel). Middle and right panels in A-D. Representative pictures of TUNEL (A), Mac3
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Figure. 5.3. Effects of local induction of CD115+ macrophage apoptosis on
advanced atherosclerotic lesion phenotype. A-D. Lesion size (A) relative lipid core
area (B), cellularity (C) and necrotic core composition (D) in MaFIA−/− ApoE−/−
(control) and MaFIA+/+ ApoE−/− (treated) atherosclerotic mice after local release of
AP20187 (0.01mg/Kg–day) during two weeks, starting eight weeks after introduction
of WTD. Local induction of macrophage apoptosis leads to two fold lesion expansion
(A). No other differences were observed. E. Representative pictures of HE staining,
used for quantification. ∗P ≤ 0.05.
that displayed reduced macrophage contents indicating intralesion induction of ma-
crophage apoptosis, as expected.
Strikingly, atherosclerotic lesions from MaFIA+/+ atherosclerotic mice receiving
intravenous injections of AP20187 displayed reduced VSMC contents (Fig. 5.4B-C),
with concomitant reduction in collagen accumulation (Fig. 5.4D) and thinning out
of the fibrous cap (Fig. 5.4D). However, no significant differences were observed on
lesion size, relative lipid core content, cellularity and necrotic core area percentage
(Fig. 5.5A-E).
Taken together, these results indicated that systemic induction of CD115+ mye-
locyte apoptosis caused lesion vulnerability in advanced atherosclerosis, without af-
fecting plaque burden. Thus while increased plaque apoptosis and reduced macro-
phage contents were observed upon systemic and local AP20187 treatment; systemic
ablation of CD115+ myelocytes clearly resulted in a distinct lesion phenotype. Corre-
spondingly, a sharp contrast was observed between the effects that local and systemic
induction of CD115+ monocyte/macrophage apoptosis had on blood and spleen mye-
locyte homeostasis. In fact, local release of AP20187 on atherosclerotic lesions had













Figure. 5.4. Effects of systemic induction of CD115+ macrophage apopto-
sis on advanced atherosclerotic lesion composition. A-D. ApoE−/− MaFIA−/− and
ApoE−/− MaFIA+/+ mice, received intravenous injections of AP20187 (1mg/Kg ev-
ery 72 hours) during two weeks, starting eight weeks after introduction of WTD. 4.5
fold increased apoptotic cells (A), with concomitant 41% reduction in macrophages
(B) was observed. The total amount of VSMC (C) and collagen (D, left panel) con-
tents was reduced by 42.5% and 41.5%; respectively. Minimal fibrous cap thickness
was reduced by 70% (D, right panel). Middle and right panels in A-D are representa-
tive pictures of TUNEL (A), Mac3 (B), ASMA (C) and collagen (D) stainings, used
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Figure. 5.5. Effects of systemic induction of CD115+ macrophage apop-
tosis on advanced atherosclerotic lesion phenotype. A-D. Lesion size (A) relative
lipid core area (B), cellularity (C) and necrotic core composition (D) in MaFIA−/−
ApoE−/− (control) and MaFIA+/+ ApoE−/− (treated) atherosclerotic mice receiving
intravenous injections of AP20187 (1mg/Kg every 72 hours) during two weeks, start-
ing eight weeks after introduction of WTD. No significant differences were observed.
E. Representative pictures of HE staining, used for quantification.
caused a slight but significant increase in CD11b+Ly6Gint myelocytes with simulta-
neous reduction in pro–atherosclerotic B220+ B2 B lymphocytes (Fig. 5.6A-C).
Intravenous injections of dimerizer during two weeks on the other hand, unex-
pectedly caused blood monocytosis (Fig. 5.6D) and expansion of the pro–inflammatory
Ly6chi subset (Fig. 5.6E) as observed at the time of sacrifice. No differences were
observed in circulatory granulocyte levels, despite depletion of bone marrow macro-
phages which, as occurs upon systemic induction of CD115+ myelocyte apoptosis in
MaFIA mice [237, 261, 262], has been shown to induce neutrophilia [238]. This, was
likely caused by counteracting depletion of CD11b+Ly6G+ granulocytes, which were
demonstrated to express MaFIA (see Appendix D. Table D.1, Appendix D. Fig. D1
and discussion in Page 139). CD11b+Ly6Gint myelocytes displayed a similar increase
as that observed upon local induction of CD115+ cell apoptosis (Compare Fig. 5.6 A
and D). No significant differences were seen on blood lymphocyte levels (Fig. 5.6F).
Local release of dimerizer had no major effects on spleen size (Fig. 5.7A) while
systemic administration of dimerizer in contrast, caused pronounced splenomegaly
(Fig. 5.7B). Similarly, local administration of dimerizer had no effect on spleen
dendritic cell and lymphocyte contents (Fig. 5.7C-E), while intravenous injection
of dimerizer caused reduced percentages of dendritic cells and T lymphocytes (Fig.













Figure. 5.6. Blood Leukocyte homeostasis upon local and systemic induction
of CD115+ myelocyte apoptosis in ApoE−/− MaFIA+/+ mice. Advanced atheroscle-
rosis was induced by WTD during 10 weeks and perivascular collar placement. Blood
leukocyte composition was analyzed by FACS upon local (A-C) and systemic (D-F)
induction of CD115+ myelocyte apoptosis. No differences in granulocytes, monocytes
(A) and Ly6chi myelocytes (B) were observed upon local treatment, which however
induced ablation of pro–atherosclerotic B220+ B2 B lymphocytes (C). In sharp con-
trast, systemic administration of AP20187 caused expansion of blood CD11b+ Ly6G−
Monocytes (D) and Ly6chi monocytosis (E). The reduction of B220+ B2 lymphocytes
did not reach statistic significance in the systemic application (F). Importantly, local
and systemic induction of CD115+ myelocyte apoptosis caused significant increase in
CD11b+ Ly6Gint myelocytes. ∗P ≤ 0.05, ∗ ∗ P ≤ 0.01, ∗ ∗ ∗P ≤ 0.001.
local treatment caused reductions in pro–atherosclerotic B220+ B2 B spleen lympho-
cytes in agreement with their expression of CD115 (Appendix D. Table D.1, Page 141.
See also References [263,264]). These results therefore indicated that besides causing
lesion vulnerability, systemic induction of CD115+ cell apoptosis had profound effects
on peripheral homeostasis.
Induction of CD115+ Myelocyte Apoptosis Causes Extra–Medullary Myelopoiesis
Extravascular monocyte homeostasis upon systemic induction of CD115+ myelocyte
apoptosis was next assessed considering that this treatment caused profound distur-
bances in peripheral leukocyte homeostasis and lesion phenotype, not observed in
atherosclerotic mice upon local administration of AP20187.
In follow up studies, systemic induction of CD115+ cell apoptosis in ApoE−/−
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Figure. 5.7. Spleen leukocyte homeostasis upon local and systemic induction
of CD115+ myelocyte apoptosis in ApoE−/− MaFIA+/+ mice. Advanced atheroscle-
rosis was induced by WTD during 10 weeks and perivascular collar placement. A-B.
Measurement of spleen weight demonstrated that local induction of CD115+ myelocyte
apoptosis had no significant effect on spleen size, relative to body weight (A). Systemic
administration of AP20187 in contrast, caused pronounced splenomegaly (B). Simi-
larly, local delivery of AP20187 had no significant effects on spleen dendritic cells
(C-D) and T lymphocytes (E). Systemic induction of CD115+ myelocyte apoptosis
in contrast caused massive depletion of rDC (F), pDC (G) and T lymphocytes (H).
Depletion of B220+ B2 B lymphocytes was observed upon both, local and systemic
induction of CD115+ myelocytes apoptosis (E, H). ∗ ∗ P ≤ 0.01, ∗ ∗ ∗P ≤ 0.001.
and spleen myelocytes (data not shown) as those observed before, in atherosclerotic
mice fed WTD during ten weeks (Fig. 5.6D-F and 5.7B, F-H). Importantly, analy-













strated that almost total ablation of circulatory monocytes and granulocytes was
followed by recovery (Appendix D. Fig. D5) indicating, a compensatory expansion
of blood myelocytes in response to induction of apoptosis. Indeed, increased levels of
spleen CD11b+Ly6G− monocytes and CD11b+Ly6Ghi granulocytes were observed in
ApoE−/− MaFIA+/+ following systemic administration of AP20187 (Fig. 5.8A-B).
However, fewer spleen CD11b+Ly6G− monocytes were CD115+ (Fig. 5.8C).
Depletion of bone marrow stromal macrophages, as occurs in AP20187 treated
MaFIA mice [237, 261, 262], causes G-CSF mediated mobilization of bone marrow
hematopoietic stem and progenitor cells (HSPC) into the circulation, leading to
splenomegaly, extramedullary myelopoieisis and severe neutrophilia [238]. In agree-
ment with this, the concentration of G-CSF has been reported to increase in AP20187
treated MaFIA mice [261]. Furthermore, depletion of CD115+ myelocytes in AP20187
treated MaFIA mice has been reported to cause mobilization of HSPC into the circu-
lation and spleen [237, 261]. This, together with the expansion of circulatory mono-
cytes and normal levels of blood granulocytes observed upon systemic administra-
tion of AP20187 in ApoE−/− MaFIA+/+ atherosclerotic mice, made us hypothesize
that enhanced extramedullary myelopoiesis might have counteracted the depletion of
CD115+ myelocytes expected.
Consistently, severe splenomegaly was observed in in atherosclerotic mice used
for assessment of lesion phenotype upon systemic ablation of CD115+ myelocytes
(Fig. 5.6H) as well as in follow up studies (Fig. 5.8D). Furthermore, FACS analysis of
spleen hematopoietic progenitors and colony forming units (CFU) assays indeed indi-
cated that systemic induction of CD115+ cell apoptosis in ApoE−/− MaFIA+/+ mice,
caused enhanced spleen granulopoiesis and monocytopoiesis. Increased levels of pri-
mordial spleen LSK progenitors were observed one week after initiation of treatment
(Fig. 5.8E). This expansion was followed by normalization at the second week, when
granulocyte–macrophage progenitor cell (GMP) levels, relative to total LK spleen
cells, were seven fold increased (Fig. 5.8F).
A slight but not significant elevation relative to the control group was observed
for common myeloid progenitors (CMP) (Fig. 5.8F), suggesting that systemic induc-
tion of CD115+ cell apoptosis, caused increased amounts of spleen granulocytes and
monocytes downstream of GMP and not at the CMP commitment stage. In agree-
ment with these results, a four fold increase in total spleen colony forming units (CFU)
was observed after one and two weeks of systemic administration of dimerizer (Fig.
5.8G). In addition, increased counts of macrophage colony forming units, (GM–CFU),
granulocyte CFU (G–CFU) and macrophage CFU (M–CFU) were observed at both
time points (Fig. 5.8G).
Reduced levels of bone marrow osteoclasts were seen in ApoE−/− MaFIA+/+
mice, fed WTD during three weeks before systemic administration of AP20187 (Fig.
5.9A), in agreement with previously published data [261]. This, would have been ex-
pected to cause accumulation of bone marrow hematopoietic stem and progenitor cells
(HSPC), considering that osteoclasts facilitate the mobilization of immature hemato-
logical progenitors into the circulation [265–267]. However, systemic administration
of AP20187 to MaFIA+/+ mice causes (i) downregulation of cytokines important for
HSPC retention, (ii) indirect loss of endosteal osteoblasts by impairment of endosteal
niches and (iii) HSC mobilization into the blood and spleen, [237,261,262] suggesting
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Figure. 5.8. Spleen myelocytosis is observed upon systemic induction of
CD115+ myelocyte apoptosis in ApoE−/− MaFIA+/+ mice fed WTD during three
weeks. Systemic administration of AP20187 during two weeks, led to increased per-
centages of spleen granulocytes two weeks after initialization of treatment (A, white
bar). Similarly, increased monocyte levels were observed, one week after initializing
treatment (B, gray bar) and upon its completion (B, white bar). Downregulation of
CD115 was observed in spleen CD11b+ Ly6G− monocytes one and two weeks upon sys-
temic induction of CD115+ myelocyte apoptosis (C). In addition, total splenocyte le-
vels were increased after two weeks of treatment, indicating induction of splenomegaly
(D). Systemic induction of CD115+ cell apoptosis led to increased levels of LSK pro-
genitors one week upon treatment (E). This was followed by expansion of GMP by the
second week (F). Increased counts of total CFU and myeloid CFU were observed one
and two weeks upon treatment (G), indicating enhanced spleen myelopoiesis. Pictures
representative of CFU assays are included (G, right panel). ∗P ≤ 0.05, ∗ ∗ P ≤ 0.01,













indirect effects on osteoblasts counteracting the ablation of osteoclasts, and leading
to HSPC mobilization.
As net result, no significant differences were found in total bone marrow cells,
both after one and two weeks of treatment (Fig. 5.9B). In addition, bone marrow
LSK, LK and LS progenitors, as well as GMP and CMP progenitors, total CFU, mul-
tipotent GEMM–CFU (data not shown) and committed CFU (GM–CFU, G–CFU,
M–CFU) precursor cell counts were not disturbed by the first and second weeks upon
intravenous injection of AP20187 (Fig. 5.9C-D).
Collectively, these results therefore indicated that systemic induction of CD115+
myelocyte apoptosis causes extramedullary myelopoiesis, likely as result of increased
mobilization of bone marrow HSPC.
Systemic administration of AP20187 (1mg/kg, every 72 hours during two weeks)
to ApoE−/− MaFIA+/+ mice fed WTD during three weeks had no impact in plasma
M–CSF (CSF–1) concentration (Control ApoE−/− MaFIA+/+ mice receiving vehicle:
1481 pg/ml, treated during one week: 1535 pg/ml, treated during 2 weeks 1475 pg/ml.
ANOVA Pval = 0.8092 ). Similarly, the amount of peritoneal granulocytes, mono-
cytes, atheroprotective CD19+ B1a lymphocytes and macrophages (Appendix E. Fig.
E4A-D) was not altered upon systemic administration of AP20187. However, a sharp
increase in Ly6chi M1 macrophages with concomitant reduction in their Ly6clo M2
counterparts was observed (Appendix E. Fig. E4E-F) in agreement with the positive
regulation of the M2 transcriptome exerted by M–CSF on macrophages [268]. The
later result suggests therefore that preferential depletion of tissue repairing macro-
phages upon systemic induction of CD115+ cell apoptosis, might have contributed to
the features of lesion vulnerability observed.
Taken together, these results therefore indicated that systemic administration
of AP20187 (1mg/kg, every 72 hours) allowed us the induction of lesion macrophage
apoptosis with continuous supply of circulatory monocytes provided by mobilization
of HSC progenitors into the circulation, extravasation into the spleen and induction
of spleen monocytopoiesis. Higher doses of AP20187 in contrast, caused massive
ablation of both, circulatory and tissue myelocytes (Appendix D. Fig. D3. See also
discussion of the MaFIA model and description of pilot experiments performed to
chose the dose regimen used 142).
5.5 Discussion
Although genetic [25, 225] and pharmacological [222, 224, 236, 269] ablation strate-
gies have helped to pinpoint the contribution of plaque macrophage apoptosis to the
development and progression of atherosclerosis, and have even been proposed as a
the- rapeutic option to stabilize atherosclerotic lesions [256, 270], the outcomes of
these studies are discrepant, possibly due to lack of site–and/or cell–specificity of the
intervention.
We therefore evaluated the impact of local and systemic induction of CD115+
myelocyte apoptosis, in advanced atherosclerotic lesions previously induced by perivas-
cular collar placement. Using this approach, we were able to segregate plaque–confined
from peripheral effects. Local and systemic administration of AP20187 caused effec-
tive lesion macrophage ablation, as illustrated by significant accumulation of TUNEL
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Figure. 5.9. Bone marrow leukocyte homeostasis upon systemic induction
of CD115+ myelocyte apoptosis in ApoE−/− MaFIA+/+ mice fed WTD during three
weeks. Except for osteoclasts (A), systemic induction of CD115+ myelocyte apoptosis
during two weeks had no significant effect on bone marrow cellularity (B) leukocyte
progenitors (C, top–left panel) GMP and CMP cells (C, bottom panel), total colony
forming units (CFU) (D, left panel) and myeloid CFU (D, right panel). Representa-
tive pictures of immunohistochemistry for quantification of bone marrow osteoclasts
are included (A, bottom panel) as well as dot plots illustrative of FACS analysis of
bone marrow progenitors (C, top–right panel). ∗P ≤ 0.05, ∗ ∗ P ≤ 0.01.
tents of Mac3+ macrophages. We show that local induction of CD115+ mono-
cyte/macrophage apoptosis causes plaque expansion, without changes in fibrous cap
thickness, collagen deposition and smooth muscle cell contents. Systemic induction of
CD115+ cell apoptosis causes, in sharp contrast, features of lesion vulnerability such













Peripheral myelocyte homeostasis, in particular circulatory and spleen monocyte
and neutrophil counts and dendritic cell percentages, although unchanged in the local
application were altered upon systemic administration of AP20187, indicating that
the differences in lesion phenotype observed could be at least in part attributed to
peripheral effects of systemic CD115+ cell ablation; with extramedullary myelopoiesis
and Ly6chi skewed monocyte differentiation as main culprits.
No differences in necrotic core size were observed upon both, systemic and local
treatment, indicating that the level of apoptosis reached was not high enough to
overload the efferocytosis capacity of remaining lesion phagocytes. Similarly, no effect
on lesion cellularity and total plasma cholesterol levels were observed, excluding cell
density and cholesterol metabolism bias in the interpretation of results.
Our study is thus the first to segregate the impact of lesion–restricted versus sys-
temic CD115+ monocyte/macrophage ablation on advanced atherosclerosis, exposing
the true therapeutic and experimental perspective of plaque macrophage depletion
strategies; and raising several fundamental questions. The first of which is how local
induction of CD115+ myelocyte apoptosis induced plaque expansion.
The only off target effect observed upon local delivery of AP20187 on atheroscle-
rotic lesions was the ablation of proatherogenic B220+ B2 lymphocytes, which accord-
ing to Ait–Oufella and colleagues [271] and contrary to our results, should have caused
reduced atherosclerotic lesion burden. This suggest that any anti–inflammatory effect
induced by ablation of B2 lymphocytes, if present, was overruled by other counter-
acting mechanism.
M–CSF, the ligand for CD115, favors the differentiation of macrophages to-
wards an anti–inflammatory and wound healing M2 phenotype [268,272]. It is there-
fore conceivable that systemic induction of CD115+ myelocyte apoptosis might have
preferentially depleted M2 macrophages in atherosclerotic lesions; shifting their bal-
ance towards higher contents of pro–inflammatory and proteolytic M1 macrophages.
However, preferential ablation of alternatively activated M2 macrophages, leading to
higher contents of pro–inflammatory M1 macrophages in atherosclerotic lesions, is un-
likely to have caused lesion expansion, because besides inflammation, higher contents
of M1 macrophages would have induced lesion vulnerability, which was not observed.
More likely, the expansion of atherosclerotic lesions observed upon local treat-
ment might be related to increased inflammation under conditions of augmented in-
tra–lesion CD115+ macrophage apoptosis [52] or local proliferation, which has re-
cently been postulated as the predominant process responsible for the replenishment
of macrophages in experimental mouse atherosclerosis [273].
A second question concerns the mechanisms responsible for inducing lesion vul-
nerability upon systemic, but not local administration of AP20187. Systemic admin-
istration of AP20187 caused splenomegaly, induced ablation of spleen dendritic cells
and exerted a profound impact in circulatory leukocyte homeostasis, characterized
by blood monocytosis and expansion of proinflammatory blood Ly6chi monocytes.
This likely predisposed the immune response towards atherosclerotic lesion vulner-
ability already in the circulation; considering that Ly6chi monocytes are prompt to
extravasation into atherosclerotic lesions, and differentiation into pro–inflammatory
and proteolytic macrophages [61,274,275].
In addition, systemic depletion of CD115+ macrophages might have caused a
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caps, lessened accumulation of VSMC and reduced deposition of collagen, as obser-
ved. In agreement with this notion, increased levels of Ly6chi macrophages, known
to display an M1 phenotype [276], were observed in the peritoneum of mice receiv-
ing systemic treatment, suggesting that a similar shift might have taken place in
atherosclerotic lesions; yet further experiments using more markers of macrophage
differentiation would be needed to reach definitive conclusions on this point.
A fundamental question is why, despite the expression of MaFIA, systemic in-
duction of CD115+ myelocyte apoptosis during two weeks had no effect in blood
granulocytes and caused increase, not depletion of circulatory monocytes in ApoE−/−
MaFIA+/+ mice fed WTD during 10 weeks. As to the first, depletion of bone mar-
row stromal macrophages, as occurs in AP20187 treated MaFIA mice [237,261,262],
causes severe neutrophilia [238], which would have counteracted the CD115+ depen-
dent depletion of neutrophils induced by AP2018 administration.
Regarding circulatory monocytes and Ly6chi monocytes, their increase at the
second week of systemic induction of CD115+ cell apoptosis, in advanced atheros-
clerosis, was rather surprising, considering their expression of MaFIA (as detailed
in the data supplement, page 139). However, systemic induction of CD115+ mye-
locyte apoptosis led to almost total ablation of blood monocytes by the first week
of treatment; followed by recovery and normalization of blood monocyte counts by
the second week, indicating that the dose given although effectively inducing mono-
cyte apoptosis, was not lethal, but rather induced a myelopoietic boost, which, as we
next explain, was mediated by mobilization of bone marrow hematopoietic stem and
progenitor cells, coupled to extramedullary myelopoiesis.
Induction of CD115+ cell apoptosis led to reduced levels of osteoclasts in agree-
ment with previously published results [261]. This would have been expected to
cause reduced intravasation and accumulation of hematopoietic progenitors in the
osteal niche. Considering that osteoclasts facilitate their mobilization into the cir-
culation [265–267]. However bone marrow progenitor cells and total bone marrow
cell counts were not altered, likely because induction of CD115+ myelocyte apoptosis
in MaFIA mice causes increased levels of G–CSF in the circulation, impairment of
endosteal niches, loss of endosteal osteoblasts, downregulation of cytokines required
for HSC retention, including CXCL12, Ang–1 and KL, and mobilization of HSC into
the circulation and spleen, leading to increased spleen myelopoiesis [237,261,262].
In agreement with these data, increased levels of spleen granulocytes and mono-
cytes were observed one and two weeks after initiation of systemic treatment, as result
of primordial LSK progenitor expansion by the first week of treatment, followed by
granulocyte–macrophage progenitor expansion and enhanced myelopoiesis by the sec-
ond week.
Therefore, spleen monocytopoiesis was likely responsible for the expansion in
pro–inflammatory Ly6chi lesion infiltrating monocytes observed upon systemic induc-
tion of CD115+ macrophage apoptosis in advanced atherosclerosis. This is consistent
with recently published studies that have identified the spleen as the major source
of inflammatory monocytes in hyperlipidemic and normolipidemic mice [66,277–279].
In addition, extramedullary produced mononuclear phagocytes have been suggested
to display a pro–inflammatory phenotype because of their profile of expression of cy-
tokines, reactive oxygen species and proteases [66]. It is therefore conceivable, that













not only provided a source of circulatory monocytes, but also promoted lesion vul-
nerability.
Downregulation of CD115 as observed in differentiated monocytes might have
contributed to their survival under conditions of CD115+ cell ablation, triggered
by systemic administration of AP20187. In fact, Robbins et al. have shown that
GM–CSF and IL–3 are sufficient to drive myelopoiesis of spleen progenitors [66]. In
addition, Leuschner and colleagues reported that IL–1β, but not M–CSF (the ligand
for CD115), regulates spleen monocytopoiesis, and is upregulated in spleens of mice
induced to develop extramedullary myelopoiesis [278]. It is therefore conceivable
that the increased myelopoiesis observed upon systemic induction of CD115+ cell
ablation proceeded independent of M–CSF and CD115. Down–regulation of CD115 in
myelocytes arise however questions, as to what extent CD115− phagocytes displayed
the complete repertoire of immune functions exhibited by their CD115+ counterparts;
which falls beyond the scope of this study and requires further investigation.
Collectively, our results indicate that systemic induction of CD115+ myelocyte
apoptosis in ApoE−/− MaFIA+/+ atherosclerotic mice allowed us the ablation of
lesion macrophages with continuous supply of circulatory monocytes provided by
mobilization of HSC progenitors into the circulation and induction of spleen mono-
cytopoiesis.
Extramedullary myelopoiesis, proinflammatory Ly6chi monocytosis, depletion
of spleen dendritic cells and increased M1/M2 tissue macrophage levels were all ef-
fects of systemic induction of CD115+ myelocyte apoptosis not observed upon local
treatment, that likely contributed to the features of lesion vulnerability observed.
In conclusion, this study is the first to address the impact of spatially confined
ablation of CD115+ monocytes and macrophages in advanced atherosclerotic lesion
phenotype. We show that systemic and local induction of CD115+ cell ablation
led to buildup of apoptotic cells and reduced contents of macrophages in advanced
atherosclerosis. In addition, we demonstrated that local induction of CD115+ mye-
locytes causes lesion expansion, with no major changes in plaque composition. In
contrast, systemic (but not local) induction of CD115+ myelocyte apoptosis causes
lesion destabilization, possibly owing to augmented extramedullary myelopoiesis and
ensuing Ly6chi monocytosis.
Simultaneous manipulation of systemic leukocyte homeostasis and local induc-
tion of macrophage apoptosis offer therefore new opportunities for research and de-

























As a chronic inflammatory disease and metabolic disorder, atherosclerosis is driven by
hyperlipidemia, altered vascular leukocyte homeostasis and pro-inflammatory immune
responses. Atherosclerotic lesions progress as result of a shift in homeostasis towards
the progressive accumulation of monocyte derived macrophages driven by increased
circulatory monocyte recruitment, secretion of proinflammatory cytokines, reduced
macrophage efflux and increased macrophage apoptosis with reduced disposal of death
cells and secondary necrosis driven inflammation.
The studies presented in this thesis describe experiments designed to manipu-
late processes controlling vascular macrophage homeostasis; in order to study their
influence in atherosclerotic lesion progression and phenotype in mice. The first part
(Chapters 2 and 3) deals with disruption of monocyte extravasation and macrophage
differentiation in atherosclerotic mice either by deficiency of Hck and Fgr (Chapter 2)
or lentiviral mediated over–expression of NAMPT in hematopoietic cells (Chapter 3).
The second part targets two subsets of lesion macrophages (CD115+ and CD169+)
for systemic and local induction of apoptosis in advanced mouse atherosclerosis. The
effect of these treatments was assessed in terms of atherosclerotic lesion phenotype as
well as vascular and extravascular leukocyte homeostasis.
6.1 Modulation of Monocyte Migration and
Macrophage Differentiation in Atherosclerosis
Extravasation is a multi-step process critical for leukocyte recruitment and accumu-
lation of macrophages in atherosclerosis. It includes selectin mediated rolling on the
endothelium, integrin dependent arrest and binding of monocytes to endothelial cells,
and diapedesis (Figure 1.1, page 2). Hck and Fgr are two Src tyrosine kinases critical
for cell migration, that display hematopoietic specific co-expression and have over-
lapping molecular functions not observable in single Hck or Fgr deficient leukocytes,
due to redundancy [80].
Specific subsets of circulatory monocytes, have been demonstrated to extravasate
and accumulate differentially into atherosclerotic lesions. These subsets are charac-














as consequence of the activation of gene networks, that control biological processes
not shared among subsets (for more details see page 9).
Two monocyte subsets identified in hyperlipidemia-mediated atherosclerotic mice
have been characterized by their differential expression of chemokine receptors (CCR2
and CX3CR1) and Ly6c, a cell surface protein involved in leukocyte migration and
integrin clustering and activation [280–282].
The first subset of circulatory monocytes, commonly referred to as ”resident”
and denoted as CX3CR1
hiCCR2−Ly6lo, is found in resting and inflamed tissues and
display high expression of CX3CR1 and two integrins: LFA-1 and VLA-4. These
monocytes, referred to as Ly6clo, downregulate the expression of Ly6c, CCR2 and
L–selectin [62,283].
The second subset, denoted as CX3CR1
loCCR2+Ly6hi monocytes and denom-
inated ”inflammatory”, are characterized by the upregulation of Ly6c (Gr1), the
chemokine receptor CCR2 and the adhesion molecule L–selectin [62, 284]. Circula-
tory Ly6chi monocytes are expanded in hyperlipidemic mice and are preferentially
recruited to inflamed arteries, leading to the expansion of atherosclerotic lesions [58].
Ly6chi monocytes either intravasate from the bone marrow or originate from bone
marrow hematopoietic stem cell precursors that intravasate in higher quantities in
hyperlipidemia [64], to home in the spleen were they differentiate into Ly6chi inflam-
matory monocytes that emigrate to the circulation, becoming the major source of
proinflammatory monocytes that infiltrate atherosclerotic lesions [66].
Once in the lesion, ingestion of oxLDL by inflammatory monocytes promotes
their maturation into macrophages [285], and induces downregulation of CCR2 with
simultaneous upregulation of the intercellular adhesion chemokine receptor CX3CR1.
This switch in chemokine receptor expression induces their adhesion to various cell
types that express CX3CL1, leading to macrophage trapping and skewing macrophage
homeostasis towards accumulation in atherosclerotic lesions.
Deficiency of Hck and Fgr in LDLr− mice caused reduced accumulation of ma-
crophages in atherosclerotic lesions as consequence of reduced monocyte adhesion to
the endothelium and diapedesis. This, although favorable in terms of lesion size, was
surprisingly accompanied by features of lesion instability such as enlarged necrotic
cores and reduced collagen deposition and SMC accumulation, that suggested re-
duced accumulation of monocyte derived fibrocytes and–or the involvement of Hck
and/or Fgr in leukocyte functions beyond cell migration.
Interestingly, Hck/Fgr deficiency caused a higher Ly6chi/Ly6clo ratio in circula-
tory monocytes, suggesting a higher availability and infiltration of pro-inflammatory
monocyte precursors in atherosclerotic lesions of Hck/Fgr double deficient chimeras,
compared to control mice.
Hematopoietic upregulation of iNAMPT in contrast, caused reduced levels of
circulatory Ly6chi monocytes due to poor intravasation out of the bone marrow.
This concurred with reduced atherosclerotic burden and lower lesion macrophage
accumulation, suggesting delayed lesion progression due to reduced availability of
inflammatory monocytes.
Lesion macrophages activate specific gene networks in response to differentia-
tion signals present in atherosclerotic lesions. Similar to monocytes, two macrophage
subsets, commonly known as M1 and M2 macrophages, have been defined in–vitro
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native activated macrophages (AAM), induce processes that promote wound repair
and inflammation smoldering in response to mediators such as IL–4 and IL–10. One
such a process is the induction of cholesterol efflux by upregulation of PPARγ and
ATP binding cassette transporters ABCA1 and ABCG1; which delay the progress of
atherosclerosis by reducing foam cell formation and inflammation. Other important
processes performed by M2 macrophages are the stimulation of smooth muscle cells to
synthesize collagen and extracellular matrix proteins [286], the negative regulation of
inflammation and inhibition of extracellular matrix degradation, by secretion of me-
diators such as TGFβ and IL–10 [287]. M2 macrophages, or their equivalent in–vivo
are expected to induce the cessation of inflammation and promote the formation of
fibrous caps that keep the thrombogenic contents of atherosclerotic lesions isolated
from the circulation, thereby preventing the formation of thrombus that cause arterial
occlusion and clinical manifestations of atherosclerosis, such as myocardial infarction,
stroke and sudden death.
M1 or classically activated macrophages (CAM), deemed to be activated by
proinflammatory mediators present in atherosclerosis such as IFNγ and oxidized lipids
[288], are in contrast detrimental for lesion stability by expression of proteases that
degrade the extracellular matrix and secretion of immune mediators such as IFNγ
and TNFα that induce accelerated recruitment of pro-inflammatory leukocytes.
M1 and M2 macrophage markers are detectable in human atherosclerotic le-
sions [166,289], but M2 macrophages are predominant in early lesions while their M1
counterparts prevail in advanced atherosclerosis [290], which suggest that M2 macro-
phages might limit the progression of atherosclerosis in the initial stages, while M1
macrophages cause lesion expansion and vulnerability in advanced atherosclerosis,
either upon differentiation from Ly6chi monocyte precursors, or after transdifferenti-
ation from M2 macrophages [117].
Analysis of the effect of Hck/Fgr deficiency on mouse macrophage function,
demonstrated that besides impairing leukocyte migration, and increasing the levels of
Ly6chi monocytes in the circulation, it caused skewed M1 macrophage differentiation
and reduced collagen deposition by smooth muscle cells. In agreement with these
results, transcriptome analysis of gene expression in human macrophages allowed
the clustering of Hck and Fgr in gene networks with different expression profiles in
response to immune modulators. Interestingly, Hck clustered with genes overrep-
resenting cytokine-cytokine receptor interaction and chemokine signaling pathways,
suggesting its preferential involvement in leukocyte extravasation and migration. Fgr
in contrast, clustered with genes characteristic of macrophage M2 differentiation.
Collectively, these results suggest that although Hck and Fgr play overlapping
molecular functions critical for leukocyte migration, which makes necessary the use
of double deficiency or inhibition approaches to avoid compensation [80, 80], they
might be differentially required for activation of macrophage M1 and M2 responses.
Disrupted M2 type macrophage responses in double deficient Hck−/−Fgr−/−LDLr−/−
mouse chimeras likely caused the vulnerable lesion phenotype observed.
In remarkable contrast, over–expression of NAMPT led to features of lesion
stabilization in LDLr−/− atherosclerotic mice by skewed M2 differentiation, with
concomitant downregulation of M1 proinflammatory cytokines, reduced intracellular
accumulation of cholesterol esters and free cholesterol and increased expression of













the proinflammatory activation of macrophages in atherosclerosis and positively regu-
lated their alternative polarization by upregulation and activation of PPARγ, SIRT1,
ABCA1 and ABCG1, which are known to modulate macrophage differentiation.
In addition, over–expression of NAMPT acted cytoprotective in response to
ox-LDL pro-apoptotic stimuli, indicating that over-expression of NAMPT in mouse
atherosclerosis has pleiotropic anti-atherosclerotic effects targeting different molecular
pathways.
Taken together, the results obtained in atherosclerotic mice chimeras deficient in
Hck/Fgr or over–expressing iNAMPT, complement to indicate that reducing Ly6chi
to Ly6clo subset balance and skewing macrophage differentiation towards an anti-
inflammatory and wound healing phenotype might be promising to reduce and stabi-
lize atherosclerotic lesions. However, the crucial role of inflammatory monocytes and
CAM in host defense imposes that these strategies are designed without interfering
with systemic innate immunity and host defense.
6.2 Induction of Macrophage Apoptosis and Its Effect
on Atherosclerosis
An increasing body of evidence from both animal models and human studies suggests
that programmed cell death in the form of apoptosis or necrosis [49], are major events
in the pathophysiology of atherosclerosis, and determinant of the phenotype adopted
by lesion macrophages. In fact, macrophages accumulate in the vicinity of ruptured
lesions and correlate with the formation of necrotic cores [291] and the progression of
lesions towards vulnerability [292,293].
In addition to increased apoptosis inside atherosclerotic lesions, M1 and M2
macrophages display reduced chemotaxis in response to modified lipids. Then, ex-
tracellular environment rich in oxidized cholesterol and proinflammatory cytokines
present in atherosclerotic lesions, not only promotes monocyte recruitment and dif-
ferentiation into M1 macrophages but also limits their exit out of lesions [68], induces
their death and impairs their phagocytic capacity, skewing all their responses towards
their accumulation, the degradation of their extracellular matrix and the induction
of lesion rupture, ultimately leading to thrombus formation and arterial occlusion.
Deficiency of anti-apoptotic genes during atherosclerosis onset and progression
has a biphasic effect in macrophage homeostasis in atherosclerosis, promoting cell
turnover and reduced atherosclerosis when coupled to prompt efferocytosis, mainly
in early lesions [248, 294]; but inducing accelerated lesion expansion and instability
when non phagocytosed apoptotic cells loose the integrity of their membrane, leaking
proinflammatory, lytic and thrombogenic intracellular contents that induce monocyte
recruitment, fibrous cap degradation and thrombus formation in advanced atheroscle-
rosis [252–254, 295]. Conversely, protection from apoptosis in atherosclerosis causes
early lesion expansion [250,251] but reduces atherosclerosis progression into advance
stages [250,251,255,296].
Collectively, these results have led to the generalized idea that macrophage apop-
tosis has a biphasic effect in atherosclerosis, which suggest that skewing the balance
of prosurvival and proapoptic genes in atherosclerosis would be inappropriate to treat
patients normally having lesions of all stages at any given time [297]. However, phar-
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of macrophage apoptosis [25, 225] have afforded contradictory results regarding the
impact of macrophage ablation on atherosclerosis, likely due to site and cell related
off target effects.
In fact, systemic induction of CD11b+ myelocyte apoptosis has no effect on le-
sion size and composition, despite inducing intra-lesion macrophage apoptosis. The
reason for this paradoxical result is that induction of CD11b+ myelocyte apopto-
sis causes massive depletion of circulatory monocytes thereby reducing the impact
of intra–lesion macrophage apoptosis on vascular inflammation and lesion expansion.
Systemic induction of CD11c+ myelocyte apoptosis in contrast, does not deplete circu-
latory monocytes and leads to lesion expansion and higher counts of lesion apopototic
cells in atherosclerotic mice. However, no reduction in CD68+ lesion macrophage con-
tents is observed [25] upon induction of CD11c+ myelocyte apoptosis in atherosclerotic
mice, which however display increased plasma cholesterol levels in response to den-
dritic cell ablation, making difficult to discriminate the contribution of macrophage
apoptosis to the effects observed [23,25]
In remarkable contrast with these two studies, induction of macrophage apop-
tosis using suicide genes expressed in CD169+ or CD115+ cells, as described in this
thesis (Chapter 4 and 5) permitted the ablation of lesion macrophages without off
target effects, either because the promoter used was highly specific for macrophages
as in the case of CD169–DTR–LDLr−/− chimeras (Chapter, 4) or because the induc-
tion of CD115+ myelocyte apoptosis was restricted to atherosclerotic lesions by local
delivery of an inducer of apoptosis (Chapter 5).
Analysis of atherosclerotic lesions following apoptosis induction and after a re-
covery period, permitted the evaluation of the impact of macrophage ablation on
atherosclerosis and its dynamics after cessation of treatment. In addition, by com-
parison with the local experimental setup, systemic induction of CD115+ myelocyte
apoptosis permitted discrimination of the effect of induction of myelocyte apoptosis
on peripheral leukocyte homeostasis, and its influence back in atherosclerotic lesions
bearing higher CD115+ myelocyte apoptosis.
Systemic induction of macrophage apoptosis using both CD169–DTR–LDLr−/−
chimeras and ApoE−/− MaFIA mice, caused reduced macrophage contents with con-
comitant increase in lesion apoptosis. In addition, lesion confined CD115+ myelo-
cyte apoptosis in ApoE−/− MaFIA+/+ mice (Chapter 5), and systemic induction
of CD169+ macrophage apoptosis (Chapter 4) in LDLr−/− chimeras, caused athe-
rosclerotic plaque expansion likely due to local proliferation or increased inflamma-
tion under conditions of augmented intra-lesion macrophage apoptosis. Furthermore,
induction of CD169+ macrophage apoptosis in CD169–DTR–LDLr−/− mice led to
necrotic core expansion; likely due to overload of the efferocytosis capacity of re-
maining phagocytes. However, necrotic cores from ApoE−/− MaFIA+/+ mice, used
for induction of CD115+ macrophage apoptosis, were not expanded, compared to
ApoE−/− MaFIA−/− controls.
Importantly, no changes in lesion composition nor features of lesion vulnerability
were observed upon local induction of CD115+ myelocyte apoptosis. In contrast, sys-
temic induction of CD115+ myelocyte apoptosis not only caused macrophage turnover
and increased apoptosis in atherosclerotic lesions but also induced features of lesion
vulnerability not observed in the local application. Simultaneously, systemic induction













hanced extramedullary myelopoiesis, proinflammatory Ly6chi monocytosis, depletion
of spleen dendritic cells and skewed pro-inflammatory macrophage differentiation.
Systemic induction of CD169+ macrophage apoptosis caused lesion vulnerabil-
ity, however a remarkable recovery was observed two weeks after cessation of apoptosis
induction, when no differences in lesion size and necrotic core contents were obser-
ved between mice receiving diphtheria toxin to induce CD169+ macrophage ablation,
and diphtheria-toxin-mutant-receiving controls. In addition, induction of apoptosis in
CD169–DTR–LDLr−/− mice caused transient elevation of pro-inflammatory plasma
cytokines and Ly6chi monocytosis, that normalized giving way to lesion stabilization,
higher contents of VSMC and increased deposition of collagen and thicker fibrous
caps.
Taken together, the experiments presented in Chapter 4 and 5 are the first
to address the dynamic response that follows induction of macrophage apoptosis in
atherosclerosis and segregate local from systemic effects of this intervention.
By comparison of the results obtained upon systemic and local induction of
CD115+ myelocyte apoptosis, and considering the dynamics of recovery following
induction of CD169+ macrophage apoptosis, the results presented in this section
indicate that simultaneous manipulation of systemic leukocyte homeostasis and acute
induction of macrophage apoptosis, might be used to achieve macrophage turnover
with concurrent atherosclerotic lesion stabilization.
6.3 Concluding Remarks and Future Perspectives
The onset and progression of atherosclerosis is the result of the interplay of thousands
of molecules in multiple interacting cells types, that contribute differently in various
organs and tissues throughout the body.
This thesis addressed multiple mechanisms that control intra and extravascular
leukocyte homeostasis, ultimately dictating the fate of atherosclerotic lesions, at the
balance between macrophage accumulation and lesion vulnerability versus resolution
of inflammation and wound healing.
The first part of this thesis demonstrated that targeting a single gene, or a combi-
nation of redundant genes, with identified molecular function, resulted in multiple dis-
turbances to different processes important in atherosclerosis. As such, hematopoietic
deficiency of Hck and Fgr was demonstrated to reduce monocyte diapedesis and skew
monocyte and macrophage differentiation towards inflammation. Over–expression of
iNAMPT in turn caused impaired intravasation of inflammatory monocytes, thereby
reducing their availability to migrate into atherosclerotic lesions, while simultane-
ously activating multiple pathways that promoted macrophage survival, resolution of
inflammation and cholesterol efflux.
The second part of this thesis indicated that the impact of acute induction of ma-
crophage apoptosis in atherosclerosis is highly dynamic and dependent on peripheral
as well as intra-lesion leukocyte homeostasis. As such, induction of CD169+ macro-
phage apoptosis exerts a response characterized by transient extramedullary myelopo-
iesis, monocytosis and atherosclerotic lesions that change their phenotype over time,
from lesion vulnerability upon induction of apoptosis, to stabilization upon recovery.
Similarly, systemic and local induction of CD115+ myelocyte apoptosis cause accumu-
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systemic induction of CD115+ cell apoptosis leads to features of lesion vulnerability,
extramedullar myelopoiesis and altered circulatory and spleen leukocyte homeostasis,
not observed in the local application.
As a whole, these results highlight the interplay of different immune system
compartments in atherosclerosis and place emphasis on the participation of genes
in pleiotropic and antagonistic biological processes due to their ability to cooperate
their molecular functions in networks, whose spatio-temporal regulation and function
proceed beyond single molecular functions of particular genes.
The future direction of the research in atherosclerosis must therefore integrate
data from different levels of complexity and take advantage of the latest technologies
to develop improved diagnostics and therapeutic solutions for atherosclerosis, the



















































Appendix A. Dual Role of Hck and Fgr in Atherosclerosis 119
Figure. A.1. Plasma IL–1α (A), IL–1β (B), IL–12p40 (C), Eotaxin (D)
and MCP–1 (E) levels are not altered in Hck/Fgr dKO, LDLr−/− chimeras. (n=12)
Figure. A.2. FACS analysis of leukocytes in aortas of Hck/Fgr dKO,
LDLr−/− atherosclerotic mice. A-B. Hck/Fgr–deficiency caused reduced accumula-
tion of F4/80+ macrophages (A) but had no effect on CD3+ lymphocyte contents (B)












120 Appendix A. Dual Role of Hck and Fgr in Atherosclerosis
Figure. A.3. Reduced thioglycolate induced peritonitis in Hck/Fgr deficient
mice. A. The absolute levels of inflammatory cells recruited to the peritoneal cavity
was reduced in dKO chimeras 24, 72 and 120 hours after intraperitoneal injection
of thioglycolate. B. Absolute monocyte/macrophage counts in peritoneal ascites were
reduced by 48.5% 120 hours after induction of peritonitis in dKO chimeras. C. Rela-
tive monocyte/macrophage numbers in the peritoneal cavity were unchanged. D. The
expression of activation markers was not perturbed by the lack of Hck/Fgr.( n=6,












Appendix A. Dual Role of Hck and Fgr in Atherosclerosis 121
Figure. A.4. Correlation analysis of atherosclerotic lesion composition in
Hck/Fgr dKO, LDLr−/− mice chimeras. A. Macrophage area correlated with plaque
area in WT and dKO chimeras (PvalWT = 0.0001, PvaldKO = 0.0001); there was
no statistical difference between WT and dKO correlations (P = 0.5). B. Adventitial
neutrophil contents did not correlate to lesion size, neither in dKO chimeras nor in
WT controls. C. Necrotic core area correlated with plaque area in WT and dKO
chimeras (PvalWT = 0.039, PvaldKO = 0.0061); there was no statistical difference
between WT and dKO correlations (P = 0.4). D. SMC area correlated with plaque
area only in WT mice (PWT = 0.0058). Fibrous cap (E) and collagen (F) contents
did not correlate to lesion size, neither in dKO chimeras, nor in WT controls. (The












122 Appendix A. Dual Role of Hck and Fgr in Atherosclerosis
Figure. A.5. Atherosclerotic Hck/Fgr dKO, LDLr−/− chimeric mice display
blood Ly6chi monocytosis. FACS analysis of bones showed essentially no differences
in neutrophil and monocyte cell contents (A) and monocyte subsets (B) (n=6, sample
duplicates per experimental unit). The surface expression of Ly6c is not influenced by
the lack of Hck/Fgr in ly6clow and Ly6chi blood monocyte subsets (C. n=6, duplicated
samples per experimental unit). D. Representative histograms of Ly6c mean fluo-
rescence intensity observed in WT and dKO blood monocyte subsets. E-G. Normal
absolute (E) and relative (F) blood granulocyte and monocyte levels were observed
in mutant chimeras (n=5, sample duplicates per experimental unit) which however
displayed a significant 1.5 fold increase in ly6chi/Ly6clo blood monocyte subset ratio












Appendix A. Dual Role of Hck and Fgr in Atherosclerosis 123
Figure. A.6. Cellular responses displayed by Hck/Fgr dKO macrophages in-
vitro. A. dKO macrophages displayed equivalent proliferation capacity as WT controls.
However, deficiency in Hck/Fgr causes higher susceptibility to induction of apoptosis
(B) with staurosporine (STS. n=3). Macrophage uptake of fluorescent labeled beads
(C) apoptotic Jurkat cells (MOI=20, n=3) (D) or IgG–opsonized zymosan particles
(OP) (MOI=20, n=3) (E), was not affected by the lack of Hck and Fgr. Similarly,












124 Appendix A. Dual Role of Hck and Fgr in Atherosclerosis
Figure. A.7. Differential expression of genes upregulated in response to
IL–4, clustered by K–means analysis. Heatmaps correspond to Clusters C-I (A), C-II
(B) and C-III (C) (See also Fig. 2.9A).
Figure. A.8. Differential expression of genes upregulated in response to
IFNγ, clustered by K–means analysis. Heatmaps correspond to Clusters C-IV (A)




















































Figure. A.9. The chemokine receptor pathway is over–represented by HCK, FGR and their common interactors (Benjamini
Hochberg corrected overrepresentation Pval ≺ 1E − 05). Genes of the pathway belonging to networks N-I, N-II, N-III, N-IV and












126 Appendix A. Dual Role of Hck and Fgr in Atherosclerosis
Figure. A.10. Expression of HCK and FGR in human atherosclerotic le-
sions. A-B. HCK/FGR expression is upregulated in vulnerable to rupture (A) and










































Appendix B. Hematopoietic NAMPT Over–Expression Attenuates Atherosclerosis 129
Figure. B1. Over expression of NAMPT has no influence on body weight
and plasma lipid levels. Body weight (A), plasma cholesterol (B) and triglyceride
levels (C) were measured in the LV.iNAMPThi and LV.CTR control chimeras 12












130 Appendix B. Hematopoietic NAMPT over–Expression Attenuates Atherosclerosis
Figure. B2. Over expression of NAMPT has no effect on granulocyte and
lymphocyte levels as well as VSMC and collagen content in atherosclerotic lesions
obtained from LV.iNAMPThi and LV.CTR chimeric LDLr−/− mice. Analysis for
plaque markers of neutrophils (A), T-lymphocytes (B), smooth muscle cells (C), and
collagen content (D) in the iNAMPThi and control chimeras 12 weeks after introduc-
tion of WTD. Data as mean ±SEM ; n =12.
Figure. B3. Reduced stromal monocyte content and increased circulatory
monocyte levels are observed in mice in response to intraperitoneal NAMPT inhibitor
(FK866) challenge. Relative abundance of CD11b+Ly6G− cells in bone marrow (A)
and blood (B) was measured in LV.iNAMPThi and LV.CTR control chimeras receiving
intraperitoneal injections of FK866 12 weeks after introduction of WTD. Data as mean












Appendix B. Hematopoietic NAMPT Over–Expression Attenuates Atherosclerosis 131
Figure. B4. Leukocyte NAMPT over expression has no influence on plasma
NAMPT and cytokine levels, in atherosclerotic mice. Plasma levels of cytokines (A)
and NAMPT (B) were measured in LV.iNAMPThi and LV.CTR chimeras 12 weeks
after introduction of WTD. Data as mean ±SEM ; n =12.
Figure. B5. iNAMPT and PPARγ expression correlate in human atheros-
clerotic plaques, but not in healthy arteries. Spearmans correlation coefficients by rank
test between iNAMPT and PPARγ were determined in samples of atherosclerotic (A;
r2=0.4377, P ≺ 0.0001) and healthy (B; r2=0.2586, P = 0.1333) arteries from kidney
transplantations (A-B) and of carotid plaques (C) at different developmental stages
(Early lesions: r2=0.5050, P = 0.0065. Advanced lesions: r2=0.4101, P = 0.0183.




















































Appendix C. Macrophage Apoptosis and Atherosclerotic Lesion Stabilization 135
Figure. C1. Effect of induction of CD169+ cell apoptosis on bone marrow
leukocyte homeostasis. CD169–DTR–LDLr−/− chimeric mice fed WTD during eight
weeks were treated with diphtheria toxin (DT) for induction of CD169+ cell apoptosis
during two weeks. Diphtheria toxin mutant (DTM) treated mice were used as con-
trol. A-C. Induction of CD169+ macrophage apoptosis has no effect on bone marrow




















































Appendix D. Characterization of ApoE−/− MaFIA+/+ Mice 139
Characterization of ApoE−/− MaFIA+/+ Mice, as Model for Induction of CD115+
Macrophage Apoptosis in Atherosclerosis Transgenic Macrophage Fas Induced
Apoptosis (MaFIA) mice, designed for inducible depletion of CD115+ cells were gen-
erated by Burnett and colleagues [257, 258]. In those mice, a suicide protein was
engineered for bicistronic co-expression with EGFP, which serves as reporter gene.
The suicide protein comprises a extracellular AP20183 binding protein motif, a trans-
membrane region of the human low affinity nerve growth factor receptor and the
cytoplasmic domain of FAS. The MaFIA transgene uses for transcriptional regulation
the promoter of CSF1R, also known as CSF1R, CD115 or M-CSFR; which is expressed
in myeloid phagocytes, including neutrophils, monocytes and macrophages.
The MaFIA mechanism of induction of CD115+ cell apoptosis relies on admin-
istration of AP20187 to experimental mice bearing the MaFIA suicide gene [257,258].
Binding to AP20187, cross links the extracellular domain of neighboring MaFIA trans-
gene proteins bringing this way their cytoplasmic FAS domains in close contact. This
triggers activation of the FAS-caspase-8 extrinsic pathway of apoptosis without off
target effects due to the high specificity provided by the system [260]. MaFIA mice
on C57BL/6J background were crossed to C57BL/6J-ApoE−/− mice to generate ho-
mozygous ApoE−/−, MaFIA+/+, atherosclerotic prone mice. Pups from every litter
were screened for zygosity and expression of MaFIA, by real-time PCR. The expres-
sion and inheritance of the transgene was stable for over 20 generations.
The expression of GFP and CD115 was used to characterize the model and
determine the cell populations liable to induction of apoptosis by administration of
AP20187 in ApoE−/−, MaFIA+/+ mice. For this, circulatory, peritoneal, bone mar-
row and spleen leukocytes were obtained and analyzed.
As expected from the reported expression of CD115 (M-CSFR) in cells of the
myeloid but not the lymphoid lineage [298], and the downregulation of CD115 in lym-
phocytes progenitors (CLP, ProT and ProB cells, [298,299]); GFP was not expressed
in bone marrow, circulatory, peritoneal and spleen CD3+ T lymphocytes (Table. D.1
and Fig. D1A-D).
Similarly , atheroprotective [300] CD19+ B1a B lymphocytes did not express
GFP (Table. D.1, Fig. D1D). However, the expression of GFP was low to intermediate
in bone marrow and spleen pro-atherosclerotic [271] B220+ B2 B lymphocytes, (Table.
D.1 and Fig. D1A-C) in agreement with previous publications that demonstrated the
expression of CD115 by these cells [263,264], and their reduction in M-CSF deficient
mice [301].
CD11b+Ly6G− bone marrow monocytes exhibited high expression of GFP (Ta-
ble D.1 and Fig. D1A). This result was in agreement to the expression of CD115 and
its role in the development and differentiation of mononuclear phagocytes [302]. Sim-
ilarly, bone marrow CD11b+Ly6G+ granulocytes displayed high expression of GFP
(Table. D.1) in agreement with the ability of bone marrow granulocytes to transd-
ifferentiate into macrophages in response to CSF-1 [303–305]. CD11b+Ly6G+ gran-
ulocytes displayed low expression of CD115 (Compare Fig. D1 A and B) suggesting
leaky expression of MaFIA in these cells. Likely because sequence specific mecha-
nisms of post transcriptional regulation, such as microRNA, RNA binding proteins
or ribonucleases, known to regulate the expression of CD115 in myelocytes [306,307],
might have failed to repress the expression of MaFIA which likely did not have post
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Figure. D1. Expression of MaFIA in bone marrow, blood and peritoneal
leukocytes of ApoE−/− MaFIA+/+ mice. A-H. Representative histograms of FACS
analysis of bone marrow, blood and peritoneal cells, used for assessment of GFP (A-D)
and CD115 (E-H) expression, and quantification of GFP mean fluorescence intensity
(MFI), (see also Table D.1). MaFIA−GFP is expressed in myeloid cells in bone
marrow (A), blood (B-C) and the peritoneum (D). Of note, intermediate expression
of MaFIA−GFP is displayed on bone marrow B220+ B2 B lymphocytes (A) but not
on CD19+ peritoneal B1a B lymphocytes (D). High expression of CD115 is observed in
bone marrow (E) and blood (F-G) monocytes and peritoneal (H) macrophages. Blood
granulocytes display intermediate expression of CD115, lower than that observed in
blood monocytes (F). This contrasts with the equivalent expression of MaFIA−GFP
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Compartment Leukocyte subset MFI Molecular Markers
Bone Marrow Tcells 93± 4 CD3+B220−NK1.1−
B2 Bcells 2748± 134 CD45+B220+NK1.1−
Monocytes 6465± 471 Ly6G−CD11b+
Granulocytes 5101± 152 Ly6G+CD11b+
LSK 2266± 149% Lin−cKit+Sca1+
LK-CMP 2544± 172% CD16−CD32−
LK-GMP 2445± 63% CD16+CD32+
Spleen Tcells 48± 0.7 CD3+B220−NK1.1−
B2 Bcells 1162± 75 CD45+B220+NK1.1−
Monocytes 8874± 354 Ly6G−CD11b+
Granulocytes 9206± 491 Ly6G+CD11b+
CD8+ rDC 3170± 167 CD11chiCD8+
CD8− rDC 8829± 491 CD11chiCD8−
pDC 2112± 115 CD11cloB220hiLy6chi
Blood Tcells 58± 3 CD3+B220−NK1.1−
B2 Bcells 729± 47 CD45+B220+NK1.1−
Monocytes 10025± 260 Ly6G−CD11b+
Granulocytes 11003± 344 Ly6G+CD11b+
Peritoneal T cells 109± 2 CD3+B220−NK1.1−
B cells 416± 7 CD19+NK1.1−CD3e−
Monocytes 1922± 46 Ly6G−CD11b+
Granulocytes 2275± 100 Ly6G+CD11b+
Macrophages 71928± 2859 CD11b++F4/80+
Table D.1. Mean fluorescence intensity (MFI) values corresponding to the
expression of GFP in leukocytes from in ApoE−/− MaFIA+/+ mice. Note that the
mean fluorescence intensity of GFP, and therefore the expression of MaFIA, is higher
in resident macrophages than in bone marrow and circulatory granulocytes and mono-
cytes, see also Fig. D1.
Circulatory and spleen monocytes and granulocytes displayed higher levels of
GFP expression than their bone marrow counterparts, with MFI values in the order
of 104 (Table. D.1 and Fig. D1B-C). Blood Ly6chi and Ly6clo monocyte subsets
had similar GFP and CD115 expression intensities (Fig. D1C) suggesting equivalent
response to apoptosis induction. CD11b+ Ly6G− monocytes and CD11b+ Ly6G+
granulocytes displayed lower expression of GFP in the peritoneum compared to the
circulation (Table. D.1 and Fig. D1B-D), concordant with the function of CSF-1 and
CD115 in the regulation of resident myelocyte cell densities under non-inflammatory
conditions [308].
Resident dendritic cells (rDC) and plasmacytoid dendritic cells (pDC) obtained
from spleens after sacrifice displayed intermediate to high expression of GFP (Ta-
ble. D.1). Similarly, bone marrow Lin−Sca–1+c–kit+ LSK progenitors, LK (Lin−
Sca–1−c–kit+) CD16+ CD32+ common myeloid progenitors (CMP) and LK CD16+
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Figure. D2. Induction of CD115+ macrophage apoptosis in MaFIA+/+
PEM in–vitro. Peritoneal macrophages obtained from MaFIA−/− ApoE−/− or
MaFIA+/+ ApoE−/− mice were incubated with AP20187 (10nm) and stained for ac-
tivated caspase (SR-FLICA R©red fluorescent) and Hoechst (blue) to label respectively
apoptotic cells and cell nuclei. A. Quantification of fluorescent photo-microscopic
pictures (n=6 fields) indicated that treatment with AP20187 caused 123 fold increase
in MaFIA+/+ macrophage apoptosis. B-C. Representative pictures of MaFIA−/−
ApoE−/− (B) and MaFIA+/+ ApoE−/− (C) treated peritoneal macrophages, used for
quantification of apoptosis. ∗ ∗ ∗P ≤ 0.001).
sion of GFP (Table D.1).
Peritoneal CD115+F4/80+CD11b+ macrophages displayed about ten fold higher
expression of GFP compared to bone marrow and circulatory monocytes and macro-
phages (Table. D.1 and Fig. D1D) suggesting that tissue CD115+ macrophages had
higher susceptibility to apoptosis induction by AP200187 administration. In fact,
ApoE−/− MaFIA+/+ peritoneal macrophages displayed almost total ablation upon
AP20187 exposure ex-vivo, compared to ApoE−/− MaFIA−/− control macrophages,
illustrating effective AP20187mediated induction of macrophage apoptosis in MaFIA
transgenics (Fig. D2).
Pilot experiments indicated that concordant with the expression profile of GFP,
intraperitoneal injections of AP20187 (10mg/kg–day) for one week caused massive
ablation of blood and peritoneal myelocytes (Fig. D3A-C) in ApoE−/− MaFIA+/+
fed WTD. Blood Ly6chi monocytes were reduced by 65% (Pval ≺ 0.001), with no
further changes in Ly6clo monocyte percentages.
Recovery from apoptosis induction was observed in circulatory monocytes (Fig.
D3A) but not in circulatory granulocytes and peritoneal macrophages (Fig. D3 A
and C). Interestingly, the reduction in blood monocytes and granulocytes observed
was accompanied by the emergence of a novel population of CD11b+ myelocytes with
intermediate expression of Ly6G (Fig. D3 A and D) that suggested that adminis-
tration of AP20187 might induce myeloid cell trans–differentiation, leading to loss of
expression of differentiation markers.
Similarly, intravenous administration of AP20187 (1mg/kg, every 72 hours) dur-
ing one week resulted in ablation blood granulocytes (Fig. D4A), monocytes (Fig.
D4B) and Ly6chi monocytes (Fig. D4C). Although these myelocytes returned to nor-
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Figure. D3. Systemic induction and recovery from ablation of CD115+
myelocyte apoptosis in ApoE−/− MaFIA+/+ mice. A-C. Mice received intraperitoneal
injections of AP20187 (5X, 10mg/kg every 24 hours) and were analyzed at the end
of treatment (top panels) or allowed to recover for one week (bottom panels). FACS
analysis indicated significant reduction in blood myelocytes (A) circulatory Ly6chi
monocytes (B) and resident peritoneal macrophages (C) upon treatment (top panels).
Note the increment in CD11b+ Ly6Gint myelocytes (A). Recovery from induction of
apoptosis only occurred in blood monocytes (A) but not in Ly6chi monocytes (B),
nor in peritoneal macrophages (C). D-E. Representative dot plots (D) and histograms
(E) of myelocytes in AP20187 treated mice (D, bottom panel), compared to vehicle
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Figure. D4. Relative levels of blood myelocytes upon systemic induction of
CD115+ myelocyte apoptosis in ApoE−/− MaFIA+/+ mice, fed WTD during three
weeks. A-B. FACS analysis indicated significant reduction in blood granulocytes (A)
and monocytes (B) of ApoE−/− MaFIA+/+ mice receiving intravenous injections of
AP20187 (1mg/Kg every 72 hours) during one week (gray bars). Ly6chi monocy-
topenia (C) was observed one week upon systemic administration of AP20187 (gray
bars). Recovery from myelocyte depletion (A-B) and monocytopenia (C) was evi-
dent at the second week of treatment (white bars). D-E. Representative dot plots (D)
and histograms (E) used for quantification of circulatory myelocytes. ∗P ≤ 0.05,
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Figure. D5. Absolute blood leukocyte counts upon systemic induction of
CD115+ myelocyte apoptosis in ApoE−/− MaFIA+/+ mice fed WTD during three
weeks. A-B. True counts FACS analysis indicated significant reduction in blood mono-
cytes and granulocytes (A) of ApoE−/− MaFIA+/+ mice receiving intravenous injec-
tions of AP20187 (1mg/Kg every 72 hours) during one week (gray bars). Ly6chi
monocytopenia (B) and depletion of pro-atherosclerotic B220+ B2 B lymphocytes (C)
was observed one week upon systemic administration of AP20187 (gray bars). Reco-
very from myelocyte depletion (A) and monocytosis (B) was observed at the second
week of treatment (white bars). Sustained depletion of B2 B lymphocytes was still
evident at the second week of treatment (C. White bars). ∗P ≤ 0.05, ∗ ∗ P ≤ 0.01,
∗ ∗ ∗P ≤ 0.001
No differences were observed in absolute T cell counts, although significant re-
ductions were observed in pro-atherosclerotic B220+ B2 B lymphocyte levels, one and
two weeks upon completion of treatment (Fig D5C).
Taken together, these results indicated recovery from sublethal induction of
CD115+ monocyte and macrophage apoptosis upon intravenous administration of
AP20187, offering an advantage over a massive induction of CD115+ monocyte and
macrophage ablation (as observed upon intraperitoneal injection of dimerizer) that
would reduce the availability of circulatory monocytes to extravasate into atheros-
clerotic lesions while reducing the scavenging capacity of lesion apoptotic cells. We
therefore choose this dose regime for assessment of systemic induction of CD115+
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Figure. E1. Plasma cholesterol levels in atherosclerotic ApoE−/−
MaFIA+/+ mice. A. No differences in plasma cholesterol levels were observed before
induction of CD115+/+ cell apoptosis; five weeks after perivascular collar placement.
Similarly, no differences were observed upon local (B) and systemic (C) administration
of AP20187, to induce CD115+ cell apoptosis in advanced atherosclerosis. Admin-
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Figure. E2. Advanced atherosclerotic lesion phenotype five weeks after
perivascular collar placement and 1 day before induction of CD115+ cell apoptosis by
administration of AP20187. A-D. Lesion size (A) relative lipid core area (B), cellu-
larity (C) and necrotic core composition (D) in MaFIA−/− ApoE−/− and MaFIA+/+
ApoE−/− mice, before systemic and local induction of CD115+ MaFIA+/+ cell apop-
tosis. No significant differences were observed, indicating that the presence of MaFIA
had no influence on atherosclerotic lesion development. E. Representative pictures of
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Figure. E3. Advanced atherosclerotic lesion composition five weeks after
perivascular collar placement and 1 day before induction of CD115+ cell apoptosis
by administration of AP20187. A-D. Immunohistochemistry and quantification of
apoptotic cells (A), macrophages (B), SMC (C) and collagen (D, left panel) contents;
as well as minimal fibrous cap thickness (D, right panel) in MaFIA−/− ApoE−/− and
MaFIA+/+ ApoE−/− mice before systemic and local induction of CD115+ MaFIA+/+
cell apoptosis. No significant differences were observed, indicating that the presence
of MaFIA had no influence on atherosclerotic lesion composition. (Middle and right
panels in A-D are representative pictures of TUNEL (A) Mac3 (B) ASMA (C) and
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Figure. E4. Peritoneal leukocyte homeostasis upon systemic induction of
CD115+ myelocyte apoptosis in ApoE−/− MaFIA+/+ mice fed WTD during three
weeks. A-F. FACS analysis demonstrated that systemic administration of AP20187
(1mg/Kg every 72 hours) during one (gray bars) and two (white bars) weeks, caused
no significant effects on relative levels of peritoneal granulocytes and monocytes (A-
B), as well as CD19+ B1a B lymphocytes (C) and macrophages (D). Increased levels
of Ly6chi macrophages was however observed at the second week of treatment (E,













AAM Alternative Activated Macrophages
ABCA1 ATP Binding Cassette Subfamily A member 1
ABCG1 ATP Binding Cassette Subfamily G member 1
ANOVA Analysis of Variance
ApoE Apolipoprotein E
ASMA α Smooth Muscle Cell
ATP Adenosine Triphosphate
BMDM Bone Marrow Derived Macrophages
BMT Bone Marrow Transplantation
CAM Classically Activated Macrophages
CD Cluster of Differentiation
CFU Colony Forming Units
CLP Common Lymphoid Progenitors
CMP Common Myeloid Progenitors
CSF Colony Stimulating Factor



















154 Acronyms and Abbreviations
DTR Diphtheria Toxin Receptor (human)
ECM Extracellular Matrix/Matrices
EGFP Enhanced Green Fluorescent Protein
EI Elongation Index
eNAMPT Extra–Cellular NAMPT
ESAM Endothelial–cell Selective Adhesion Molecule
FACS Fluorescence Activated Cell Sorting
FC Fold Change
FcγR Fc–γ Receptor




G–CSF Granulocyte Colony Stimulating Factor
GEMM–CFU Multipotent Granulocyte, Erythrocyte, Macrophage and Megakary-
ocyte –CFU
GFP Green Fluorescent Protein
GM–CFU Granulocyte–Macrophage CFU
GM–CSF Granulocyte–Macrophage Colony Stimulating Factor
GMP Granulocyte and Macrophage Progenitors
GOI Gene of Interest
Hck Tyrosine–protein kinase
HE Haematoxilin Eosin staining
HMG–CoA 3–hydroxy–3–methylglutaryl–coenzyme A
HP–TLC High Performance Thin Layer Chromatography
HSCP Hematopoietic Stem Cell Progenitors
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iNAMPT Intracellular NAMPT
IPH Intraplaque Hemorrhaged Lesions
IQR Inter-Quartile Range
IT Intimal Thickening
JAM Junctional Adhesion Molecule
KC Keratinocyte Chemoattractant
LDL Low Density Lipoprotein
LDLr Low Density Lipoprotein Receptor
LFA1 Lymphocyte Function Associated Antigen–1
LPS Lipopolysaccharide
M–CFU Macrophage CFU
M–CSF Macrophage–Colony Stimulating Factor
M–CSFR Macrophage Colony Stimulating Factor–Receptor
MAC1 Macrophage Antigen–1
MAC3 Macrophage–1–antigen
MADCAM1 Mucosal Vascular Addressin Cell Adhesion Molecule–1
MaFIA Macrophage Fas Induced Apoptosis
MCP Monocyte Chemoattractant Protein
mDC Myeloid Dendritic Cells
MFI Mean Fluorescent Intensity
MHC Major Histocompatibility Complex
MIP Monocyte Inflammatory
MMP Matrix Metallo–proteinase
MOI Multiplicity of Infection
NAD Nicotinamide Adenine Dinucleotide
NADH Reduced Nicotinamide Adenine Dinucleotide
NAMPT Nicotinamide Phosphoribosyl Transferase













156 Acronyms and Abbreviations
oxLDL oxidized Low Density Lipoproteins
PAI Plasminogen Activator Inhibitor
PBEF Pre–B–cell–colony Enhancing Factor
PBMC Peripheral Blood Mononuclear Cells
PCA Principal Component Analysis
PCR Polymerase Chain Reaction
pDC Plasmacytoid Dendritic Cells




PMN Poly–Morpho Nuclear cells
PPAR Peroxisome Proliferator Activated Receptor
PSGL1 P–Selectin Glycoprotein Ligand–1
PYK Protein Tyrosine Kinase
RIN RNA Integration Number
RMA Robuts Multi–Array Average
SEM Standard Error Mean
SIRT1 NAD–Dependent Deacetylase Sirtuin–1
SMC Smooth Muscle Cells
SSC Side Scatter
SYK Spleen Tyrosine Kinase
TF Tissue Factor
TG Thioglycolate
TIA Transient Ischemic Attack
TkfcA Thick Fibrous Atheroma
TLC Thin Layer Chromatography
TLR Toll–Like Receptor
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TUNEL Terminal Deoxynucleotidyl Transferase Nick End Labelin
VCAM1 Vascular Cell Adhesion Molecule–1
VLA4 Very Late Antigen–4
VSMC Vascular Smooth Muscle Cells
WT Wild Type


























increased expression in NAMPT
over expressing BMDM, 60




increased expression in NAMPT
over expressing BMDM, 60
increased expression in NAMPT
over-expressing chimeric mice,
111
Absolute blood leukocyte counts
upon systemic induction of CD115+
myelocyte apoptosis in MaFIA
mice, 101, 145
Adoptive fluorescent cell transfer
for assessment of Hck/Fgr dKOma-
crophage migration in–vivo, 19




Apoptosis of CD11b+ myelocytes
induction in atherosclerosis
systemic, 113
Apoptosis of CD11c+ myelocytes
induction in atherosclerosis
systemic, 113
Apoptosis of CD169+ myelocytes
induction in atherosclerosis, 73–77,
113–114
recovery from induction in athe-
rosclerosis, 73–77, 113–114
Apoptotic lesion macrophage apopto-
sis
increased upon local induction of
CD115+ macrophage apopto-
sis in atherosclerotic mice, 95





biphasic phenotype in, 112
clinical manifestations, 8







unaltered upon local induction of
CD115+ macrophage apopto-
sis, 94, 96
unaltered upon recovery from sys-
temic induction of CD169+ ma-
crophage apoptosis, 77, 80
unaltered upon systemic induction
of CD115+ myelocyte apop-
tosis, 96, 98
unaltered upon systemic induction
of CD169+ macrophage apop-
tosis, 74, 75
Atherosclerotic lesion collagen
increased upon recovery from sys-
temic induction of CD169+ ma-
crophage apoptosis in atheros-
clerotic mice, 77, 81
not altered upon local induction of
CD115+ macrophage apopto-
sis in atherosclerotic mice, 94,
95
not altered upon systemic induc-














apoptosis in atherosclerotic mice,
74, 76
reduced in Hck/Fgr dKO atheros-
clerotic mice, 30, 34
reduced upon systemic induction
of CD115+ myelocyte apop-
tosis in atherosclerotic mice,
96, 97
unaltered in iNAMPT over expres-
sing atherosclerotic mice, 54,
130
Atherosclerotic lesion lipid core
unaltered upon local induction of
CD115+ macrophage apopto-
sis, 94, 96
unaltered upon systemic induction
of CD115+ macrophage apop-
tosis, 96, 98
Atherosclerotic lesion macrophage apop-
tosis
increased upon local induction of
CD115+ macrophage apopto-
sis in atherosclerotic mice, 94
increased upon systemic induction
of CD115+ myelocyte apop-
tosis in atherosclerotic mice,
75, 94, 97
increased upon systemic induction
of CD169+ myelocyte apop-
tosis in atherosclerotic mice,
74
reduced in iNAMPT over expres-
sing atherosclerotic mice, 54,
55
Atherosclerotic lesion macrophages
reduction upon recovery from sys-
temic induction of Cd169+ ma-
crophage apoptosis, 77, 80
reduction upon systemic induction
of Cd169+ macrophaeg apop-
tosis, 74
reduction upon systemic induction
of Cd169+ macrophage apop-
tosis, 75
reduction in Hck/Fgr deficient athe-
rosclerotic mice, 25, 26, 119
reduction in iNAMPT over expres-
sing atherosclerotic mice, 54,
55
reduction upon local induction of
CD115+ macrophage apopto-
sis in atherosclerotic mice, 94,
95
reduction upon systemic induction
of CD115+ macrophage apop-
tosis in atherosclerotic mice,
96, 97
Atherosclerotic lesion necrosis
increased in Hck/Fgr dKO athe-
rosclerotic mice, 30, 34
increased upon systemic induction
of CD169+ macrophage apop-
tosis, 74, 75
normalized upon recovery from sys-
temic induction of CD169+ ma-
crophage apoptosis, 77, 80
reduced in iNAMPT over expres-
sing atherosclerotic mice, 54,
55
unaltered upon local induction of
CD115+ macrophage apopto-
sis, 94, 96
unaltered upon systemic induction
of CD115+ macrophage apop-
tosis, 96, 98
Atherosclerotic lesion neutrophils
not altered in iNAMPT over ex-
pressing atherosclerotic mice,
54, 130
reduction in Hck/Fgr deficient athe-
rosclerotic mice, 25, 26
Atherosclerotic lesion size
expansion upon induction of Cd169+
macrophage apoptosis in athe-
rosclerotic mice, 74, 75
expansion upon local induction of
CD115+ macrophage apopto-
sis in atherosclerotic mice, 94,
96
reduction in Hck/Fgr deficient athe-
rosclerotic mice, 25, 26
reduction in iNAMPT over expres-














reduction upon recovery from in-
duction of Cd169+ macrophage
apoptosis in atherosclerotic mice,
77, 80
unaltered upon systemic induction
of CD115+ macrophage apop-
tosis in atherosclerotic mice,
96, 98
Atherosclerotic lesion SMC
reduced in Hck/Fgr dKO atheros-
clerotic mice, 30, 34
Atherosclerotic lesion T cells
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upon recovery from systemic in-
duction of CD169+ myelocyte
apoptosis in atherosclerotic mice,
77, 81
not altered contents
upon systemic induction of CD169+
myelocyte apoptosis in athe-
rosclerotic mice, 74, 76
reduced upon systemic induction
of CD115+ myelocyte apop-
tosis in atherosclerotic mice,
96, 97
unaltered in iNAMPT over expres-
sing atherosclerotic mice, 54,
130
unaltered upon local induction of
CD115+ macrophage apopto-
sis in atherosclerotic mice, 94,
95
Blood leukocytes
in Hck/Fgr dKO mice, 27, 122
in iNAMPT over expressing athe-
rosclerotic mice, 57, 58
upon local induction of CD115+
myelocyte apoptosis in athe-
rosclerotic mice, 98
upon systemic and local induction
of CD115+ myelocyte apop-
tosis in atherosclerotic mice,
99
upon systemic induction of CD115+
myelocyte apoptosis in athe-
rosclerotic mice, 98
upon induction of CD169+ macro-
phage apoptosis in atheroscle-
rotic mice, 74, 78, 135
upon recovery from induction of
CD169+ macrophage apopto-
sis in atherosclerotic mice, 76,
78
Blood monocytes
in response to NAMPT inhibitor
challenge, 57, 130
Ly6chi/Ly6clo ratio
skewed in Hck/Fgr dKO mice,
27
Bone marrow leukocytes
in Hck/Fgr dKO chimeric mice,
27, 122
in iNAMPT over expressing athe-
rosclerotic mice, 56, 58
upon systemic induction of CD115+
myelocyte apoptosis in MaFIA
mice, 101, 103, 104
upon systemic induction of CD169+
macrophage apoptosis in athe-
rosclerotic mice, 77
Bone marrow monocytes
in response to NAMPT inhibitor
challenge, 57, 130
Bone marrow transplantation
CD169-DTR donors, 71, 73, 78
chimerism, 71, 73
Hck/Fgr dKO donors, 17, 18, 25
chimerism, 19, 25





















in NAMPT over expressing chime-
ric mice, 62
Cholesterol uptake
in NAMPT over expressing chime-
ric mice, 61, 63
Circulatory leukocytes
fluorescent label, 19, 20, 27–29, 31,
41
Cytokines
role in atherosclerosis, 1
Dendritic cells
reduced in atherosclerosis, 3
Apoptosis induction in atheroscle-
rosis, 3
Diapedesis, 2
reduced in Hck/Fgr deficient mye-
locytes, 110
Extramedullary myelopoiesis
upon systemic induction of CD115+




reduced upon systemic induction
of CD115+ macrophage apop-
tosis in atherosclerotic mice,
96, 97
thickening upon recovery from sys-
temic induction of CD169+ ma-
crophage apoptosis in atheros-
clerotic mice, 77, 81
thinning out in Hck/Fgr dKO athe-
rosclerotic mice, 30, 34
unaltered upon local induction of
CD115+ macrophage apopto-
sis in atherosclerotic mice, 94,
95
unaltered upon systemic induction
of CD169+ macrophage apop-
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in–vivo, 28
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[2] Véronique L. Roger, Alan S. Go, Donald M. Lloyd-Jones, Emelia J. Benjamin,
Jarett D. Berry, William B. Borden, Dawn M. Bravata, Shifan Dai, Earl S. Ford,
Caroline S. Fox, Heather J. Fullerton, Cathleen Gillespie, Susan M. Hailpern,
John A. Heit, Virginia J. Howard, Brett M. Kissela, Steven J. Kittner, Daniel T.
Lackland, Judith H. Lichtman, Lynda D. Lisabeth, Diane M. Makuc, Gre-
gory M. Marcus, Ariane Marelli, David B. Matchar, Claudia S. Moy, Dariush
Mozaffarian, Michael E. Mussolino, Graham Nichol, Nina P. Paynter, Elsayed Z.
Soliman, Paul D. Sorlie, Nona Sotoodehnia, Tanya N. Turan, Salim S. Virani,
Nathan D. Wong, Daniel Woo, Melanie B. Turner, American Heart Association
Statistics Committee , and Stroke Statistics Subcommittee. Heart disease and
stroke statistics–2012 update: a report from the american heart association.
Circulation, 125(1):e2–e220, Jan 2012.
[3] Scarborough P Luengo-Fernandez R Leal J Gray A Nichols M, Townsend N and
Rayner M. European Cardiovascular Disease Statistics 2012. European Heart
Network, Brussels, European Society of Cardiology, Sophia Antipolis., 2012.
[4] Visseren FLJ-Bots ML. Vaartjes I, van Dis I. Hart- en vaatziekten in Neder-
land 2011, cijfers over leefstijl- en risicofactoren, ziekte en sterfte. Nederlandse
Hartstichting, 2011.
[5] Alan S. Go, Dariush Mozaffarian, Vronique L. Roger, Emelia J. Benjamin,
Jarett D. Berry, William B. Borden, Dawn M. Bravata, Shifan Dai, Earl S.
Ford, Caroline S. Fox, Sheila Franco, Heather J. Fullerton, Cathleen Gille-
spie, Susan M. Hailpern, John A. Heit, Virginia J. Howard, Mark D. Huffman,
Brett M. Kissela, Steven J. Kittner, Daniel T. Lackland, Judith H. Lichtman,
Lynda D. Lisabeth, David Magid, Gregory M. Marcus, Ariane Marelli, David B.
Matchar, Darren K. McGuire, Emile R. Mohler, Claudia S. Moy, Michael E.
Mussolino, Graham Nichol, Nina P. Paynter, Pamela J. Schreiner, Paul D. Sor-
lie, Joel Stein, Tanya N. Turan, Salim S. Virani, Nathan D. Wong, Daniel Woo,
Melanie B. Turner, American Heart Association Statistics Committee , and
Stroke Statistics Subcommittee. Heart disease and stroke statistics–2013 up-















[6] Klaus Ley, Carlo Laudanna, Myron I Cybulsky, and Sussan Nourshargh. Get-
ting to the site of inflammation: the leukocyte adhesion cascade updated. Nat
Rev Immunol, 7(9):678–689, Sep 2007.
[7] Christian Weber, Alma Zernecke, and Peter Libby. The multifaceted contribu-
tions of leukocyte subsets to atherosclerosis: lessons from mouse models. Nat
Rev Immunol, 8(10):802–815, Oct 2008.
[8] Abraho Afiune Neto, Antonio de Pdua Mansur, Solange Desire Avakian, Everly
P S G. Gomes, and Jos Antonio F. Ramires. [monocytosis is an independent
risk marker for coronary artery disease]. Arq Bras Cardiol, 86(3):240–244, Mar
2006.
[9] Oliver Soehnlein, Maik Drechsler, Mihail Hristov, and Christian Weber. Func-
tional alterations of myeloid cell subsets in hyperlipidaemia: relevance for athe-
rosclerosis. J Cell Mol Med, 13(11-12):4293–4303, 2009.
[10] L. E. Averill, R. C. Meagher, and R. G. Gerrity. Enhanced monocyte pro-
genitor cell proliferation in bone marrow of hyperlipemic swine. Am J Pathol,
135(2):369–377, Aug 1989.
[11] D. L. Feldman, T. C. Mogelesky, B. F. Liptak, and R. G. Gerrity. Leukocytosis
in rabbits with diet-induced atherosclerosis. Arterioscler Thromb, 11(4):985–
994, 1991.
[12] Maik Drechsler, Remco T A. Megens, Marc van Zandvoort, Christian Weber,
and Oliver Soehnlein. Hyperlipidemia-triggered neutrophilia promotes early
atherosclerosis. Circulation, 122(18):1837–1845, Nov 2010.
[13] H. Kawaguchi, T. Mori, T. Kawano, S. Kono, J. Sasaki, and K. Arakawa. Band
neutrophil count and the presence and severity of coronary atherosclerosis. Am
Heart J, 132(1 Pt 1):9–12, Jul 1996.
[14] P. M. Sweetnam, H. F. Thomas, J. W. Yarnell, I. A. Baker, and P. C. Elwood.
Total and differential leukocyte counts as predictors of ischemic heart disease:
the caerphilly and speedwell studies. Am J Epidemiol, 145(5):416–421, Mar
1997.
[15] Emily A. van–Vre, Vicky Y. Hoymans, Hidde Bult, Marc Lenjou, Dirk R. Van
Bockstaele, Christiaan J. Vrints, and Johan M. Bosmans. Decreased number of
circulating plasmacytoid dendritic cells in patients with atherosclerotic coronary
artery disease. Coron Artery Dis, 17(3):243–248, May 2006.
[16] Atilla Yilmaz, Jana Weber, Iwona Cicha, Christian Stumpf, Michael Klein,
Dieter Raithel, Werner G. Daniel, and Christoph D. Garlichs. Decrease in
circulating myeloid dendritic cell precursors in coronary artery disease. J Am
Coll Cardiol, 48(1):70–80, Jul 2006.
[17] Ilse Van Brussel, Emily A. Van Vr, Guido R Y. De Meyer, Christiaan J. Vrints,
Johan M. Bosmans, and Hidde Bult. Expression of dendritic cell markers
cd11c/bdca-1 and cd123/bdca-2 in coronary artery disease upon activation in













[18] Ilse Van Brussel, Emily A. Van Vr, Guido R Y. De Meyer, Christiaan J. Vrints,
Johan M. Bosmans, and Hidde Bult. Decreased numbers of peripheral blood
dendritic cells in patients with coronary artery disease are associated with di-
minished plasma flt3 ligand levels and impaired plasmacytoid dendritic cell
function. Clin Sci (Lond), 120(9):415–426, May 2011.
[19] Emily A. van–Vre, Ilse Van Brussel, Ken Op de Beeck, Vicky Y. Hoymans,
Christiaan J. Vrints, Hidde Bult, and Johan M. Bosmans. Changes in blood
dendritic cell counts in relation to type of coronary artery disease and brachial
endothelial cell function. Coron Artery Dis, 21(2):87–96, Mar 2010.
[20] Atilla Yilmaz, Tina Schaller, Iwona Cicha, Regina Altendorf, Christian Stumpf,
Lutz Klinghammer, Josef Ludwig, Werner G. Daniel, and Christoph D. Garlichs.
Predictive value of the decrease in circulating dendritic cell precursors in stable
coronary artery disease. Clin Sci (Lond), 116(4):353–363, Feb 2009.
[21] Kazunori Shimada. Immune system and atherosclerotic disease: heterogeneity
of leukocyte subsets participating in the pathogenesis of atherosclerosis. Circ
J, 73(6):994–1001, Jun 2009.
[22] Heather M. Perry and Coleen A. McNamara. Refining the role of b cells in
atherosclerosis. Arterioscler Thromb Vasc Biol, 32(7):1548–1549, Jul 2012.
[23] Emmanuel L. Gautier, Thierry Huby, Flora Saint-Charles, Betty Ouzilleau,
John Pirault, Virginie Deswaerte, Florent Ginhoux, Elizabeth R. Miller,
Joseph L. Witztum, M John Chapman, and Philippe Lesnik. Conventional
dendritic cells at the crossroads between immunity and cholesterol homeostasis
in atherosclerosis. Circulation, 119(17):2367–2375, May 2009.
[24] Kim E. Paulson, Su-Ning Zhu, Mian Chen, Sabrina Nurmohamed, Jenny
Jongstra-Bilen, and Myron I. Cybulsky. Resident intimal dendritic cells ac-
cumulate lipid and contribute to the initiation of atherosclerosis. Circ Res,
106(2):383–390, Feb 2010.
[25] Emmanuel L. Gautier, Thierry Huby, Joseph L. Witztum, Betty Ouzilleau,
Elizabeth R. Miller, Flora Saint-Charles, Pierre Aucouturier, M John Chap-
man, and Philippe Lesnik. Macrophage apoptosis exerts divergent effects on
atherogenesis as a function of lesion stage. Circulation, 119(13):1795–1804, Apr
2009.
[26] Roberto A. Maldonado and Ulrich H. von Andrian. How tolerogenic dendritic
cells induce regulatory t cells. Adv Immunol, 108:111–165, 2010.
[27] Manikandan Subramanian, Edward Thorp, Goran K. Hansson, and Ira Tabas.
Treg-mediated suppression of atherosclerosis requires myd88 signaling in dcs. J
Clin Invest, 123(1):179–188, Jan 2013.
[28] Jae-Hoon Choi, Cheolho Cheong, Durga B. Dandamudi, Chae Gyu Park, An-
thony Rodriguez, Saurabh Mehandru, Klara Velinzon, In-Hyuk Jung, Ji-Young
Yoo, Goo Taeg Oh, and Ralph M. Steinman. Flt3 signaling-dependent dendritic













[29] Masafumi Takeda, Tomoya Yamashita, Naoto Sasaki, Kenji Nakajima, To-
moyuki Kita, Masakazu Shinohara, Tatsuro Ishida, and Ken-ichi Hirata. Oral
administration of an active form of vitamin d3 (calcitriol) decreases atheroscle-
rosis in mice by inducing regulatory t cells and immature dendritic cells with
tolerogenic functions. Arterioscler Thromb Vasc Biol, 30(12):2495–2503, Dec
2010.
[30] Ilse Van Brussel, Dorien M. Schrijvers, Emily A. Van Vr, and Hidde Bult.
Potential use of dendritic cells for anti-atherosclerotic therapy. Curr Pharm
Des, Feb 2013.
[31] Kim L L. Habets, Gijs H M. van Puijvelde, Leonie M. van Duivenvoorde, Eva
J A. van Wanrooij, Paula de Vos, Jan-Willem Cohen Tervaert, Theo J C. van
Berkel, Rene E M. Toes, and Johan Kuiper. Vaccination using oxidized low-
density lipoprotein-pulsed dendritic cells reduces atherosclerosis in ldl receptor-
deficient mice. Cardiovasc Res, 85(3):622–630, Feb 2010.
[32] Andreas Hermansson, Daniel K. Johansson, Daniel F J. Ketelhuth, John Ander-
sson, Xinghua Zhou, and Gran K. Hansson. Immunotherapy with tolerogenic
apolipoprotein b-100-loaded dendritic cells attenuates atherosclerosis in hyper-
cholesterolemic mice. Circulation, 123(10):1083–1091, Mar 2011.
[33] Zory Shaposhnik, Xuping Wang, Michael Weinstein, Brian J. Bennett, and
Aldons J. Lusis. Granulocyte macrophage colony-stimulating factor regulates
dendritic cell content of atherosclerotic lesions. Arterioscler Thromb Vasc Biol,
27(3):621–627, Mar 2007.
[34] Jiusong Sun, Karsten Hartvigsen, Meng-Yun Chou, Yadong Zhang, Galina K.
Sukhova, Jie Zhang, Marco Lopez-Ilasaca, Cody J. Diehl, Niva Yakov, Dror
Harats, Jacob George, Joseph L. Witztum, Peter Libby, Hidde Ploegh, and
Guo-Ping Shi. Deficiency of antigen-presenting cell invariant chain reduces athe-
rosclerosis in mice. Circulation, 122(8):808–820, Aug 2010.
[35] Neil Macritchie, Gianluca Grassia, Suleman R. Sabir, Marcella Maddaluno, Paul
Welsh, Naveed Sattar, Armando Ialenti, Mariola Kurowska-Stolarska, Iain B.
McInnes, James M. Brewer, Paul Garside, and Pasquale Maffia. Plasmacytoid
dendritic cells play a key role in promoting atherosclerosis in apolipoprotein
e-deficient mice. Arterioscler Thromb Vasc Biol, 32(11):2569–2579, Nov 2012.
[36] Maren Luchtefeld, Christina Grothusen, Andreas Gagalick, Kumaravelu Ja-
gavelu, Harald Schuett, Uwe J F. Tietge, Oliver Pabst, Karsten Grote, Helmut
Drexler, Reinhold Frster, and Bernhard Schieffer. Chemokine receptor 7 knock-
out attenuates atherosclerotic plaque development. Circulation, 122(16):1621–
1628, Oct 2010.
[37] M. Pataki, G. Lusztig, and H. Robenek. Endocytosis of oxidized ldl and re-
versibility of migration inhibition in macrophage-derived foam cells in vitro. a














[38] Jana Barlic and Philip M. Murphy. An oxidized lipid-peroxisome proliferator-
activated receptor gamma-chemokine pathway in the regulation of macrophage-
vascular smooth muscle cell adhesion. Trends Cardiovasc Med, 17(8):269–274,
Nov 2007.
[39] Falk Weih, Rolf Grbner, Desheng Hu, Michael Beer, and Andreas J R.
Habenicht. Control of dichotomic innate and adaptive immune responses by
artery tertiary lymphoid organs in atherosclerosis. Front Physiol, 3:226, 2012.
[40] Jean-Charles Fruchart. International atherosclerosis society, dyslipidemia and
atherosclerosis slide collection; available at http://www.athero.org.
[41] Prediman K. Shah. Pathophysiology of plaque rupture and the concept of plaque
stabilization. Cardiol Clin, 21(3):303–14, v, Aug 2003.
[42] Murray Clarke and Martin Bennett. The emerging role of vascular smooth
muscle cell apoptosis in atherosclerosis and plaque stability. Am J Nephrol,
26(6):531–535, 2006.
[43] M. Yamagishi, M. Terashima, K. Awano, M. Kijima, S. Nakatani, S. Daikoku,
K. Ito, Y. Yasumura, and K. Miyatake. Morphology of vulnerable coronary
plaque: insights from follow-up of patients examined by intravascular ultrasound
before an acute coronary syndrome. J Am Coll Cardiol, 35(1):106–111, Jan
2000.
[44] Giovanni Cimmino, Stefano Conte, Alberto Morello, Saverio D’Elia, Valeria
Marchese, and Paolo Golino. The complex puzzle underlying the pathophysi-
ology of acute coronary syndromes: from molecular basis to clinical manifesta-
tions. Expert Rev Cardiovasc Ther, 10(12):1533–1543, Dec 2012.
[45] F. D. Kolodgie, J. Narula, A. P. Burke, N. Haider, A. Farb, Y. Hui-Liang,
J. Smialek, and R. Virmani. Localization of apoptotic macrophages at the site
of plaque rupture in sudden coronary death. Am J Pathol, 157(4):1259–1268,
Oct 2000.
[46] Emily A. van–Vre, Hafid Ait-Oufella, Alain Tedgui, and Ziad Mallat. Apoptotic
cell death and efferocytosis in atherosclerosis. Arterioscler Thromb Vasc Biol,
32(4):887–893, Apr 2012.
[47] Jiahuai Han, Chuan-Qi Zhong, and Duan-Wu Zhang. Programmed necrosis:
backup to and competitor with apoptosis in the immune system. Nat Immunol,
12(12):1143–1149, Dec 2011.
[48] Wim Martinet, Dorien M. Schrijvers, and Guido R Y. De Meyer. Necrotic cell
death in atherosclerosis. Basic Res Cardiol, 106(5):749–760, Sep 2011.
[49] Juan Lin, Hanjie Li, Min Yang, Junming Ren, Zhe Huang, Felicia Han, Jian
Huang, Jianhui Ma, Duanwu Zhang, Zhirong Zhang, Jianfeng Wu, Deli Huang,
Muzhen Qiao, Guanghui Jin, Qiao Wu, Yinghui Huang, Jie Du, and Jiahuai
Han. A role of rip3-mediated macrophage necrosis in atherosclerosis develop-













[50] Klitos Konstantinidis, Russell S. Whelan, and Richard N. Kitsis. Mechanisms
of cell death in heart disease. Arterioscler Thromb Vasc Biol, 32(7):1552–1562,
Jul 2012.
[51] Y. Geng and P. Libby. Evidence for apoptosis in advanced human atheroma.
colocalization with interleukin-1 beta-converting enzyme. Am J Pathol,
147(2):251–266, Aug 1995.
[52] Ira Tabas. Macrophage death and defective inflammation resolution in atheros-
clerosis. Nat Rev Immunol, 10(1):36–46, Jan 2010.
[53] Yankun Li, Marie-Christine Gerbod-Giannone, Heather Seitz, Dongying Cui,
Edward Thorp, Alan R. Tall, Glenn K. Matsushima, and Ira Tabas. Cholesterol-
induced apoptotic macrophages elicit an inflammatory response in phagocytes,
which is partially attenuated by the mer receptor. J Biol Chem, 281(10):6707–
6717, Mar 2006.
[54] Edward B. Thorp. Mechanisms of failed apoptotic cell clearance by phagocyte
subsets in cardiovascular disease. Apoptosis, 15(9):1124–1136, Sep 2010.
[55] Fernando O. Martinez. Regulators of macrophage activation. Eur J Immunol,
41(6):1531–1534, Jun 2011.
[56] Wei Xu, Anja Roos, Nicole Schlagwein, Andrea M. Woltman, Mohamed R.
Daha, and Cees van Kooten. Il-10-producing macrophages preferentially clear
early apoptotic cells. Blood, 107(12):4930–4937, Jun 2006.
[57] Filip K Swirski, Peter Libby, Elena Aikawa, Pilar Alcaide, F. William Lus-
cinskas, Ralph Weissleder, and Mikael J Pittet. Ly-6chi monocytes dominate
hypercholesterolemia-associated monocytosis and give rise to macrophages in
atheromata. J Clin Invest, 117(1):195–205, Jan 2007.
[58] Frank Tacke, David Alvarez, Theodore J Kaplan, Claudia Jakubzick, Rainer
Spanbroek, Jaime Llodra, Alexandre Garin, Jianhua Liu, Matthias Mack, Nico
van Rooijen, Sergio A Lira, Andreas J Habenicht, and Gwendalyn J Randolph.
Monocyte subsets differentially employ ccr2, ccr5, and cx3cr1 to accumulate
within atherosclerotic plaques. J Clin Invest, 117(1):185–194, Jan 2007.
[59] Matthias Nahrendorf, Filip K Swirski, Elena Aikawa, Lars Stangenberg,
Thomas Wurdinger, Jose-Luiz Figueiredo, Peter Libby, Ralph Weissleder, and
Mikael J Pittet. The healing myocardium sequentially mobilizes two monocyte
subsets with divergent and complementary functions. J Exp Med, 204(12):3037–
3047, Nov 2007.
[60] Peter Panizzi, Filip K Swirski, Jose-Luiz Figueiredo, Peter Waterman, David E
Sosnovik, Elena Aikawa, Peter Libby, Mikael Pittet, Ralph Weissleder, and
Matthias Nahrendorf. Impaired infarct healing in atherosclerotic mice with
ly-6c(hi) monocytosis. J Am Coll Cardiol, 55(15):1629–1638, Apr 2010.
[61] Filip K Swirski, Ralph Weissleder, and Mikael J Pittet. Heterogeneous in vivo














[62] Frederic Geissmann, Steffen Jung, and Dan R. Littman. Blood monocytes
consist of two principal subsets with distinct migratory properties. Immunity,
19(1):71–82, Jul 2003.
[63] Mihail Hristov, Thorsten Leyendecker, Christoph Schuhmann, Philipp von Hun-
delshausen, Nicole Heussen, Eva Kehmeier, Florian Krtz, Hae-Young Sohn,
Volker Klauss, and Christian Weber. Circulating monocyte subsets and cardio-
vascular risk factors in coronary artery disease. Thromb Haemost, 104(2):412–
414, Aug 2010.
[64] Ana L. Gomes, Tnia Carvalho, Jacinta Serpa, Cheila Torre, and Srgio Dias.
Hypercholesterolemia promotes bone marrow cell mobilization by perturbing
the sdf-1:cxcr4 axis. Blood, 115(19):3886–3894, May 2010.
[65] Filip K. Swirski. The spatial and developmental relationships in the macrophage
family. Arterioscler Thromb Vasc Biol, 31(7):1517–1522, Jul 2011.
[66] Clinton S. Robbins, Aleksey Chudnovskiy, Philipp J. Rauch, Jose-Luiz
Figueiredo, Yoshiko Iwamoto, Rostic Gorbatov, Martin Etzrodt, Georg F. We-
ber, Takuya Ueno, Nico van Rooijen, Mary Jo Mulligan-Kehoe, Peter Libby,
Matthias Nahrendorf, Mikael J. Pittet, Ralph Weissleder, and Filip K. Swirski.
Extramedullary hematopoiesis generates ly-6c(high) monocytes that infiltrate
atherosclerotic lesions. Circulation, 125(2):364–374, Jan 2012.
[67] Eugene Trogan, Jonathan E. Feig, Snjezana Dogan, George H. Rothblat,
Vronique Angeli, Frank Tacke, Gwendalyn J. Randolph, and Edward A. Fisher.
Gene expression changes in foam cells and the role of chemokine receptor ccr7
during atherosclerosis regression in apoe-deficient mice. Proc Natl Acad Sci U
S A, 103(10):3781–3786, Mar 2006.
[68] Jaime Llodr, Vronique Angeli, Jianhua Liu, Eugene Trogan, Edward A. Fisher,
and Gwendalyn J. Randolph. Emigration of monocyte-derived cells from athe-
rosclerotic lesions characterizes regressive, but not progressive, plaques. Proc
Natl Acad Sci U S A, 101(32):11779–11784, Aug 2004.
[69] Stephane Potteaux, Emmanuel L. Gautier, Susan B. Hutchison, Nico van Rooi-
jen, Daniel J. Rader, Michael J. Thomas, Mary G. Sorci-Thomas, and Gwenda-
lyn J. Randolph. Suppressed monocyte recruitment drives macrophage removal
from atherosclerotic plaques of apoe-/- mice during disease regression. J Clin
Invest, 121(5):2025–2036, May 2011.
[70] Peter J. Murray and Thomas A. Wynn. Protective and pathogenic functions of
macrophage subsets. Nat Rev Immunol, 11(11):723–737, Nov 2011.
[71] Yoshiyuki Rikitake and Yoshimi Takai. Directional cell migration regulation
by small g proteins, nectin-like molecule-5, and afadin. Int Rev Cell Mol Biol,
287:97–143, 2011.
[72] William A Muller. Mechanisms of leukocyte transendothelial migration. Annu













[73] C. A. Lowell and P. Soriano. Knockouts of src-family kinases: stiff bones, wimpy
t cells, and bad memories. Genes Dev, 10(15):1845–1857, Aug 1996.
[74] Tadayuki Yago, Bojing Shao, Jonathan J Miner, Longbiao Yao, Arkadiusz G
Klopocki, Kenichiro Maeda, K. Mark Coggeshall, and Rodger P McEver. E-
selectin engages psgl-1 and cd44 through a common signaling pathway to induce
integrin alphalbeta2-mediated slow leukocyte rolling. Blood, 116(3):485–494, Jul
2010.
[75] A. Baruzzi, E. Caveggion, and G. Berton. Regulation of phagocyte migration
and recruitment by src-family kinases. Cell Mol Life Sci, 65(14):2175–2190, Jul
2008.
[76] Diala Harb, Kim Bujold, Maria Febbraio, Martin G. Sirois, Huy Ong, and
Sylvie Marleau. The role of the scavenger receptor cd36 in regulating mononu-
clear phagocyte trafficking to atherosclerotic lesions and vascular inflammation.
Cardiovasc Res, 83(1):42–51, Jul 2009.
[77] Ingo Hilgendorf, Sara Eisele, Imke Remer, Jochen Schmitz, Katharina Zeschky,
Christian Colberg, Peter Stachon, Dennis Wolf, Florian Willecke, Maike Buch-
ner, Katja Zirlik, Alexandra Ortiz-Rodriguez, Andrey Lozhkin, Natalie Hoppe,
Constantin von zur Muhlen, Axel zur Hausen, Christoph Bode, and Andreas
Zirlik. The oral spleen tyrosine kinase inhibitor fostamatinib attenuates in-
flammation and atherogenesis in low-density lipoprotein receptor-deficient mice.
Arterioscler Thromb Vasc Biol, 31(9):1991–1999, Sep 2011.
[78] Asako Katsume, Mitsuhiko Okigaki, Akihiro Matsui, Jishan Che, Yasushi
Adachi, Eigo Kishita, Shinichiro Yamaguchi, Koji Ikeda, Tomomi Ueyama,
Satoaki Matoba, Hiroyuki Yamada, and Hiroaki Matsubara. Early inflammatory
reactions in atherosclerosis are induced by proline-rich tyrosine kinase/reactive
oxygen species-mediated release of tumor necrosis factor-alpha and subsequent
activation of the p21cip1/ets-1/p300 system. Arterioscler Thromb Vasc Biol,
31(5):1084–1092, May 2011.
[79] Zubair Shah, Thomas Kampfrath, Jeffrey A. Deiuliis, Jixin Zhong, Colleen
Pineda, Zhekang Ying, Xiaohua Xu, Bo Lu, Susan Moffatt-Bruce, Rekha
Durairaj, Qinghua Sun, Georgeta Mihai, Andrei Maiseyeu, and Sanjay Ra-
jagopalan. Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis
and inflammation via effects on monocyte recruitment and chemotaxis. Circu-
lation, 124(21):2338–2349, Nov 2011.
[80] P. W. Suen, D. Ilic, E. Caveggion, G. Berton, C. H. Damsky, and C. A. Lowell.
Impaired integrin-mediated signal transduction, altered cytoskeletal structure
and reduced motility in hck/fgr deficient macrophages. J Cell Sci, 112 ( Pt
22):4067–4078, Nov 1999.
[81] Giorgio Berton, Attila Mcsai, and Clifford A. Lowell. Src and syk kinases: key














[82] Ashish Bhattacharjee, Srabani Pal, Gerald M. Feldman, and Martha K. Cath-
cart. Hck is a key regulator of gene expression in alternatively activated human
monocytes. J Biol Chem, 286(42):36709–36723, Oct 2011.
[83] Edwin Kanters, Manolis Pasparakis, Marion J J. Gijbels, Monique N. Ver-
gouwe, Iris Partouns-Hendriks, Remond J A. Fijneman, Bjrn E. Clausen, Irm-
gard Frster, Mark M. Kockx, Klaus Rajewsky, Georg Kraal, Marten H. Hofker,
and Menno P J. de Winther. Inhibition of nf-kappab activation in macro-
phages increases atherosclerosis in ldl receptor-deficient mice. J Clin Invest,
112(8):1176–1185, Oct 2003.
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[287] Stéphane Potteaux, Bruno Esposito, Olivia van Oostrom, Valérie Brun, Patrice
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The immune system is known for its vigorous response to foreign stimuli upon
infection. But many of the recognition molecules and mechanisms involved in im-
mune responses have no bias towards external stimuli, but also sense and respond
to pathological and physiological changes of non infectious origin taking place within
the body.
Responses of the immune system to homeostatic disturbances are determinant
of the balance between disease progression or resolution; not only after bacterial or
viral infection, but also upon the onset and development of pathological conditions
including atherosclerosis; the leading cause of death in the world.
Aiming at defining potential immuno–therapeutic strategies to treat human
atherosclerosis, the focus of this work was the modulation of immune processes deter-
minant of atherosclerosis lesion progression or cessation in mice, such as hematopoiesis,
diapedesis and intravasation, leukocyte differentiation, cholesterol uptake apoptosis
and cell survival.
Modulation of these processes, by using bone marrow transplantation of he-
matopoietic stem cells with genetic deficiencies or over-expressing human or mouse
engineered genes, demonstrated to alter the fate of atherosclerotic lesions at the bal-
ance between macrophage accumulation and lesion vulnerability versus resolution of
inflammation and wound healing.
In particular, the experiments described in Chapter 2 indicate that hemato-
poietic deficiency of Hck and Fgr receptor tyrosine kinases, cause reduced diapedesis
and skew immune responses towards inflammation leading to increased vulnerability
of lesions to rupture despite reduced accumulation of macrophages. In contrast to
these results, over–expression of iNAMPT, as described in Chapter 3, blocked the
intravasation of monocytes, thereby reducing their availability to extravasate into
atherosclerotic lesions, while simultaneously activating multiple pathways that pro-
moted macrophage survival, resolution of inflammation and cholesterol efflux.
Regarding the balance between cell death and survival, induction of CD169+
macrophage apoptosis caused transient extramedullar myelopoiesis, and atheroscle-
rotic lesions that transitioned from lesion vulnerability to rupture to stabilization
and wound healing (Chapter 4). Systemic and local induction of CD115+ myelocyte
apoptosis caused accumulation of apoptotic cells and macrophage turnover in athe-
rosclerotic lesions. However, systemic induction of CD115+ myelocyte apoptosis led
to features of lesion vulnerability, extramedullar myelopoiesis and altered circulatory















Overall, the results obtained shift the paradigm of macrophage accumulation
as prime responsible factor of lesion vulnerability towards the notion of intra–lesion
macrophage phenotype as crucial determinant of plaque stability.
This thesis demonstrates that processes responsible for the development and
progression of atherosclerosis are dynamic and can be modulated to induce lesion
stabilization and disease resolution. These results are promising for the development
of novel therapeutics and challenge the current notion that atherosclerosis has a pre-
determined fate towards lesion vulnerability to rupture, which in humans results in














Het afweersysteem is bekend om zijn krachtige reactie op lichaamsvreemde
prikkels waaraan het lichaam blootgesteld wordt tijdens infectie. Een belangrijk
deel van deze reactie berust op de direct binding aan en activatie van bepaalde
herkenningseiwitten, zoals receptoren. Deze receptoren herkennen echter ook lichaam-
seigen prikkels die bijvoorbeeld vrijkomen na weefselschade (”steriele infectie”). Het
afweersysteem draagt dan niet alleen bij aan het opruimen van de door weefselschade
veroorzaakte afval (o.a. dood celmateriaal) maar ook aan het herstellen van de schade
(via littekenvorming, inkapseling van de schade, of reconstructie van het beschadigde
weefsel) .
Zowel na bacteriële of virale infectie als bij ”steriele infectie” weet het afweer-
systeem een balans te vinden tussen deze twee processen en een onevenwichtige af-
stemming van deze functies kan leiden tot chronische ontsteking en escalatie van
het ziekteproces, waarbij het middel schadelijker is dan de kwaal. Er zijn duidelijk
aanwijzingen dat een dergelijke onevenwichtige afweerreactie en dan vooral een teko-
rtschietende demping van de ontstekingsreactie bijdraagt aan de ontwikkeling van
chronische aandoeningen zoals aderverkalking, een van de belangrijkste doodsoorza-
ken in de wereld.
Mijn onderzoek had tot doel de effecten van een veranderde ontstekingsreac-
tie op het ontstaan en voortschrijden van de aderverkalking in kaart te brengen, dit
met de ontwikkeling van nieuwe therapien voor behandeling van aderverkalking als
uiteindelijk eindpunt. Ik heb hierbij twee deelprocessen bestudeerd: de celdood en
de mobiliteit van bepaalde ontstekingscellen (opruimercellen of macrofagen) in de
ontstekingshaard van de slagaderwand. Hierbij heb ik gebruik gemaakt van muizen-
modellen voor aderverkalking waarin de functie van sleutelmoleculen in deze processen
uitgeschakeld of juist geactiveerd werd.
Via deze aanpak heb ik weten aan te tonen dat het versneld afsterven van
opruimcellen in de plaque het ziekteproces onaangedaan laat en soms zelfs mogelijk
verergert, afhankelijk van de aanpak (lokaal, in de ontstoken vaatwand dan wel over
het hele lichaam) en de aangedane deelpopulatie van dit veelzijdige celtype. Een ver-
hoogde weerstand van opruimcellen tegen celdood, door stimulatie van een bepaald
enzym, NAMPT, sorteerde daarentegen een gunstig effect op de omvang als de samen-
stelling (stabiliteit) van de aderverkalking. Ten slotte heb ik aan weten te tonen dat
afremming van de mobiliteit van opruimcellen door uitschakeling van twee leden van
de familie van receptor-onafhankelijk tyrosine kinase enzymen, HCK and FGR, de
ontwikkeling van de aderverkalking weliswaar sterk vertraagde maar uiteindelijk lei-














(mogelijk door ongewenste opstapeling van de ontstekingscellen in het beschermende
kapsel van de aderverkalking).
Samenvattend heb ik in dit proefschrift aan weten te tonen dat het ontstek-
ingsproces dat verantwoordelijk is voor de ontwikkeling en vordering van aderverkalk-
ing complex en dynamisch is, en dat zij zodanig kan worden bijgesteld of afgestemd dat
de ontwikkeling van de aderverkalking wordt afgeremd en de bestaande aderverkalking
kan worden gestabiliseerd, wat de kans op een hartinfarct aanzienlijk zou kunnen ver-
minderen. Deze resultaten stellen de hypothese aan de orde dat de ontwikkeling van
aderverkalking een vooraf bepaalde vaste koers volgt, en voeden de hoop op nieuwe
behandelingswijzen die gericht zijn op het ontstekingsproces zelf, en niet zozeer op
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